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t is important that the medical profession plays a significant
ole in critically evaluating the use of diagnostic procedures
nd therapies as they are introduced and tested in the
etection, management, or prevention of disease states.
igorous and expert analysis of the available data docu-
enting absolute and relative benefits and risks of those
rocedures and therapies can produce helpful guidelines
hat improve the effectiveness of care, optimize patient
utcomes, and favorably affect the overall cost of care by
ocusing resources on the most effective strategies.
The American College of Cardiology Foundation
ACCF) and the American Heart Association (AHA) have
ointly engaged in the production of such guidelines in the
rea of cardiovascular disease since 1980. The ACC/AHA
ask Force on Practice Guidelines, whose charge is to
evelop, update, or revise practice guidelines for important
ardiovascular diseases and procedures, directs this effort.
he Task Force is pleased to have this guideline developed
n conjunction with the European Society of Cardiology
ESC). Writing committees are charged with the task of
erforming an assessment of the evidence and acting as an
ndependent group of authors to develop or update written
ecommendations for clinical practice.
Experts in the subject under consideration have been
elected from all 3 organizations to examine subject-specific
ata and write guidelines. The process includes additional
epresentatives from other medical practitioner and specialty
roups when appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
utcomes where data exist. Patient-specific modifiers, co-
orbidities, and issues of patient preference that might
nfluence the choice of particular tests or therapies are
onsidered as well as frequency of follow-up and cost
ffectiveness. When available, information from studies on
ost will be considered; however, review of data on efficacy
nd clinical outcomes will constitute the primary basis for
reparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and
he ESC Committee for Practice Guidelines make every
ffort to avoid any actual, potential, or perceived conflict of
nterest that might arise as a result of an industry relation-
hip or personal interest of the writing committee. Specif-
cally, all members of the Writing Committee, as well as
eer reviewers of the document, were asked to provide
isclosure statements of all such relationships that might be
erceived as real or potential conflicts of interest. Writing
ommittee members are also strongly encouraged to declare
previous relationship with industry that might be per-
eived as relevant to guideline development. If a Writing
ommittee member develops a new relationship with in-
ustry during his or her tenure, he or she is required to
otify guideline staff in writing. The continued participation wf the Writing Committee member will be reviewed. These
tatements are reviewed by the parent Task Force, reported
rally to all members of the Writing Committee at each
eeting, and updated and reviewed by the Writing Com-
ittee as changes occur. Please refer to the methodology
anuals for further description of the policies used in
uideline development, including relationships with indus-
ry, which are available on the ACC, AHA and ESC World
ide Web sites (http://www.acc.org/clinical/manual/
anual_introltr.htm, http://circ.ahajournals.org/manual,
nd http://www.escardio.org/knowledge/guidelines/Rules,
espectively). Please see Appendix 1 for author relationships
ith industry and Appendix 2 for peer reviewer relation-
hips with industry that are pertinent to these guidelines.
These practice guidelines are intended to assist health
are providers in clinical decision making by describing a
ange of generally acceptable approaches for the diagnosis
nd management of specific diseases or conditions. These
uidelines attempt to define practices that meet the needs of
ost patients in most circumstances. These guideline rec-
mmendations reflect a consensus of expert opinion after a
horough review of the available, current scientific evidence
nd are intended to improve patient care. If these guidelines
re used as the basis for regulatory/payer decisions, the
ltimate goal is quality of care and serving the patient’s best
nterests. The ultimate judgment regarding care of a partic-
lar patient must be made by the health care provider and
he patient in light of all of the circumstances presented by
hat patient. There are circumstances in which deviations
rom these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
HA Task Force on Practice Guidelines and the ESC
ommittee for Practice Guidelines and will be considered
urrent unless they are updated, revised, or sunsetted and
ithdrawn from distribution. The executive summary and
ecommendations are published in the September 5, 2006
ssue of the Journal of the American College of Cardiology,
eptember 5, 2006 issue of Circulation, and September 17,
006 issue of the European Heart Journal. The full-text
uideline is e-published in the same issues of the Journal of
he American College of Cardiology and Circulation and
ublished in the September 2006 issue of Europace, as well
s posted on the ACC (www.acc.org), AHA (www.ameri-
anheart.org), and ESC (www.escardio.org) World Wide
eb sites. Copies of the full text and the executive summary
re available from all 3 organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA, FESC,
Chair, ACC/AHA Task Force on Practice Guidelines
Silvia G. Priori, MD, PhD, FESC,
Chair, ESC Committee for Practice Guidelines
. INTRODUCTION
everal excellent guidelines already exist on treating patients
ho have ventricular arrhythmias (Table 1). The purpose of
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346his document is to update and combine the previously
ublished recommendations into one source approved by
he major cardiology organizations in the United States and
urope. We have consciously attempted to create a stream-
ined document, not a textbook, that would be useful
pecifically to locate recommendations on the evaluation
nd treatment of patients who have or may be at risk for
entricular arrhythmias. Thus, sections on epidemiology,
echanisms and substrates, and clinical presentations are
rief, because there are no recommendations for those
ections. For the other sections, the wording has been kept
o a minimum, and clinical presentations have been con-
ned to those aspects relevant to forming recommendations.
.1. Organization of Committee and Evidence Review
riting Committee members were selected with attention to
ardiovascular subspecialties, broad geographical representa-
ion, and involvement in academic medicine and clinical
ractice. The Writing Committee on the Management of
atients With Ventricular Arrhythmias and Prevention of
udden Cardiac Death also included members of the ACC/
HA Task Force on Practice Guidelines, ESC Committee on
able 1. Clinical Practice Guidelines and Policy Statements That
f Patients with Ventricular Arrhythmias and the Prevention of S
Document
uidelines
SCD ESC
Syncope ESC
Exercise testing ACC
Cardiac pacemakers and antiarrhythmia devices ACC
Echocardiography ACC
Supraventricular arrhythmias ACC
SCD Update ESC
Congenital heart disease ESC
European guidelines on CVD prevention ESC
Infective endocarditis ESC
Pericardial disease ESC
Pulmonary arterial hypertension ESC
AED use in Europe ESC
ST-elevation myocardial infarction ACC
Chronic heart failure ACC
Chronic heart failure ESC
CPR and ECC AH
Resuscitation ERC
Valvular heart disease ACC
tatements
Invasive electrophysiology studies, catheter ablation, and
cardioversion
ACC
Hypertrophic cardiomyopathy ACC
Cardiovascular disease during pregnancy ESC
Physical activity and recreational sports AHA for young
patients with genetic CVD
36th Bethesda Conference: Eligibility recommendations for
competitive athletes with cardiovascular abnormalities
ACC
he guidelines from the ACC, AHA, and ESC are available at www.acc.org, www.
ACC  American College of Cardiology; AHA  American Heart Association;
ardiovascular care; ERC  European Resuscitation Council; ESC  European
ASPE Heart Rhythm Society (formerly North American Society for Pacing andractice Guidelines, ACC Board of Trustees, ACC Board of covernors, ESC Board, the European Heart Rhythm Asso-
iation (EHRA), and the Heart Rhythm Society (HRS).
The committee was co-chaired by A. John Camm, MD,
ACC, FAHA, FESC, and Douglas P. Zipes, MD,
ACC, FAHA, FESC. This document was reviewed by 2
fficial reviewers nominated by the ACC, 2 official reviewers
ominated by the AHA, 2 official reviewers nominated by
he ESC, 1 official reviewer from the ACC/AHA Task
orce on Practice Guidelines, reviewers from the EHRA
nd HRS, and 18 content reviewers, including members
rom ACCF Clinical Electrophysiology Committee, AHA
ouncil on Clinical Cardiology, Electrocardiography, and
rrhythmias, and AHA Advanced Cardiac Life Support
ubcommittee.
The committee conducted comprehensive searching of
he scientific and medical literature on ventricular arrhyth-
ias and sudden cardiac death (SCD). Literature searching
as limited to publications on humans and in English from
990 to 2006. The search parameters were extended for
elected topics when a historical reference was needed or if
imited studies existed in English. In addition to broad-
ased searching on ventricular arrhythmias and SCD, spe-
rlap With ACC/AHA/ESC Guidelines for the Management
nsor Citation
Eur Heart J 2001;22:1374–450
Eur Heart J 2004;25:2054–72
A Circulation 2002;106:1883–92
A/NASPE Circulation 2002;106:2145–61
A J Am Coll Cardiol 2003;42:954–70
A/ESC Eur Heart J 2003;24:1857–97
J Am Coll Cardiol 2003;42:1493–531
Eur Heart J 2003;24:13–5
Eur Heart J 2003;24:1035–84
Eur J Cardiovasc Prev Rehab 2003;10 Suppl 1:S1–78
Eur Heart J 2004;25:267–76
Eur Heart J 2004;25:587–610
Eur Heart J 2004;25:2243–78
Eur Heart J 2004;25:437–45
A J Am Coll Cardiol 2004;44:e1–211
A J Am Coll Cardiol 2005;46:e1–82
Eur Heart J 2005;26:1115–40
OR Circulation 2005;112:IV-1–203
Resuscitation 2005;67 Suppl:539–86
A J Am Coll Cardiol 2006;48:e1–e148
A J Am Coll Cardiol 2000;36:1725–36
C Eur Heart J 2003;24:1965–91
J Am Coll Cardiol 2003;42:1687–713
Eur Heart J 2003;24:761–81
Circulation 2004;109:2807–16
J Am Coll Cardiol 2005;45:1318–75
anheart.org, and www.escardio.org, respectively.
 cardiovascular disease; CPR  cardiopulmonary resuscitation; ECC  emergency
ty of Cardiology; ILCOR  International Liaison Committee on Resuscitation;
rophysiology); SCD  sudden cardiac death.Ove
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelineshythmias and SCD and the following subtopics:
echanisms, substrates, clinical presentations, ECG, exer-
ise testing, echocardiography, imaging, electrophysiologi-
al (EP) testing, drug therapy (antiarrhythmic and nonan-
iarrhythmic), implantable and external cardioverter devices,
blation, surgery, acute specific arrhythmias (e.g., acute
oronary syndrome [ACS], heart failure [HF], stable sus-
ained monomorphic ventricular tachycardia [VT], torsades
e pointes), specific pathology (e.g., congenital heart dis-
ase, myocarditis, endocrine disorders, renal failure), cardio-
yopathies, genetic arrhythmias, structurally normal hearts,
thletes, elderly, gender, pediatric, and drug-induced ar-
hythmias. The complete list of keywords is beyond the
cope of this section. The committee reviewed all compiled
eports from computerized searches and conducted addi-
ional manual searching. Literature citations were generally
estricted to published manuscripts appearing in journals in
he Index Medicus. Because of the scope and importance of
ertain ongoing clinical trials and other emerging informa-
ion, published abstracts were cited in the text when they
ere the only published information available.
The final recommendations for indications for a diagnos-
ic procedure, a particular therapy, or an intervention for
anagement of patients with ventricular arrhythmias and
revention of SCD summarize both clinical evidence and
xpert opinion. Once recommendations were written, a
lassification of Recommendation and Level of Evidence
rade was assigned to each recommendation.
Classification of Recommendations and Level of Evi-
ence are expressed in the ACC/AHA/ESC format as
ollows:
lassification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or treatment is
beneficial, useful, and effective.
Class II: Conditions for which there is conflicting
evidence and/or divergence of opinion about the useful-
ness/efficacy of a procedure or treatment.
● Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
● Class IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treatment is not
useful/effective and in some cases may be harmful.
evel of Evidence
Level of Evidence A: Data derived from multiple
randomized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single
randomized trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of ex-
perts, case studies, or standard-of-care. pThe schema for classification of recommendations and
evel of evidence is summarized in Table 2, which also
llustrates how the grading system provides an estimate of
he size of treatment effect and an estimate of the certainty
f the treatment effect.
Recommendations with respect to therapy have consid-
red the following:
. The therapy to be offered (implantable cardioverter-
defibrillator [ICD], antiarrhythmic drugs, surgery, and
miscellaneous other treatments)
. The point at which therapy is offered (primary preven-
tion for those who are at risk but have not yet had a
life-threatening ventricular arrhythmia or sudden car-
diac “death” episode, or secondary for those patients
who have already experienced such arrhythmias or
events)
. The purpose of therapy (life preservation or symptom
reduction/improved quality of life)
. The etiology of the arrhythmia substrate (coronary heart
disease [CHD], cardiomyopathy, or other conditions)
. The functional status of the patient (New York Heart
Association [NYHA] functional class)
. The state of left ventricular (LV) function (LV ejection
fraction [LVEF])
. The specific arrhythmia concerned (e.g., sustained
monomorphic VT, polymorphic VT, and ventricular
fibrillation [VF])
Not all therapeutic combinations are clinically relevant,
nd many have no evidence base and probably will not have
ne in the future because of the lack of clinical relevance or
he relative rarity of the particular grouping. In many
nstances, the probable value of therapy may be reasonably
nferred by the response of similar patients to specific
herapies.
.2. Prophylactic Implantable Cardioverter-Defibrillator
ecommendations Across Published Guidelines
he ACC/AHA/NASPE 2002 Guidelines Update for
mplantation of Cardiac Pacemakers and Antiarrhythmia
evices (1), the ACC/AHA 2004 Guidelines for the
anagement of Patients With ST-Elevation Myocardial
nfarction (2), the ESC 2001 and 2003 Guidelines on
revention of Sudden Cardiac Death (3,4), the ESC 2005
uidelines for the Diagnosis and Treatment of Chronic
eart Failure (5a), and the ACC/AHA 2005 Guideline
pdate for the Diagnosis and Management of Chronic
eart Failure in the Adult (6) include a large number of
ecommendations on ICD therapy that merit attention.
Recommendations for prophylactic ICD implantation
ased on ejection fractions (EFs) have been inconsistent
ecause clinical investigators have chosen different EFs for
nrollment in trials of therapy, average values of the EF in
uch trials have been substantially lower than the cutoff
alue for enrollment, and subgroup analyses of clinical trial
opulations based on EF have not been consistent in their
Table 2. Applying Classification of Recommendations and Level of Evidence†
“SIZE of TREATMENT EFFECT” 
Class I 
  
Benefit >>> Risk 
 
 
Procedure/Treatment
SHOULD be 
performed/administered
Class IIa 
  
Benefit >> Risk 
Additional studies with focused 
objectives needed 
 
IT IS REASONABLE to perform 
procedure/administer treatment 
Class IIb 
  
Benefit ≥ Risk 
Additional studies with broad 
objectives needed; Additional 
registry data would be helpful
Procedure/Treatment
MAY BE CONSIDERED
Level A 
  
 
Multiple (3-5) population risk 
strata evaluated* 
 
General consistency of direction 
and magnitude of effect
• Recommendation that 
procedure or treatment is 
useful/effective
• Sufficient evidence from 
multiple randomized trials or 
meta-analyses
• Recommendation in favor of 
treatment or procedure being 
useful/effective
• Some conflicting evidence from 
multiple randomized trials or 
meta-analyses
• Recommendation’s 
usefulness/efficacy less well 
established
• Greater conflicting evidence 
from multiple randomized trials 
or meta-analyses 
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Sufficient evidence from 
multiple randomized trials or 
meta-analyses
Level B 
 
Limited (2-3) population risk 
strata evaluated* 
 
• Recommendation that 
procedure or treatment is 
useful/effective
• Limited evidence from single 
randomized trial or non-
randomized studies 
• Recommendation in favor of 
treatment or procedure being 
useful/ effective 
• Some conflicting evidence from 
single randomized trial or non-
randomized studies 
• Recommendation’s 
usefulness/efficacy less well 
established
• Greater conflicting evidence 
from single randomized trial or 
non-randomized studies 
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Limited evidence from single 
randomized trial or non-
randomized studies 
Level C 
  
Very limited (1-2) population risk 
strata evaluated* 
 
 
• Recommendation that
procedure or treatment is 
useful/effective
• Only expert opinion, case 
studies, or standard-of-care 
• Recommendation in favor of 
treatment or procedure being 
useful/ effective 
• Only diverging expert opinion, 
case studies, or standard-of-
care
• Recommendation’s 
usefulness/efficacy less well 
established
• Only diverging expert opinion, 
case studies, or standard-of-care
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Only expert opinion, case 
studies, or standard-of-care 
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Class III 
  
Risk ≥ Benefit 
No additional studies needed 
 
Procedure/Treatment should 
NOT be performed/administered 
SINCE IT IS NOT HELPFUL 
AND MAY BE HARMFUL 
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. †A recommendation with
a Level of Evidence of B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available,
there may be a very clear consensus that a particular therapy is useful or effective.
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesmplications. Substantial differences between guidelines
ave resulted. However, no trial has randomized patients
ith an intermediate range of EFs. For instance, there is no
rial that has specifically studied patients with an LVEF
etween 31% and 35%, yet recommendations have been set
or such patients on the basis of data derived from trials that
tudied groups with EFs less than or equal to 30%, others
hat enrolled patients with an EF less than or equal to 35%,
nd one trial that enrolled patients with an EF less than or
qual to 40%. Recognizing these inconsistencies, this
uideline Writing Committee decided to construct recom-
endations to apply to patients with an EF less than or
qual to a range of values. The highest appropriate class of
ecommendation was then based on all trials that recruited
atients with EFs within this range. In this way, potential
onflicts between guidelines were reduced and errors due to
rawing false conclusions relating to unstudied patient
roups were minimized (Table 3).
It is important to note that experts can review the same
ata and arrive at different interpretations. Attempting to
omogenize heterogeneous trials invariably leads to varying
nterpretations of the trial data. Furthermore, differences
etween the United States and Europe may modulate how
ecommendations are implemented. Guidelines are com-
osed of recommendations on the basis of the best available
edical science; however, implementation of these recom-
endations will be affected by the financial, cultural, and
ocietal differences between individual countries.
able 3. Inconsistencies Between ACC/AHA/ESC Guidelines fo
he Prevention of SCD and Other Published ACC/AHA and ES
revention to Reduce Total Mortality by a Reduction in SCD
Group Addressed in
Recommendation
Guideline and Class o
2005 ACC/AHA
HF 2005 ESC HF
2004
S
VD d/t MI, LVEF 30% or
less, NYHA II, III
VD d/t MI, LVEF 30% to
35%, NYHA II, III
VD d/t MI, LVEF 30% to
40%, NSVT, positive EP
study
Class I; LOE: B
Class IIa; LOE: B
N/A
Class I; LOE: A
Class I; LOE: A
N/A
Class
N/A
Class
VD d/t MI, LVEF 30% or
less, NYHA I
VD d/t MI, LVEF 31% to
35% or less, NYHA I
Class IIa; LOE: B
N/A
N/A
N/A
N/A
N/A
ICM, LVEF 30% or less,
NYHA II, III
ICM, LVEF 30% to 35%,
NYHA II, III
Class I; LOE: B
Class IIa; LOE: B
Class I; LOE: A
Class I; LOE: A
N/A
N/A
ICM, LVEF 30% or less,
NYHA I
ICM, LVEF 31% to 35% or
less, NYHA I
Class IIb; LOE: C
N/A
N/A
N/A
N/A
N/A
For an explanation of Class Recommendation and Level of Evidence, see Table 2.
ACC/AHA HF  ACC/AHA 2005 Guideline Update for the Diagnosis and
CD  ACC/AHA/NASPE 2002 Guidelines Update for Implantation of Cardiac
uidelines for the Management of Patients With ST-Elevation Myocardial Infarctio
reatment of Chronic Heart Failure (5); LOE level of evidence; LVD d/t MI leftraction; N/A  populations not addressed; NICM  nonischemic cardiomyopathy; NSV
unctional class; SCD  sudden cardiac death; VA  ventricular arrhythmias..3. Classification of Ventricular
rrhythmias and Sudden Cardiac Death
his classification table is provided for direction and intro-
uction to the guidelines (Table 4).
. EPIDEMIOLOGY
he epidemiology of ventricular arrhythmias spans a range
f risk descriptors and clinical applications, ranging from
remature ventricular complexes (PVCs) and nonsustained
entricular tachycardia (NSVT) in normal subjects to SCD
ue to ventricular tachyarrhythmias in patients with and
ithout structural heart disease (9). Epidemiological pat-
erns have implications that help improve profiling risk
ased on individual subject characteristics and for efficient
esigns of clinical trials (10). Techniques include identifi-
ation of clinical and lifestyle risk factors for disease devel-
pment, measurement of risk among subgroups of patients
ith established disease, and the newly emerging field of
enetic epidemiology (9,11).
.1. Ventricular Arrhythmias
.1.1. Premature Ventricular Complexes
nd Nonsustained Ventricular Tachycardia
ingle and repetitive forms of PVCs have been studied for
heir role in risk prediction in several contrasting clinical
ircumstances, including implications in apparently normal
ubjects compared with those with identified disease states,
Management of Patients With Ventricular Arrhythmias and
uidelines With Respect to ICD Therapy for Primary
mmendation with Level of Evidence* for Each Group
/AHA
I
2002 ACC/
AHA/NASPE
PM and ICD
Comment from the ACC/AHA/ESC VA
and SCD Guidelines
OE: B
: B
Class IIa; LOE: B
N/A
Class IIb; LOE: B
VA and SCD has combined all trials that
enrolled patients with LVD d/t MI into one
recommendation, Class I; LOE: A
N/A
N/A
VA and SCD has expanded the range of LVEF
to 30% to 35% or less for patients with LVD
d/t MI and NYHA functional class I into
one recommendation, Class IIa; LOE: B
N/A
N/A
VA and SCD has combined all trials of NICM,
NYHA II, III into one recommendation,
Class I; LOE: B
N/A
N/A
VA and SCD has expanded the range of LVEF
to 30% to 35% or less for patients with
NICM and NYHA functional class I into
one recommendation, Class IIb; LOE: B
rther discussion, please see the Introduction.
gement of Chronic Heart Failure in the Adult (6); ACC/AHA/NASPE PM and
akers and Antiarrhythmia Devices (1); ACC/AHA STEMI  ACC/AHA 2004
EP  electrophysiological; ESC HF  ESC 2005 Guidelines for the Diagnosis and
cular dysfunction due to prior myocardial infarction; LVEF left ventricular ejectionr the
C G
f Reco
ACC
TEM
IIa; L
I; LOE
For fu
Mana
Pacem
n (2);
ventriT  nonsustained ventricular tachycardia; NYHA  New York Heart Association
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346n steady-state pathophysiology versus transient events, and
n inactive subjects versus those under physical stress. The
pidemiological implications vary for each of these contin-
able 4. Classification of Ventricular Arrhythmias
Classification by Clinica
emodynamically stable Asymptomatic The abs
Minimal symptoms,
e.g., palpitations
Patient
the f
 He
 An
 Fe
emodynamically unstable Presyncope Patient
 Di
 Lig
 Fe
 “G
Syncope Sudden
with
exper
Sudden cardiac death Death f
occur
Sudden cardiac arrest Death f
occur
inter
Classification by Electr
onsustained VT Three
VT is a
ema
less
Monomorphic Nonsus
Polymorphic Nonsus
and
ustained VT VT gre
hem
Monomorphic Sustain
Polymorphic Sustain
betw
undle-branch re-entrant
tachycardia
VT du
mor
idirectional VT VT wit
with
orsades de pointes Charac
elect
com
 “T
 Sh
entricular flutter A regu
appr
appe
entricular fibrillation Rapid,
irreg
mor
Classification by Dis
hronic coronary heart disease
eart failure
ongenital heart disease
eurological disorders
tructurally normal hearts
udden infant death syndrome
ardiomyopathies
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular
cardiomyopathy
BBB  left bundle-branch block; VT  ventricular tachycardia.encies. p.1.1.1. Premature Ventricular
omplexes in the Absence of Heart Disease
Among presumably normal individuals, estimates of the
entation Reference
f symptoms that could result from an arrhythmia. (7)
s palpitations felt in either the chest, throat, or neck as described by
g:
(7)
t sensations that feel like pounding or racing
asant awareness of heartbeat
kipped beats or a pause
s presyncope as described by the following:
dedness
aint
out”
(7)
f consciousness with loss of postural tone, not related to anesthesia,
neous recovery as reported by the patient or observer. Patient may
syncope when supine.
(7)
n unexpected circulatory arrest, usually due to a cardiac arrhythmia
ithin an hour of the onset of symptoms.
(7a)
n unexpected circulatory arrest, usually due to a cardiac arrhythmia
ithin an hour of the onset of symptoms, in whom medical
(e.g., defibrillation) reverses the event.
(7)
iography
e beats in duration, terminating spontaneously in less than 30 s. (7)
ac arrhythmia of three or more consecutive complexes in duration
from the ventricles at a rate of greater than 100 bpm (cycle length
00 ms)
VT with a single QRS morphology. (7)
VT with a changing QRS morphology at cycle length between 600
s.
(7)
an 30 s in duration and/or requiring termination due to
mic compromise in less than 30 s.
(7)
with a stable single QRS morphology. (7)
with a changing or multiform QRS morphology at cycle length
00 and 180 ms.
(7)
-entry involving the His-Purkinje system, usually with LBBB
y; this usually occurs in the setting of cardiomyopathy.
(7)
at-to-beat alternans in the QRS frontal plane axis, often associated
lis toxicity.
(7)
by VT associated with a long QT or QTc, and
iographically characterized by twisting of the peaks of the QRS
around the isoelectric line during the arrhythmia:
,” initiated following “short-long-short” coupling intervals.
upled variant initiated by normal-short coupling.
(7)
cle length variability 30 ms or less) ventricular arrhythmia
tely 300 bpm (cycle length—200 ms) with a monomorphic
; no isoelectric interval between successive QRS complexes.
(7)
y more than 300 bpm/200 ms (cycle length 180 ms or less), grossly
entricular rhythm with marked variability in QRS cycle length,
y, and amplitude.
(7)
ntityl Pres
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesampling technique used and the source of data. PVCs were
ecorded on standard 12-lead electrocardiograms (ECGs) in
.8% of subjects in a healthy military population, with a
ange of 0.5% among those under the age of 20 y to 2.2% of
hose over 50 y of age (12). In a study of middle-aged men,
oth with and without known heart disease, a 6-h monitor
ampling technique identified a 62% incidence of asymp-
omatic ventricular arrhythmias, more than one half of
hich were infrequent single PVCs (13). The incidence,
requency, and complexity of ventricular arrhythmias were
reater in the presence of known or suspected heart disease,
nd mortality risk implications were absent in those without
eart disease (13,14). In contrast to PVCs and monomor-
hic patterns of NSVT, polymorphic ventricular tachyar-
hythmias in the absence of structural heart disease are
ndicators of risk (15). Many nonsustained polymorphic VT
vents occurring in individuals free of grossly evident
tructural abnormalities of the heart are due to abnormalities
t a molecular level or a consequence of electrolyte distur-
ances or adverse drug effects.
In the Tecumseh, Michigan, communitywide cardiovas-
ular epidemiology study, PVCs in subjects with structurally
ormal hearts carried no adverse prognostic significance
nder the age of 30 y, but in those older than 30 y, PVCs
nd short runs of NSVT began to influence risk (16). More
ecent studies provide conflicting implications regarding risk
n asymptomatic subjects. In one study (17), asymptomatic
entricular arrhythmias in the absence of identifiable heart
isease predicted a small increase in risk, while another
tudy (18) suggested no increased risk.
In contrast to the apparently non–life-threatening impli-
ation of PVCs at rest, PVCs elicited during exercise
esting, even in apparently normal individuals, appear to
mply risk over time. In one study (19), PVCs and NSVT
nduced during exercise correlated with increased risk of
otal mortality, while in another study (20), both exercise-
nd recovery-phase PVCs correlated with risk, with the
reater burden associated with recovery-phase arrhythmias.
selection bias, based on indications for stress testing, may
ave influenced these observations (21).
.1.1.2. Premature Ventricular Complexes
n the Presence of Established Heart Disease
PVCs and runs of NSVT in subjects with structural heart
isease contribute to an increased mortality risk, the mag-
itude of which varies with the nature and extent of the
nderlying disease. Among survivors of myocardial infarc-
ion (MI), frequent and repetitive forms of ventricular
ctopic activity, accompanied by a reduced EF, predict an
ncreased risk of SCD during long-term follow-up (21–23).
ost studies cite a frequency cutoff of 10 PVCs per hour
nd the occurrence of repetitive forms of ventricular ectopy
s thresholds for increased risk. Several investigators have
mphasized that the most powerful predictors among the
arious forms of PVCs are runs of NSVT (21,22). Although
he specificity of this relationship is now questioned. The oower of risk prediction conferred by the presence of PVCs
nd NSVT appears to be directly related to the extent of
tructural disease as estimated by EF and to cardiovascular
imitations as estimated by functional capacity (24).
Ventricular arrhythmias during ambulatory recording in
atients with HF do not specifically predict risk for SCD
25). Risk is already high because of the underlying disease.
uppression of ambient ventricular arrhythmias is no longer
onsidered a therapeutic target for prevention of death in
he post-MI or nonischemic cardiomyopathy subgroups.
.1.2. Ventricular Tachycardia and Ventricular
ibrillation During Acute Coronary Syndromes
bservations of both post-MI patients (26) and survivors of
ardiac arrest that occurred during the acute phase of
ransmural MI (27) suggest that life-threatening ventricular
achyarrhythmias occurring during the first 24 to 48 h of MI
o not imply continuing risk over time. A study done on
ollow-up after in-hospital VF does suggest an adverse
rognosis over the ensuing 6 mo (28), but the patients were
ot selected for acute-phase arrhythmias. Later in-hospital
F has previously been reported to confer long-term risk
29). In contrast, patients presenting with non–ST-
levation myocardial infarction (NSTEMI) are at increased
ong-term risk of SCD (30), possibly related in part to a
ersistent propensity for ventricular tachyarrhythmias (31).
uch patients have generally been excluded from clinical
rials for interventions targeting long-term arrhythmic
eath risk because of low absolute risk, but it remains
nclear whether the magnitude of risk is modulated by the
xtent of myocardial damage that occurs during the acute
vent. The long-term risk implications of sustained VT and
F during the acute phase of MI may also be applied to
requent PVCs and runs of NSVT (32). It is important to
tress that the clinician’s ability to recognize individuals with
eversible or transient causes of ventricular tachyarrhythmias
s limited (33).
.2. Sudden Cardiac Death
.2.1. Incidence of Sudden Cardiac Death
he geographical incidence of SCD varies as a function of
HD prevalence in different regions (3). Estimates for the
nited States (34–38) range from less than 200,000 to more
han 450,000 SCDs annually, with the most widely used
stimates in the range of 300,000 to 350,000 SCDs annually
39). The variation is based, in part, on the inclusion criteria
sed in individual studies. Overall, event rates in Europe are
imilar to those in the United States (3), with significant
eographic variations reported.
The temporal definition of SCD strongly influences
pidemiological data (40). The proportion of all natural
eaths due to SCD is 13% when a definition of 1 h from
nset of symptoms is used. In contrast, the communitywide
tudy in Maastricht, the Netherlands, reported that 18.5%
f all deaths were SCD, using a 24-h definition (41). The
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raction of all natural deaths falling into the “sudden”
ategory but reduces the proportion of all sudden natural
eaths that are due to cardiac causes (40).
Approximately 50% of all CHD deaths are sudden and
nexpected, occurring shortly (instantaneous to 1 h) after
he onset of a change in clinical status, with some geograph-
cal variation in the fraction of coronary deaths that are
udden (42). The decreasing age-adjusted CHD mortality
oes not imply a decrease in absolute numbers of cardiac or
udden deaths (43,44) because of the growth and aging of
he U.S. and European populations and the increasing
revalence of chronic heart disease (45).
.2.2. Population Subgroups and Risk Prediction
hree factors affect the ability to identify subjects and
opulation subgroups at risk and consideration of strategies
or prevention of SCD:
Absolute numbers and event rates (incidence) among
population subgroups (Fig. 1)
Clinical subgroups in which SCDs occur
Time dependence of risk (39).
The overall incidence of SCD in the United States is 1 to
per 1000 population (0.1% to 0.2%) annually, with some
ariations in estimates based on differences in various
ources of data. This large population base includes those in
hom SCD occurs as a first cardiac event, as well as those
or whom SCDs can be predicted with greater accuracy
ecause they are included in higher risk subgroups (Fig. 1).
igher levels of risk resolution can be achieved by identi-
cation of more specific subgroups. However, the corre-
igure 1. Absolute numbers of events and event rates of SCD in the
eneral population and in specific subpopulations over 1 y. General
opulation refers to unselected population age greater than or equal to 35 y,
nd high-risk subgroups to those with multiple risk factors for a first
oronary event. Clinical trials that include specific subpopulations of
atients are shown in the right side of the figure. AVID Antiarrhythmics
ersus Implantable Defibrillators; CASH  Cardiac Arrest Study Ham-
urg; CIDS  Canadian Implantable Defibrillator Study; EF  ejection
raction; HF  heart failure; MADIT Multicenter Automatic Defibril-
ator Implantation Trial; MI  myocardial infarction; MUSTT  Mul-
icenter UnSustained Tachycardia Trial; SCD-HeFT  Sudden Cardiac
eath in Heart Failure Trial. Modified with permission from Myerburga
J, Kessler KM, Castellanos A. SCD. Structure, function, and time-
ependence of risk. Circulation 1992;85:I2–10.ponding absolute number of deaths becomes progressively
maller as the subgroups become more focused, limiting the
otential impact of interventions to a much smaller fraction
f the total population (10). At least 50% of all SCDs due
o CHD occur as a first clinical event or among subgroups
f patients thought to be at relatively low risk for SCD (43).
.2.3. Time-Dependent Risk
he risk of SCD after a clinical event is not linear as a
unction of time (39,46). Survival curves after major cardio-
ascular events, which identify risk for both sudden and
otal cardiac death, demonstrate that the most rapid rate of
ttrition usually occurs during the first 6 to 18 mo after the
ndex event. Curves with these characteristics have been
enerated from data on survivors of out-of-hospital cardiac
rrest, new onset of HF, and unstable angina and on
igh-risk subgroups of patients with recent MI. In contrast
o inherent (baseline) risk patterns over time, however,
enefit patterns from controlled trials may show divergence
f curves early (e.g., post-MI beta-blocker therapy, clopi-
ogrel in ACSs) or later (e.g., angiotensin-converting en-
yme [ACE] inhibitors and statins). Mortality is highest in
he first month after acute MI (AMI) in patients with EF of
ess than 30% (47).
.2.4. Age, Heredity, Gender, and Race
he incidence of SCD increases as a function of advancing
ge (48), in parallel with the age-related increase in the
ncidence of total CHD deaths, but may undergo a relative
ecrease in the eighth decade and beyond because of
ompeting causes of death. The incidence is 100-fold less in
dolescents and adults younger than 30 y (1 in 100 000 per
ear) than it is in adults older than 35 y (49–51). The
roportion of coronary deaths and of all cardiac causes of
eath that are sudden is highest in the younger age groups.
Hereditary factors that contribute to CHD risk have been
hought to operate nonspecifically for the SCD syndrome.
owever, several studies have identified mutations and
elevant polymorphisms along multiple steps of the cascade
rom atherogenesis to plaque destabilization, thrombosis,
nd arrhythmogenesis, each of which is associated with a
isk of a coronary event (52–55). Integration of these
ndividual markers may provide more powerful individual
isk prediction in the future (56). In addition, 2 population
tudies suggest that SCD, as an expression of CHD, clusters
n specific families (57,58). There is a large preponderance
f SCD in males compared with females during the young
dult and early middle-age years because of the protection
emales enjoy from coronary atherosclerosis before meno-
ause (59–61). As coronary event risk increases in post-
enopausal women, SCD risk increases proportionately.
ven though the overall risk is much lower in younger
omen, the established coronary risk factors are still pre-
ictive of events (59,61–63).
Studies comparing racial differences in risk of SCDmong whites and African Americans with CHD in the
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesnited States have yielded conflicting and inconclusive
ata. However, some studies have demonstrated excess risk
f cardiac arrest and SCD among African Americans
ompared with whites (61,64). SCD rates among Hispanic
opulations were lower (61).
.2.5. Risk Profiles and Sudden Cardiac Death
iological and behavioral risk profiling for coronary artery
isease, using the conventional risk factors for coronary
therogenesis (65), is useful for identifying levels of popu-
ation risk but has limited value for distinguishing individual
atients at risk for SCD. Multivariate analyses of selected
isk factors for atherogenesis have determined that approx-
mately one half of all SCDs occur among the 10% of the
opulation in the highest risk decile. Thus, the cumulative
isk associated with conventional risk factors for coronary
therosclerosis exceeds the simple arithmetic sum of the
ndividual risks (65). The comparison of risk factors in the
ictims of SCD with those in people who developed any
anifestations of coronary artery disease does not provide
seful patterns. In addition, certain angiographic and he-
odynamic patterns discriminate SCD risk from non-SCD
isk only under limited conditions (66).
Markers of risk that move beyond the direct lipid depo-
ition concept of atherogenesis into more complex patho-
iology are now being identified, largely focusing on mech-
nisms responsible for destabilization of lipid-laden plaques.
nflammatory markers, such as C-reactive protein and other
ndicators of inflammation and destabilization (67), have
ntered into risk formulations, offering potentially useful
dditions to conventional risk markers (68,69). In addition,
amilial clustering of SCD as a specific manifestation of the
isease (57,58) may lead to identification of specific genetic
bnormalities that predispose to SCD (52–54,70).
Hypertension is an established risk factor for CHD and
lso emerges as a risk factor for SCD (71). Both the ECG
attern of left ventricular hypertrophy (LVH) and echocar-
iographic evidence or LVH are associated with a higher
roportion of sudden and unexpected cardiac death. Intra-
entricular conduction abnormalities such as left bundle-
ranch block (LBBB) are also suggestive of a disproportion-
te number of SCD (72,73).
There are also meaningful associations between cigarette
moking, obesity, diabetes, and lifestyle and SCD. The
ramingham Study demonstrates that cigarette smokers
ave a 2- to 3-fold increase in SCD risk; this is one of the
ew risk factors in which the proportion of CHD deaths that
re sudden increases in association with the risk factor (72).
n addition, in a study of 310 survivors of out-of-hospital
ardiac arrest, the recurrent cardiac arrest rate was 27% at
y of follow-up among those who continued to smoke after
heir index event, compared with 19% in those who stopped
74). Obesity is a second factor that appears to influence the
roportion of coronary deaths that occur suddenly (72).
Associations between levels of physical activity and SCDave been studied, with varying results (75). A high resting neart rate with little change during exercise and recovery is
risk factor for SCD. Epidemiological observations have
uggested a relationship between sedentary activity and
ncreased CHD death risk. The Framingham Study, how-
ver, showed an insignificant relationship between low levels
f physical activity and incidence of SCD but a high
roportion of sudden to total cardiac deaths at higher levels
f physical activity (72). An association between acute
hysical exertion and SCD demonstrated a 17-fold relative
ncrease for the risk of SCD during vigorous exercise for the
ntire populations (active and inactive). For the habitually
nactive, the relative risk was 74 (76). Habitual vigorous
xercise attenuates risk (76,77). Therefore, these data indi-
ate that, while the risk of cardiac arrest is higher during
igorous exercise (especially among individuals who are
sually sedentary), habitual exercise attenuates the risk of
ardiac arrest, both during exercise and at rest (78).
The magnitude of recent life changes in the realms of
ealth, work, home, and family and personal and social
actors have been related to MI and SCD (79–82). There is
n association between significant elevations of life-change
cores during the 6 mo before a coronary event, and the
ssociation is particularly striking in victims of SCD. After
ontrolling for other major prognostic factors, the risk of
CD and total mortality is increased by social and economic
tresses (83), and alteration of modifiable lifestyle factors has
een proposed as a strategy for reducing risk of SCD in
atients with CHD (84). Acute psychosocial stressors have
een associated with risk of cardiovascular events, including
CD (85,86). The risk appears to cluster around the time of
he stress and appear to occur among victims at preexisting risk,
ith the stressor simply advancing the time of an impending
vent (85). The possibility of physical stress–induced coronary
laque disruption has also been suggested (87).
. MECHANISMS AND SUBSTRATES
.1. Substrate for Ventricular Arrhythmias
he substrate for SCD varies depending on the underlying
tructural heart disease, if any, and ranges from no obvious
vidence of structural damage to advanced cardiomyopathic
tates. Most studies suggest that three quarters of the
atients dying of SCD have CHD. Extensive coronary
therosclerosis is generally found, with a high proportion of
earts having 3- or 4-vessel coronary disease involvement.
natomical findings at autopsy include acute changes in
oronary plaque morphology, such as thrombus, plaque
isruption, or both, in more than 50% of cases of sudden
oronary death. Hearts that have myocardial scars and no
cute infarction show active coronary lesions in approxi-
ately 50% of cases (88). Erosion of proteoglycan- and
mooth muscle cell–rich plaques lacking a superficial lipid
ore, or plaque rupture, is a frequent pathological finding
89). Plaque rupture appears to be more common in older
omen (90). However, these anatomical abnormalities are
ot represented by specific clinical risk factors different from
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346hose that identify patients with CHD in general. Naturally,
he substrate will be different depending on the nature of the
eart disease. As noted in Section 2, other diseases predis-
osing to SCD include both hypertrophic cardiomyopathy
HCM) and dilated cardiomyopathy (DCM), right ventric-
lar (RV) cardiomyopathy, congenital abnormalities (espe-
ially coronary artery anomalies), coronary artery spasm, and
ther less common problems (44,46,91). Obesity, hyperten-
ion, lipid abnormalities, and diabetes are important risk
actors (92–95). The heritable abnormalities of RV cardio-
yopathy and HCM are the major substrates found in the
udden deaths of pre–coronary artery age groups (96–98).
he cumulative risk of SCD has been estimated at 15% to
0% of adults with aortic stenosis, with the risk being higher
n symptomatic patients and equal to or less than 5% in
symptomatic patients (99). Mitral valve prolapse is usually
on–life threatening, and its link with SCD has never been
onclusively demonstrated (3). Reported SCD rates in
atients with Wolff-Parkinson-White (WPW) syndrome
ave been 0.15%, due in most to the development of atrial
brillation (AF) with a rapid ventricular response that
egenerates to VF (100,101).
Genetic influences modulate the risk of SCD in the
etting of coronary (and likely other) heart disease
3,55,102). The Paris Prospective Study I, analyzing more
han 7000 men followed for an average of 23 y, found that
parental history of SCD increased the relative risk of SCD
or offspring to 1.8, without elevating the risk for MI. When
oth parents had SCD, the relative risk for SCD in
ffspring was 9.4 (58). A retrospective study performed on
ardiac arrest survivors in King County, Washington, also
eported family history to be a significant, independent risk
or SCD, with an odds ratio of 1.57 (57). Genetic influences
ay act through multiple, though, not necessarily exclusive
echanisms: by modulating the fixed substrate, athero-
hrombosis, electrogenesis impulse propagation, neural con-
rol and regulation.
In 5% to 10% of cases, SCD occurs in the absence of
HD or cardiomyopathy. There exists a group of inherited
bnormalities such as the long QT syndrome (LQTS), short
T syndrome (SQTS), Brugada syndrome, and cat-
cholaminergic VT, which can precipitate SCD without
vert structural changes in the heart (103–105). Abnormal-
ties in potassium and sodium channels, in ankyrin B, and in
he ryanodine receptor of the sarcoplasmic reticulum which
s responsible for release of the calcium required for cardiac
uscle contraction, can disrupt the normal electrical pro-
esses of the heart to cause life-threatening ventricular
rrhythmias. It is important to stress that some individuals
an have inherited abnormalities that are not manifest until
riggered by an external event. For example, autonomic
odulation associated with certain types of activity, as well
s drugs that affect cardiac repolarization, can convert a
ubclinical genetic abnormality to SCD. It is highly likely
hat additional genetic causes of SCD will be found in the
uture (56). mAmong the genetic factors, the most common are DNA
ariants called “polymorphisms” that may be present in a
arge proportion of the population and create susceptibility
or SCD. Single nucleotide polymorphisms (SNPs) are
NA variants that can be associated with a functional
onsequence. For example, a polymorphism identified in the
lpha 2b adrenergic receptor is associated with an increased
isk of MI and SCD (106). Studies such as these require
alidation before they enter clinical practice. Nevertheless,
ecause millions of SNPs are present in the DNA of each
ndividual, a specific combination of polymorphisms in
ifferent genes, interacting with a specific trigger or sub-
trate, may be required to create a risk for SCD (56).
.2. Mechanisms of Sudden Cardiac Death
he rhythm most often recorded at the time of sudden
ardiac arrest is VF. Previous studies suggest that 75% to
0% occur via this mechanism and 15% to 20% are
ttributed to bradyarrhythmias, including advanced atrio-
entricular (AV) block and asystole (107). Bayes de Luna et
l. (108) noted that in 157 ambulatory patients who had
CD while undergoing Holter recording, 62.4% had VF,
6.5% had bradyarrhythmias, 12.7% had torsades de
ointes, and 8.3% had primary VT. The true incidence of
radyarrhythmias is not clear because a rhythm beginning as
F may appear to be asystole when the first ECG is
ecorded. However, a study reported by Cobb et al. (37)
uggests that VF accounts for a smaller proportion of events
han previously thought. Advanced AV block or significant
radycardia can cause VF. It is difficult to identify accurately
he EP mechanism(s) responsible for SCD. The reason for
his is that the mechanisms may be multifactoral and are
uite likely to be different depending on the specific cardiac
bnormality and a rhythm can start via one mechanism and
e perpetuated via another. It is also important to remember
hat while many studies have investigated EP mechanisms
esponsible for the onset of VT and VF and their continu-
tion, no class I or III antiarrhythmic agent (109) has clearly
een demonstrated to reduce total and SCD mortality in
atients at risk for SCD (7a,109). In fact, it is the drugs
ithout direct EP actions on cardiac muscle or specialized
onducting tissue that have been shown effective for pre-
ention of SCD. These drugs include beta blockers, ACE
nhibitors, angiotensin receptor–blocking agents, lipid-
owering agents, spironolactone, and fibrinolytic and anti-
hrombotic agents; some data also suggest a protective effect
f n-3 fatty acids (110), although this remains to be
onfirmed (111) (see Section 6.4).
Because SCD is for the most part the result of a
entricular tachyarrhythmia, these drugs must be acting on
he fundamental biochemical, ischemic, fibrotic, or other
rocesses that underlie the onset or maintenance of the
ife-threatening ventricular arrhythmias. Thought of in this
ashion, VF can be considered a final common pathway for
he expression of an electrically unstable heart. The funda-
ental mechanisms of cardiac arrest include electromechan-
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinescal dissociation, asystole and heart block, and VF, with VF
eing the most common. It is the “upstream” events
riggering the electrical instability upon which these drugs
robably act. While we unquestionably need to pursue
nvestigations into the electrophysiology of these ventricular
achyarrhythmias, more study needs to be applied to the
rugs affecting upstream events, because these events appear
o yield the greatest dividends, at least for the present, and
ust be the reason why the asymptomatic, apparently
table, individual suddenly develops SCD at a particular
ime on a particular day. It must be that a dynamic factor or
actors, possibly transient, interact with a fixed substrate to
recipitate the arrhythmia. The possibilities fill a long list
nd include such things as physical activity, transient ischemia,
H and electrolyte changes, inflammation, hypoxia, stretch,
on channel abnormalities, neuroendocrine actions, drugs,
nd so forth, all of which are capable of modulating
onduction in ways we mostly do not understand. More
ermanent changes could also occur, such as plaque rupture,
s mentioned earlier (112).
. CLINICAL PRESENTATIONS
F PATIENTS WITH VENTRICULAR
RRHYTHMIAS AND SUDDEN CARDIAC DEATH
entricular arrhythmias can occur in individuals with or
ithout a cardiac disorder. There is a great deal of overlap
etween clinical presentations (Table 5) and the severity and
ype of heart disease. For example, stable and well-tolerated
T can occur in the individual with previous MI and
mpaired ventricular function. The prognosis and manage-
ent are individualized according to symptom burden and
everity of underlying heart disease, in addition to the
linical presentation.
.1. Asymptomatic
entricular arrhythmias may be detected as an incidental
nding during ECG monitoring or physical examination.
hey may also be uncovered during an attempt to further
efine prognosis in an individual with known heart disease.
able 5. Clinical Presentations of Patients With Ventricular
rrhythmias and Sudden Cardiac Death
Asymptomatic individuals with or without electrocardiographic
abnormalities
Persons with symptoms potentially attributable to ventricular
arrhythmias
Œ Palpitations
Œ Dyspnea
Œ Chest pain
Œ Syncope and presyncope
Ventricular tachycardia that is hemodynamically stable
Ventricular tachycardia that is not hemodynamically stable
Cardiac arrest
Œ Asystolic (sinus arrest, atrioventricular block)
Œ Ventricular tachycardia
Œ Ventricular fibrillationaŒ Pulseless electrical activityn general, treatment is indicated to prevent potential
orbidity (e.g., “tachycardia-induced cardiomyopathy”), re-
uce symptom burden, or reduce the risk of SCD. There is
o reason to treat asymptomatic ventricular arrhythmias in
he absence of such potential benefit. The major determi-
ants of risk of SCD are related more to the type and
everity of associated cardiac disease and less to the fre-
uency or classification of ventricular arrhythmia (44,113).
ertain arrhythmias such as rapid polymorphic VT may be
ompelling to treat even in the asymptomatic individual
ithout evident heart disease. Nonetheless, such arrhyth-
ias are rarely asymptomatic and are probably related to
onic channel abnormalities yet to be elucidated (114,115).
SVT in the patient with previous MI and impaired LV
unction indicates increased risk of SCD and the need for
urther evaluation or treatment (116). The contribution of
symptomatic ventricular arrhythmias to the patient’s man-
gement is not well established for other cardiac diseases
uch as DCM (117) or HCM (118).
.2. Symptoms Potentially
elated to Ventricular Arrhythmias
alpitations or a perception of cardiac rhythm irregularity
ay be caused by the whole spectrum of arrhythmias and
re also frequently reported in patients in the absence of any
rrhythmia (119). Less frequently, patients with VT may
resent with symptoms of paroxysmal dyspnea or chest pain
n the absence of a sensation of rapid heart beating. In such
nstances, the dyspnea or chest pain may be related to the
emodynamic consequences of tachycardia. “Presyncope” is
vague term that is poorly defined but probably is inter-
reted by most as a feeling of impending syncope (120). It
s not specific as a symptom. VT may be a cause of
ndiagnosed syncope, especially in patients with structural
eart disease (121). Patients with poor ventricular function
nd inducible VT or VF have a high incidence of subse-
uent appropriate therapies when implanted with an ICD
122–128). Similar patients with poor ventricular function
ay be at risk of SCD (129). Patients with sudden onset of
ery rapid VT such as torsades de pointes with the repolar-
zation syndromes will typically present with syncope or
eizure rather than an awareness of rapid heart beating or
alpitations (130).
.2.1. Hemodynamically Stable Ventricular Tachycardia
atients with slower, stable VT may be asymptomatic but
ore frequently present with a sensation of rapid heart
eating possibly accompanied by dyspnea or chest discom-
ort. The stability or tolerance of VT is related to the rate of
achycardia, presence of retrograde conduction, ventricular
unction, and the integrity of peripheral compensatory
echanisms. A presentation with stable, relatively well-
olerated VT does not suggest the absence of heart disease
nd can be observed in patients with very poor LV function.
ven patients with poor ventricular function may not beware of palpitations during VT. Presentation with stable
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346T does not in itself indicate a benign prognosis in patients
ith significant heart disease (131). Incessant VT, although
emodynamically stable, can be a cause of hemodynamic
eterioration leading to HF (132). In patients with an ICD,
he VT rate can fall below the lower rate of VT detection,
ausing underdetection of VT that can prevent arrhythmia
ermination. Immediate reinitiation of the VT following
roper ICD therapy can also result in hemodynamic dete-
ioration and an early battery depletion (132,133).
.2.2. Hemodynamically
nstable Ventricular Tachycardia
he term “hemodynamically unstable” has not been rigidly
efined but is widely used. It connotes a tachycardia
ssociated with hypotension and poor tissue perfusion that
s considered to have the imminent potential to lead to
ardiac arrest or shock if left untreated. Hemodynamically
nstable VT is usually, but not exclusively, observed in
atients with poor ventricular function. Patients with
ormal ventricular function can have unstable VT or VF
f the tachycardia is rapid enough, as in the LQTS and
ther abnormal repolarization syndromes (103). Some
atients with a normal heart and idiopathic monomor-
hic VT or even supraventricular tachycardia (SVT) can
ecome hypotensive during the arrhythmia because of a
asovagal reaction.
.3. Sudden Cardiac Arrest
apid sustained VT or VF results in presentation with
arkedly impaired tissue perfusion and loss of conscious-
ess as a result of inadequate cardiac output, leading to
CD if not expediently reversed. Sudden cardiac arrest may
e the presenting symptom with any cardiac disease or even
n individuals with no apparent heart disease (44). The
nitiating mechanism of sudden cardiac arrest may or may
ot be related to arrhythmia.
. GENERAL EVALUATION
F PATIENTS WITH DOCUMENTED
R SUSPECTED VENTRICULAR ARRHYTHMIAS
.1. History and Physical Examination
alpitations, presyncope, and syncope are the 3 most im-
ortant symptoms requiring further characterization in pa-
ients suspected of having ventricular arrhythmias. Palpita-
ions are usually of a sudden onset/offset pattern and may be
ssociated with presyncope and/or syncope. Sudden epi-
odes of collapse with loss of consciousness without any
remonition that usually last for a few seconds must raise
he suspicion of conduction defects or ventricular arrhyth-
ias. Other symptoms related to underlying structural heart
isease may also be present, especially chest discomfort,
yspnea, and fatigue. A thorough drug history including
osages used must be included in the evaluation of patients
uspected of having ventricular arrhythmias. Two important
tudies (57,58) have confirmed that a positive family history of SCD is a strong independent predictor of susceptibility to
entricular arrhythmias and SCD, as noted earlier. Physical
xamination is often unrevealing in patients suspected of
aving ventricular arrhythmias unless the arrhythmia occurs
hile the patient is being examined or has other findings
ndicative of structural heart disease.
.2. Noninvasive Evaluation
.2.1. Resting Electrocardiogram
ecommendations
lass I
Resting 12-lead ECG is indicated in all patients who
are evaluated for ventricular arrhythmias. (Level of
Evidence: A)
A standard resting 12-lead ECG allows not only identi-
cation of various congenital abnormalities associated with
entricular arrhythmias and SCD (e.g., LQTS, SQTS,
rugada syndrome, ARVC) but also identification of vari-
us other ECG parameters, such as those due to electrolyte
isturbances, or evidence suggesting underlying structural
isease, such as bundle-branch block, AV block, ventricular
ypertrophy, and Q waves indicative of ischemic heart
isease or infiltrative cardiomyopathy. QRS duration and
epolarization abnormalities are both independent predic-
ors of SCD. A prolonged QRS duration greater than 120
o 130 ms has been shown in a number of studies to be
ssociated with increased mortality in patients with a
educed LVEF (equal to or less than 30%). Prospective
tudies have also reported an association between ST-
egment depression or T-wave abnormalities and increased
isk of cardiovascular death and SCD in particular. These
tudies have demonstrated a risk ratio for cardiovascular
eath of 2.16 (95% confidence interval [CI] 1.30 to 3.58) to
.4 (95% CI 1.70 to 3.53) in the presence of an “ischemic”
CG (134) and 4.4 (95% CI 2.6 to 7.4) for SCD in the
resence of an abnormal T-wave axis (135,136). A pro-
onged QTc interval is also an independent predictor of
CD. QTc greater than 420 ms has been shown to have a
igher risk of cardiovascular death relative to a shorter QTc.
nd a QTc greater than 440 ms significantly predicted
ardiovascular death with adjusted relative risk of 2.1 (137).
lthough a prolonged QTc interval predicts SCD, it is
orth noting that some data suggest that the correlation
etween QTc and survival may be “J-shaped.” In other
ords, relatively short QTc intervals have also been associ-
ted with increased risk. For instance, it has been reported
hat patients with a mean QTc shorter than 400 ms during
4-h ECG have a more than 2-fold risk of dying suddenly
han do patients with a mean QTc between 400 and 440 ms
fter a 2-y follow-up (138). A QTc less than 300 ms is often
sed to define the SQTS, which is an independent predictor
f SCD (139,140).
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ecommendations
lass I
. Exercise testing is recommended in adult patients
with ventricular arrhythmias who have an intermedi-
ate or greater probability of having CHD by age,
gender, and symptoms* to provoke ischemic changes
or ventricular arrhythmias. (Level of Evidence: B) *See
Table 4 in the ACC/AHA 2002 Guideline Update for
Exercise Testing (141) for further explanation of CHD
probability.
. Exercise testing, regardless of age, is useful in pa-
tients with known or suspected exercise-induced ven-
tricular arrhythmias, including catecholaminergic
VT, to provoke the arrhythmia, achieve a diagnosis,
and determine the patient’s response to tachycardia.
(Level of Evidence: B)
lass IIa
Exercise testing can be useful in evaluating response
to medical or ablation therapy in patients with known
exercise-induced ventricular arrhythmias. (Level of
Evidence: B)
lass IIb
. Exercise testing may be useful in patients with ven-
tricular arrhythmias and a low probability of CHD by
age, gender, and symptoms.* (Level of Evidence: C)
*See Table 4 in the ACC/AHA 2002 Guideline Update
for Exercise Testing (141) for further explanation of
CHD probability.
. Exercise testing may be useful in the investigation of
isolated premature ventricular complexes (PVCs) in
middle-aged or older patients without other evidence
of CHD. (Level of Evidence: C)
lass III
See Table 1 in the ACC/AHA 2002 Guideline Up-
date for Exercise Testing (141) for contraindications.
(Level of Evidence: B)
Exercise-ECG is commonly used in the evaluation of
atients with ventricular arrhythmias. Its most common
pplication is for detection of silent ischemia in patients
uspected of having underlying CHD (141). In patients
ith known or silent CHD or cardiomyopathies, the
resence of frequent PVCs during or after exercise has been
ssociated with greater risk for serious cardiovascular events
ut not specifically SCD (19,20,24). Exercise-induced
VCs in apparently normal individuals should not be used
o dictate therapy unless associated with documented isch-
mia or sustained VT. With the exception of beta blockers,
t the present time the use of antiarrhythmic drugs to rbolish exercise-induced PVCs has not been proved to be
ffective in reducing SCD.
Exercise testing in adrenergic-dependent rhythm distur-
ances, including monomorphic VT and polymorphic VT,
ay be useful in evaluating symptomatic subjects and
valuating response to therapy. Ambulatory ECG or event
onitoring may fail to capture the arrhythmia, particularly
f the patient is relatively sedentary. Moreover, exercise
esting may provide prognostic information in these pa-
ients, given that the presence of exercise-induced ventric-
lar ectopy increases mortality at 12 mo by 3-fold relative to
atients with ectopy at rest only (142). Patients with
xercise-induced paired ventricular complexes or VT have a
ower survival rate than those with exercise-induced simple
entricular ectopy (143).
Although the safety of supervised exercise testing is well
stablished, less data are available in patients at risk for
erious ventricular arrhythmias. In one series, exercise test-
ng in patients with life-threatening ventricular arrhythmias
as associated with a 2.3% incidence of arrhythmias requir-
ng cardioversion, intravenous drugs, or resuscitation (144).
uch an exercise study may still be warranted because it is
etter to expose arrhythmias and risk under controlled
ircumstances. Exercise testing should be performed where
esuscitation equipment and trained personnel are immedi-
tely available.
.2.3. Ambulatory Electrocardiography
ecommendations
lass I
. Ambulatory ECG is indicated when there is a need to
clarify the diagnosis by detecting arrhythmias, QT-
interval changes, T-wave alternans (TWA), or ST
changes, to evaluate risk, or to judge therapy. (Level
of Evidence: A)
. Event monitors are indicated when symptoms are
sporadic to establish whether or not they are caused
by transient arrhythmias. (Level of Evidence: B)
. Implantable recorders are useful in patients with
sporadic symptoms suspected to be related to ar-
rhythmias such as syncope when a symptom-rhythm
correlation cannot be established by conventional
diagnostic techniques. (Level of Evidence: B)
The use of continuous or intermittent ambulatory record-
ng techniques can be very helpful in diagnosing a suspected
rrhythmia, establishing its frequency, and relating symptoms
o the presence of the arrhythmia. Silent myocardial ischemic
pisodes may also be detected. A 24- to 48-h continuous
olter recording is appropriate whenever the arrhythmia is
nown or suspected to occur at least once a day. For sporadic
pisodes producing palpitations, dizziness, or syncope, conven-
ional event monitors are more appropriate because they can
ecord over extended periods of time (145).
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hythm and can record on patient activation or automati-
ally for prespecified criteria. Although these devices require
urgical implantation, they have been shown to be extremely
seful in diagnosing serious tachyarrhythmias and brady-
rrhythmias in patients with life-threatening symptoms
uch as syncope (120,146).
.2.4. Electrocardiographic Techniques
nd Measurements
ecommendations
lass IIa
It is reasonable to use TWA to improve the diagnosis
and risk stratification of patients with ventricular
arrhythmias or who are at risk for developing life-
threatening ventricular arrhythmias. (Level of Evi-
dence: A)
lass IIb
ECG techniques such as signal-averaged ECG
(SAECG), heart rate variability (HRV), baroflex sen-
sitivity, and heart rate turbulence may be useful to
improve the diagnosis and risk stratification of pa-
tients with ventricular arrhythmias or who are at risk
of developing life-threatening ventricular arrhyth-
mias. (Level of Evidence: B)
ICD trials, especially Multicenter Automatic Defibrilla-
or Implantation Trial (MADIT) II, have highlighted the
eed to develop novel tools in order to identify patients at
ighest risk of ventricular arrhythmias and SCD. Numerous
odalities exist at present for assessing this risk but only 2
re currently approved by the U.S. Food and Drug Admin-
stration (FDA): SAECG and TWA. However, HRV and
aroflex sensitivity also show considerable promise.
AECG improves the signal-to-noise ratio of a surface
CG, permitting the identification of low-amplitude (mi-
rovolt level) signals at the end of the QRS complex referred
o as “late potentials.” Late potentials indicate regions of
bnormal myocardium demonstrating slow conduction, a
ubstrate abnormality that may allow for reentrant ventric-
lar arrhythmias, and they are believed to serve as a marker
or the presence of an EP substrate for reentrant ventricular
achyarrhythmias. The presence of an abnormal SAECG
as shown to increase the risk of arrhythmic events by 6- to
-fold in a post-MI setting (147). However, the restoration
f patency to the infarct-related coronary artery with fibri-
olysis or angioplasty and the widespread use of surgical
evascularization have modified the arrhythmogenic sub-
trate, leading to a noticeable reduction in the predictive
ower of this tool. SAECG in isolation, therefore, is no
onger useful for the identification of post-MI patients at
isk of ventricular arrhythmias. However, a high negative
redictive value of 89% to 99% rendered the SAECG aseful tool with which to exclude a wide-complex tachycar-
ia as a cause of unexplained syncope (148,149).
TWA, which is a fluctuation in the amplitude or mor-
hology of the T wave that alternates every other beat
ssessed during exercise testing or atrial pacing, has been
hown to be an effective tool for identifying high-risk
atients post-MI (150) and in the presence of ischemic or
onischemic cardiomyopathy. This association appears to
e independent of EF and equally strong in patients with
schemic and nonischemic cardiomyopathy. TWA appears
o have a very high negative predictive accuracy (151–153).
WA may also be used to identify risk of arrhythmic
ortality in patients with LV dysfunction due to prior MI
154). In a small study of patients with MADIT II
haracteristics (post-MI with EF less than or equal to 30%),
microvolt TWA test was found to be better than QRS
uration at identifying a high-risk group and also a low-risk
roup unlikely to benefit from ICD therapy (155).
HRV, which is a beat-to-beat variation in cardiac cycle
ength resulting from autonomic influence on the sinus node
f patients in sinus rhythm, has been shown to indepen-
ently predict the risk of SCD and total mortality in
atients post-MI (156) both with and without impaired LV
unction (157–159). Observational studies also suggest its
sefulness in the presence of nonischemic cardiomyopathy,
ut this has to be confirmed with large clinical trials. There
re many different forms of heart rate analysis, some of
hich, such as heart rate turbulence, may be more produc-
ive than others. Reduced baroflex sensitivity, a quantitative
ssessment of the ability of the autonomic nervous system to
eact to acute stimulation involving primarily vagal reflexes,
ompared with a continuous assessment of basal sympatho-
agal information provided by HRV, has also proved suc-
essful in assessing the risk of SCD both alone (increased
nducibility of arrhythmic events including VT during EP
esting) (160,161) and when used in combination with
RV (increased risk of cardiac mortality post-MI) (157)
nd TWA (increased risk of arrhythmic events if both
arameters are abnormal in a cohort of patients with ICDs)
162). Additional prospective studies are needed to further
larify the role of these ECG parameters in assessing risk in
iffering clinical settings.
.2.5. Left Ventricular Function and Imaging
ecommendations
lass I
. Echocardiography is recommended in patients with
ventricular arrhythmias who are suspected of having
structural heart disease. (Level of Evidence: B)
. Echocardiography is recommended for the subset of
patients at high risk for the development of serious
ventricular arrhythmias or SCD, such as those with
dilated, hypertrophic, or RV cardiomyopathies, AMI
survivors, or relatives of patients with inherited dis-
orders associated with SCD. (Level of Evidence: B)
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelines. Exercise testing with an imaging modality (echocar-
diography or nuclear perfusion [single-photon emis-
sion computed tomography (SPECT)]) is recom-
mended to detect silent ischemia in patients with
ventricular arrhythmias who have an intermediate
probability of having CHD by age, symptoms, and
gender and in whom ECG assessment is less reliable
because of digoxin use, LVH, greater than 1-mm
ST-segment depression at rest, WPW syndrome, or
LBBB. (Level of Evidence: B)
. Pharmacological stress testing with an imaging modal-
ity (echocardiography or myocardial perfusion SPECT)
is recommended to detect silent ischemia in patients
with ventricular arrhythmias who have an intermediate
probability of having CHD by age, symptoms, and
gender and are physically unable to perform a symptom-
limited exercise test. (Level of Evidence: B)
lass IIa
. MRI, cardiac computed tomography (CT), or radio-
nuclide angiography can be useful in patients with
ventricular arrhythmias when echocardiography does
not provide accurate assessment of LV and RV
function and/or evaluation of structural changes.
(Level of Evidence: B)
. Coronary angiography can be useful in establishing
or excluding the presence of significant obstructive
CHD in patients with life-threatening ventricular
arrhythmias or in survivors of SCD, who have an
intermediate or greater probability of having CHD by
age, symptoms, and gender. (Level of Evidence: C)
. LF imaging can be useful in patients undergoing
biventricular pacing. (Level of Evidence: C)
.2.5.1. Echocardiograph
Echocardiography is the imaging technique that is most
ommonly used because it is inexpensive in comparison with
ther techniques such as MRI and cardiac CT, it is readily
vailable, and it provides accurate diagnosis of myocardial,
alvular, and congenital heart disorders associated with
entricular arrhythmias and SCD (163,164) (Table 6). In
ddition, LV systolic function and regional wall motion can
e evaluated and, in a majority of patients, EF can be
etermined (165). Echocardiography is therefore indicated
able 6. Conditions Associated With Ventricular Arrhythmias
hat Can Be Diagnosed With Echocardiography
Disease Entity Diagnostic Accuracy
ilated cardiomyopathy High
schemic cardiomyopathy High
ypertension with moderate to severe LVH High
ypertrophic cardiomyopathy High
alvular heart disease High
RVC Moderate
rugada syndrome Poorc
RVC  arrhythmogenic right ventricular cardiomyopathy; LVH  left ventricular
ypertrophy.n patients with ventricular arrhythmias suspected of having
tructural heart disease and in the subset of patients at high
isk for the development of serious ventricular arrhythmias
r SCD, such as those with dilated, hypertrophic or RV
ardiomyopathies, AMI survivors, or relatives of patients
ith inherited disorders associated with SCD. The combi-
ation of echocardiography with exercise or pharmacologi-
al stress (commonly known as “stress echo”) is applicable to
selected group of patients who are suspected of having
entricular arrhythmias triggered by ischemia and who are
nable to exercise or have resting ECG abnormalities that
imit the accuracy of ECG for ischemia detection (164).
nomalous origin of coronary arteries can be detected by
chocardiography or other imaging techniques.
.2.5.2. Cardiac Magnetic Resonance Imaging
Advances in cardiac MRI have made possible the use of
his imaging technique to evaluate both the structure and
unction of the beating heart. The excellent image resolu-
ion obtained with current techniques allows for the accu-
ate quantification of chamber volumes, LV mass, and
entricular function (166–168). This is of particular value to
atients with suspected arrhythmogenic RV cardiomyopa-
hy (ARVC), in whom MRI provides excellent assessment
f RV size, function, and regional wall motion and, impor-
antly, may allow the detection of fatty infiltration within
he RV myocardium (169,170). RV angiography may also
e useful. Cardiac MRI increasingly is being applied and
alidated for the detection of ischemia (adenosine stress per-
usion and dobutamine stress wall motion studies) and the
etection and quantification of infarction/fibrosis, a substrate
or VT. The cost and availability of cardiac MRI are becoming
ore competitive. Cardiac MRI can provide a comprehensive
ardiac evaluation in a single study. It is important to stress
hat, as with all imaging modalities, accurate interpretation
ffects its usefulness (171).
.2.5.3. Cardiac Computed Tomography
As with MRI, the field of CT has advanced greatly with
he development of fast scanners with better resolution that
llow tomographic imaging of the heart and coronary
rteries. These systems allow precise quantification of LV
olumes, EF, and LV mass with results comparable to MRI
ut in addition provide segmental images of the coronary
rteries from which the extent of calcification can be
uantified (172–176). The majority of cardiac disorders
ssociated with serious ventricular arrhythmias or SCD are
ssessed well with echocardiography. Cardiac CT can be
sed in selected patients in whom evaluation of cardiac
tructures is not feasible with echocardiography and MRI is
ot available. There is currently no incremental clinical
enefit derived from imaging the coronary arteries by
ardiac CT in patients with ventricular arrhythmias.
.2.5.4. Radionuclide Techniques
Myocardial perfusion SPECT using exercise or pharma-ological agents is applicable for a selected group of patients
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346ho are suspected of having ventricular arrhythmias trig-
ered by ischemia and who are unable to exercise or have
esting ECG abnormalities that limit the accuracy of ECG
or ischemia detection. Myocardial perfusion SPECT can
lso be used to assess viability in patients with LV dysfunc-
ion due to prior MI (177). Accurate quantification of
VEF is possible with gated radionuclide angiography
multiple gated acquisition scan) and thus this technique
ay be helpful in patients for whom this measurement is
ot available with echocardiography.
.2.5.5. Coronary Angiography
In patients with life-threatening ventricular arrhyth-
ias or in survivors of SCD, coronary angiography plays
n important diagnostic role in establishing or excluding
he presence of significant obstructive coronary artery
isease. It is common for these patients to undergo this
rocedure as part of their diagnostic evaluation, particu-
arly if they have an intermediate or greater probability
or CHD. Detailed recommendations regarding imaging
nd exercise testing can be found in the respective
uidelines (141,164,177).
.3. Electrophysiological Testing
P testing with intracardiac recording and electrical stim-
lation at baseline and with drugs has been used for
rrhythmia assessment and risk stratification for SCD. EP
esting for the evaluation of VT was introduced in 1972 by
ellens et al. (178). The sensitivity, specificity, and predic-
ive values of EP testing have been extensively assessed by
arious authors, usually in small patient groups. EP testing
s used to document the inducibility of VT, guide ablation,
valuate drug effects, assess the risks of recurrent VT or
CD, evaluate loss of consciousness in selected patients
ith arrhythmias suspected as a cause, and assess the
ndications for ICD therapy (121,179–183). The yield of
P testing varies fundamentally with the kind and severity
f the underlying heart disease, the presence or absence of
pontaneous VT, concomitant drug therapy, the stimulation
rotocol, and the site of stimulation. Highest induction
ates and reproducibility are observed in patients after MI
184–186).
To evaluate patients with ventricular arrhythmias, most
enters use 8 ventricular stimuli at drive cycle lengths
etween 600 and 400 ms at the RV apex, at twice diastolic
hreshold and the pulse duration of 0.5 to 2 ms, delivering
to 3 ventricular extrastimuli at baseline. This test may be
epeated during isoproterenol infusion (187–189). The pre-
aturity of extrastimuli is increased until refractoriness or
nduction of sustained ventricular tachyarrhythmia is
chieved. Long-short cycle sequences may be tested. Be-
ause premature ventricular stimulation with a very short
oupling interval is more likely to induce VF as opposed to
onomorphic VT, it may be reasonable to limit the
rematurity of the extrastimuli to a minimum of 180 ms
hen studying patients for whom only inducible sustained ronomorphic VT would be considered a positive endpoint
190). EP testing may be repeated at the RV outflow tract
RVOT) or LV (189). In some patients with rate-
ependent induction of VT, rapid atrial or ventricular
timulation may induce VT (191).
.3.1. Electrophysiological Testing
n Patients With Coronary Heart Disease
ecommendations
lass I
. EP testing is recommended for diagnostic evaluation
of patients with remote MI with symptoms suggestive
of ventricular tachyarrhythmias, including palpitations,
presyncope, and syncope. (Level of Evidence: B)
. EP testing is recommended in patients with CHD to
guide and assess the efficacy of VT ablation. (Level of
Evidence: B)
. EP testing is useful in patients with CHD for the
diagnostic evaluation of wide-QRS-complex tachy-
cardias of unclear mechanism. (Level of Evidence: C)
lass IIa
EP testing is reasonable for risk stratification in
patients with remote MI, NSVT, and LVEF equal to
or less than 40%. (Level of Evidence: B)
Drug testing for assessing antiarrhythmic drug efficacy
as largely been abandoned. EP testing was required in the
ADIT, Multicenter UnSustained Tachycardia Trial
MUSTT), and Beta-Blocker Strategy plus Implantable
ardioverter Defibrillator (BEST-ICD) trials and others,
ut not in the MADIT II, Sudden Cardiac Death in Heart
ailure (SCD-HeFT), or Antiarrhythmics Versus Implant-
ble Defibrillators (AVID) trials. Inducibility of VT in
atients with NSVT on Holter monitoring identified a
opulation at high risk for VT/VF and ICD use in the
ADIT trial (192).
In a MUSTT trial substudy, the ECG characteristics of
SVT (rate, duration, frequency, occurrence in-hospital vs.
ut-of-hospital) did not correlate with inducibility (193–
95). Survival was worse for in-hospital compared with
ut-of-hospital NSVT, (193) suggesting that different risk
tratification criteria may be necessary in asymptomatic
mbulatory patients. In a MADIT II substudy, inducibility
as 36%. Lower heart rate, lower EF, and a longer interval
etween MI and an EP study correlates with higher
nducibility (196).
In patients with CHD, asymptomatic NSVT, and an
F less than 40%, inducibility of sustained VT ranges
etween 20% and 40% (116). Inducibility conferred a
orse prognosis. Inducibility identifies patients at high
isk of subsequent VT and that the absence of inducibility
ndicated a low risk with MADIT-like patients (197).
owever, these patients had a high rate of percutaneous
evascularization. In CHD patients with a low EF (less
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelineshan 30%), noninducibility does not portend a good
rognosis (198). Persistent inducibility while receiving
ntiarrhythmic drugs predicts a worse prognosis (199).
atients in whom amiodarone suppressed VT inducibility
r slowed VT to a mean cycle length of greater than 400
s had 30% higher mortality compared with patients
ho did not respond to amiodarone and had an ICD
laced instead (200). EP-guided antiarrhythmic drug
ffectiveness in patients with NSVT who had induced
ustained VT conferred no benefit (195).
The prognostic value of inducible ventricular flutter and
F is still controversial. Limited data on the prognostic
alue of inducible ventricular flutter suggest that it may be
n important endpoint (201,202).
.3.2. Electrophysiological Testing
n Patients With Dilated Cardiomyopathy
n DCM, EP testing plays a minor role in the evaluation
nd management of VT. This is related to low inducibility,
eproducibility of EP study, and the predictive value of
nduced VT (203,204) (see Section 9.1).
.3.3. Electrophysiological Testing in Repolarization
nomalies Due to Genetic Arrhythmia Syndromes
.3.3.1. Long QT Syndrome
P testing has not proved useful in LQTS (103,205) (see
ection 11.1.1 for further discussion).
.3.3.2. Brugada Syndrome
The role of EP testing for risk stratification in Brugada
yndrome is debated (104,206–208), and it will probably
emain undefined until prospective data are obtained in
atients studied with a uniform protocol in a large popula-
ion with adequate follow-up (see Section 11.1.3 for further
iscussion).
.3.3.3. Hypertrophic Cardiomyopathy
The value of EP testing in HCM has been controversial
see Section 9.2 for further discussion).
.3.3.4. Arrhythmogenic Right Ventricular Cardiomyopathy
The arrhythmic manifestations of ARVC are variable
96). The prognostic role of EP testing in patients present-
ng with isolated PVCs or NSVT is not known. The
esponse to EP testing may be influenced by the severity of
he disease. Progression of disease has to be considered (see
ection 9.3 for further discussion).
.3.4. Electrophysiological Testing in Patients
ith Outflow Tract Ventricular Tachycardia
P testing for the evaluation of outflow tract VT is
asically similar to that for other VT entities. It is
otivated by the need to establish precise diagnosis to
uide curative catheter ablation (209,210) (see Section
2.1 for further discussion). s.3.5. Electrophysiological Testing in
atients With Syncope
ecommendations
lass I
EP testing is recommended in patients with syncope
of unknown cause with impaired LV function or
structural heart disease. (Level of Evidence: B)
lass IIa
EP testing can be useful in patients with syncope
when bradyarrhythmias or tachyarrhythmias are sus-
pected and in whom noninvasive diagnostic studies
are not conclusive. (Level of Evidence: B)
Syncope is a transient symptom that may be caused by an
nderlying rhythm disorder with or without an associated
ardiac disease. EP testing is used to document or exclude
he arrhythmic cause of syncope (120,211). It is most useful
n patients with CHD and LV dysfunction. EP testing is
sually not the first evaluation step but rather is comple-
entary to a full syncope work-up. Lack of correlation
etween symptoms and a documented arrhythmia elicited
uring EP testing may lead to overinterpretation or un-
erinterpretation of the predictive value of the results.
ransient drug effects that can provoke syncope may remain
ndetected. Other causes such as a neurological etiology
eed to be considered in some patients.
.3.5.1. Electrophysiological Testing When
radyarrhythmia Is Suspected
Syncope can be due to bradyarrhythmias from sinus node
ysfunction or AV block. Antiarrhythmic drugs, beta-
locking agents, cardiac glycosides, and calcium channel
lockers can induce symptomatic bradycardia. EP testing
an be used to document or provoke bradyarrhythmias or
V block when other investigations have failed to provide
onclusive information. The diagnostic yield varies greatly
ith the selected patient populations (212). EP testing is
ore useful in the presence of structural heart disease (213).
he diagnostic yield in the absence of structural heart
isease or abnormal ECG is low. False-positive results of
P testing can be present in up to 24% of the patients. In
yncopal patients with chronic BBB and reduced EF (less
han 45%), EP-induced VT is present in up to 42%
184,214,215). In patients with syncope and BBB, false-
egative EP studies are common (216,217). EP testing in
atients with sporadic bradycardia and syncope has limited
ensitivity, even when adding electropharmacological stress
uch as intravenous procainamide or atropine (218). EP
esting can provoke nonspecific tachyarrhythmic responses
n patients with preserved LV function who do not have
tructural heart disease (219).
5
S
t
m
(
r
a
i
c
c
d
5
V
p
H
h
(
E
w
p
4
m
e
s
I
p
p
6
6
T
v
m
n
n
m
t
r
2
d
a
a
6
W
a
c
p
t
a
a
s
a
w
d
m
s
v
o
o
v
c
(
s
t
g
p
b
d
v
o
t
m
s
6
6
U
d
t
c
i
a
r
s
h
s
l
m
d
a
a
6
t
a
H
a
m
m
a
t
p
e268 Zipes et al. JACC Vol. 48, No. 5, 2006
ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346.3.5.2. Electrophysiological Testing When
upraventricular Tachyarrhythmia Is Suspected
The role of EP testing is to document the type of
achyarrhythmia and to guide management of patients. In a
ixed population, the diagnostic yield of EP testing was 5%
220). In supraventricular tachyarrhythmias, syncope is
arely the only symptom and palpitations are usually present
s well. Vasodepressive reaction in a few patients with
nduced SVT, mainly AV node reentry (221), may be the
ause of syncope. Syncope did not correlate with the rate or
ycle length of preexcited R-R intervals in WPW syndrome
uring AF (221).
.3.5.3. Electrophysiological Testing When
entricular Tachycardia Is Suspected
Syncope in patients with structural heart disease and, in
articular, significant LV dysfunction is ominous. NSVT on
olter monitoring, syncope, and structural heart disease are
ighly sensitive for predicting the presence of inducible VT
184). Syncope associated with heart disease and reduced
F has high recurrence and death rates (222,223), even
hen EP testing results are negative. EP testing is useful in
atients with LV dysfunction due to prior MI (EF less than
0%) but not sensitive in patients with nonischemic cardio-
yopathy (184). Induction of polymorphic VT or VF,
specially with aggressive stimulation techniques, is not
pecific. In CHD, the diagnostic yield may reach 50% (222).
n HCM, EP testing is not diagnostic in the majority of
atients (224). Induction of nonspecific VTs in 23% of
atients with slightly reduced EF has been observed (225).
. THERAPIES FOR VENTRICULAR ARRHYTHMIAS
.1. General Management
he selection of appropriate therapy for the management of
entricular arrhythmias (PVCs, NSVT, sustained mono-
orphic and polymorphic VT, and ventricular flutter/VF)
ecessitates an understanding of the etiology and mecha-
ism of the arrhythmia, an appreciation of the associated
edical conditions that may contribute to and/or exacerbate
he arrhythmia, the risk posed by the arrhythmia, and
isk-to-benefit aspects of the selected therapy (31,99,226–
35). Management of the manifest arrhythmia may involve
iscontinuation of offending proarrhythmic drugs, specific
ntiarrhythmic therapy with drugs, implantable devices,
blation, and surgery.
.2. Drug Therapy
ith the exception of beta blockers, the currently available
ntiarrhythmic drugs have not been shown in randomized
linical trials to be effective in the primary management of
atients with life-threatening ventricular arrhythmias or in
he prevention of SCD. As a general rule, antiarrhythmic
gents may be effective as adjunctive therapy in the man-
gement of arrhythmia-prone patients under special circum-
tances. Because of potential adverse side effects of the dvailable antiarrhythmic drugs, these agents must be used
ith caution. This section provides general comments about
rug and interventional therapy for life-threatening arrhyth-
ias. The recommendations and level of evidence for
pecific therapy of ventricular arrhythmias that occur in
arious cardiac disease states are provided in other sections
f these guidelines, with the exception of recommendations
n ablation, which are located in Section 6.6.
Many marketed cardiac and noncardiac drugs prolong
entricular repolarization and have the potential to pre-
ipitate life-threatening ventricular tachyarrhythmias
202,236–239) (see Section 13.6). Some patients are more
usceptible than others to the QT-prolonging effects of
hese drugs even at an ordinary dosage, possibly due to a
enetic propensity or female gender. More commonly, the
roarrhythmic effect of the agent is related to elevated drug
lood levels as a result of excessive dosage, renal disease, or
rug interactions. Once it is appreciated that a patient’s
entricular arrhythmia may be due to QT prolongation from
ne or more prescribed medications, the possible offending
herapies should be discontinued and appropriate follow-up
onitoring of ventricular repolarization and cardiac rhythm
hould be carried out.
.3. Antiarrhythmic Drugs
.3.1. Value of Antiarrhythmic Drugs
ses of antiarrhythmic drugs in the acute setting are
escribed in Section 7.
The available antiarrhythmic drugs can be classified by
he Vaughan Williams 4-level schema (type I: fast sodium
hannel blockers, type II: beta blockers, type III: repolar-
zation potassium current blockers, type IV: calcium channel
ntagonists) (240) or by the more mechanistic and clinically
elevant Sicilian Gambit (241). The Vaughan Williams
chema is somewhat outdated because antiarrhythmic drugs
ave complex actions that do not easily fit into 1 of the 4
pecified classes of drug effects. This classification is of
imited usefulness when choosing an antiarrhythmic drug to
anage a specific arrhythmia. The Sicilian Gambit, intro-
uced in 1991, was an attempt to provide a classification of
ntiarrhythmic drugs based on their mechanism of action
nd on arrhythmogenic mechanisms.
.3.1.1. Beta Blockers
These drugs are effective in suppressing ventricular ec-
opic beats and arrhythmias as well as in reducing SCD in
spectrum of cardiac disorders in patients with and without
F. Beta blockers are safe and effective antiarrhythmic
gents that can be considered the mainstay of antiarrhyth-
ic drug therapy (242,243). The mechanism of antiarrhyth-
ic efficacy of this class of drugs involves competitive
drenergic-receptor blockade of sympathetically mediated
riggering mechanisms, slowing of the sinus rate, and
ossibly inhibition of excess calcium release by the ryano-
ine receptor (244).
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Amiodarone has a spectrum of actions that includes
lock of potassium repolarization currents that can in-
ibit or terminate ventricular arrhythmias by increasing
he wavelength for reentry. The overall long-term sur-
ival benefit from amiodarone is controversial, with most
tudies showing no clear advantage over placebo. A few
tudies and one meta-analysis of several large studies have
hown reduction in SCD using amiodarone for LV
ysfunction due to prior MI and nonischemic DCM
245–247), but the SCD-HeFT trial showed no survival
enefit from amiodarone compared with placebo
7a,248). Chronic administration of amiodarone is asso-
iated with complex drug interactions and a host of
dverse side effects involving the lung, liver, thyroid, and
kin. As a general rule, the longer the therapy and the
igher dose of amiodarone, the greater is the likelihood
hat adverse side effects will require discontinuance of the
rug. Sotalol, like amiodarone, is effective in suppressing
entricular arrhythmias, but it has greater proarrhythmic
ffects and has not been shown to provide a clear increase
n survival; worsening ventricular arrhythmias occur in
% to 4% of treated patients (249).
.3.1.3. Efficacy of Antiarrhythmic Drugs
Overall, the available antiarrhythmic drugs other than
eta blockers should not be used as primary therapy in the
anagement of ventricular arrhythmias and the preven-
ion of SCD. The efficacy of non– beta-blocker antiar-
hythmic drugs is equivocal at best, and each drug has
ignificant potential for adverse events including
roarrhythmia.
.3.2. Special Considerations Where
ntiarrhythmic Drugs May Be Indicated
miodarone therapy may be considered in special situa-
ions (109); secondary subset analyses indicate possible
urvival benefit when amiodarone is combined with beta
lockers (250,251). However, the SCD-HeFT study
howed no benefit in patients with NYHA functional
lass II HF and potential harm in patients with NYHA
unctional class III HF and EF equal to or less than
5% (8). Azimilide was shown to decrease the risk of
ppropriate and inappropriate shocks in patients with
CDs (252). Both sotalol and amiodarone have also been
hown to reduce the frequency of ICD shock therapy
253,254).
.3.2.1. Patients With Ventricular
achyarrhythmias Who Do Not Meet Criteria
or an Implantable Cardioverter-Defibrillator
Beta blockers are the first-line therapy, but if this therapy
t full therapeutic dose is not effective, then amiodarone or
otalol can be tried with monitoring for adverse effects
uring administration. p.3.2.2. Patients With Implantable Cardioverter-Defibrillators
ho Have Recurrent Ventricular Tachycardia/Ventricular
ibrillation With Frequent Appropriate Implantable
ardioverter-Defibrillator Firing
This scenario, in its extreme, has been called defibrillator
tachycardia) storm, and it requires the addition of antiar-
hythmic drugs and/or catheter ablation for control of the
ecurrent VT and associated ICD shocks. Sotalol is effective
n suppressing atrial and ventricular arrhythmias (253); the
ombination of beta blockers and amiodarone is an alterna-
ive approach. Because many such patients have low EF and
oor renal function, amiodarone and beta blockers rather
han sotalol can be the first-line therapy for defibrillator
torm. Sotalol should be avoided in patients with severely
epressed LV function or significant HF. Animal studies
255,256) and a case report showed the benefits of neural
odulation via spinal cord approaches (257). Intravenous
miodarone has been useful.
.3.2.3. Patients With Implantable
ardioverter-Defibrillators Who Have Paroxysmal
r Chronic Atrial Fibrillation With Rapid Rates and
nappropriate Implantable Cardioverter-Defibrillator Firing
Control of the rapid ventricular response to atrial tachy-
rrhythmias is essential, and combination therapy with a
eta blocker and/or a calcium channel blocker is useful.
miodarone has been used off-label for rate control if other
herapies are contraindicated, not tolerated, or ineffective.
blation of the AV node may be required when pharma-
ological therapy is not effective.
.4. Nonantiarrhythmic Drugs
se of nonantiarrhythmic drugs in the acute setting is
urther discussed in Section 7.
.4.1. Electrolytes
dministration of potassium and magnesium, either as
ntravenously in the acute setting or orally for chronic
ugmentation in the blood levels of these electrolytes, can
avorably influence the EP substrate involved in ventricular
rrhythmias. These drugs are especially useful in the pres-
nce of hypokalemia and hypomagnesemia and should be
onsidered as adjunctive therapies in the absence of low-
evel electrolytes. Adverse remodeling occurs in the ventricle
ollowing MI or in association with nonischemic cardiomy-
pathy; these structural changes with secondary ion channel
lterations can exacerbate the potential for ventricular ar-
hythmias. Several drugs, such as ACE inhibitors, angio-
ensin II receptor antagonists, and aldosterone blockade
ith spironolactone or eplerenone, improve the myocardial
ubstrate through reverse remodeling, and these therapies
ave been associated with a reduction in SCD as well as
on-SCD (110,258). It is important to remember that
lectrolyte disturbances are common in patients with HF,
articularly those using high doses of loop diuretics.
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n a retrospective analysis of more than 6700 patients
articipating in the Studies Of Left Ventricular Dysfunc-
ion (SOLVD) prevention and treatment trials, antithrom-
in therapy was associated with reduction in SCD (259).
ntiplatelet therapy that included aspirin and anticoagulant
herapy contributed to this reduction in SCD, possibly as a
esult of reducing the frequency of coronary thrombotic
cclusions in this high-risk group of patients.
.4.3. n-3 Fatty Acids and Lipids
ncreasing experimental and clinical evidence suggests that
-3 fatty acids are antiarrhythmic (260) and may prevent
CD in humans (261). However, data are conflicting. In a
andomized trial in patients with a recent episode of
ustained ventricular arrhythmia and an ICD, fish oil
upplementation did not reduce the risk of VT/VF and
erhaps was proarrhythmic in some patients (262). How-
ver, a second similar study found a trend toward prolon-
ation of the first VT/VF event or death from any cause
p  0.057) and significant risk reduction when all probable
T/VF events were included (262,263).
Findings indicate that statins reduce the occurrence of
ife-threatening ventricular arrhythmias in high-risk cardiac
atients with electrical instability (264). Both of these
herapies suggest that the mechanism of the antiarrhythmic
ffects may be related to EP stabilization of the bilipid
yocyte membrane involved in maintaining electrolyte
radients.
igure 2. Major implantable cardioverter-defibrillator (ICD) trials. Hazar
rom any cause in the ICD group compared with the non-ICD group. *In
ames, see Appendix 3. CABG  coronary artery bypass graft surgery; Eeft ventricular ejection fraction; MI  myocardial infarction; N  number of p
entricular tachycardia; PVCs  premature ventricular complexes; SAECG .5. Implantable and External Cardioverter Devices
.5.1. Implantable Cardioverter-Defibrillator
everal prospective multicenter clinical trials have docu-
ented improved survival with ICD therapy in high-risk
atients with LV dysfunction due to prior MI and nonische-
ic cardiomyopathy (8,192,265–270) (Fig. 2). ICD therapy,
ompared with conventional or traditional antiarrhythmic
rug therapy, has been associated with mortality reductions
rom 23% to 55% depending on the risk group participating
n the trial, with the improvement in survival due almost
xclusively to a reduction in SCD. The trials may be
ubcategorized into 2 types: primary prevention (prophylac-
ic) trials in which the subjects have not experienced a
ife-threatening ventricular arrhythmia or a symptomatic
quivalent and secondary prevention trials involving subjects
ho have had an abortive cardiac arrest, a life-threatening
T, or unexplained syncope with work-up suggesting a high
robability that a ventricular tachyarrhythmia was the cause
f the syncope.
Important ICD advancements continue to occur in the
ransvenous implantation procedure, generator size reduc-
ion, system longevity, arrhythmia detection, and multipro-
rammable features. However, it is important to remember
hat device failure, although rare, can occur. Current ICDs
nclude options for single-chamber, dual-chamber, and
iventricular cardiac resynchronization pacing for nonshock
ermination of ventricular arrhythmia in addition to multi-
evel shock discharge for VT or VF. Problems associated
ith ICD therapy include inappropriate shock discharge
os (vertical line) and 95% confidence intervals (horizontal lines) for death
s only ICD and amiodarone patients from CASH. For expansion of trial
electrophysiological study; LVD  left ventricular dysfunction; LVEF d rati
clude
P atients; NICM  nonischemic cardiomyopathy; NSVT  nonsustained
signal-averaged electrocardiogram.
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesostly for AF with rapid ventricular response, defibrillator
torm with appropriate recurrent ICD discharge for recur-
ent ventricular tachyarrhythmias or inappropriate discharge
or a multiplicity of reasons, infections related to device
mplantation, and exacerbation of HF when a high percent-
ge of the heartbeats are paced from the RV apex, especially
hen ventricular function is already compromised. It is
robably advisable to limit RV pacing to a minimum for any
iven patient. Possible solutions include the selection of an
ppropriately low minimum rate and an appropriately long
V interval. Avoidance of overly aggressive rate acceleration
n rate-modulated modes and, in some recent pacemaker
odels, the use of an automatic pacing mode selecting
lgorithms that strongly favor atrial over ventricular pacing
271). The HF is likely to occur in the setting of advanced
V dysfunction with the ICD unit programmed to dual-
hamber (DDD) pacing at heart rates that dominate the
hythm, thus contributing to paced ventricular desynchro-
ization.
The ACC/AHA/NASPE 2002 Guidelines Update for
mplantation of Cardiac Pacemakers and Antiarrhythmia
evices, the ACC/AHA 2004 Guidelines for Management
f Patients With ST-Elevation Myocardial Infarction, the
SC 2001 and 2003 Guidelines on Prevention of SCD, the
SC Guidelines for the Diagnosis and Treatment of
hronic Heart Failure, and the ACC/AHA 2005 Guide-
ine Update for the Diagnosis and Management of Chronic
eart Failure in the Adult include a large number of
ecommendations on ICD therapy which merit attention
1–6). Details and background references are provided in
he full-text guidelines, which are on the ACC, AHA, HRS
formerly known as NASPE), and ESC Websites. The
ndings from the SCD-HeFT trial provide additional
vidence that the ICD is effective in high-risk cardiac
atients with ischemic and nonischemic cardiomyopathy
8). Differences in the recommendations in these guidelines
rom those previously published reflect primarily data from
ew studies. Detailed discussion on the considerations for
herapy recommendations is found in the Introduction.
owever, there are inconsistencies among guidelines re-
arding the EF cutoff used in the recommendations.
.5.2. Automated External Defibrillator
he automated external defibrillator (AED) saves lives
hen external defibrillation can be rendered within minutes
f onset of VF. The AED represents an efficient method of
elivering defibrillation to persons experiencing out-of-
ospital cardiac arrest, and its use by both traditional and
ontraditional first responders appears to be safe and effec-
ive (272,273). Appropriate device location to reduce time
elay after onset of cardiac arrest is critical. Federal, state,
nd community efforts have been effective in placing AEDs
n schools, sporting events, high-density residential sites,
nd airports as well as on airplanes and in police and fire
epartment vehicles (274–277). Approximately 80% of
ardiac arrests occur in the home, and placement of AEDsn the home appears to be reasonable and appropriate for
atients at high risk for life-threatening arrhythmias. Fed-
ral regulatory authorities in the United States have ap-
roved the AED for home use in families with high-risk
nherited arrhythmias such as the LQTS and HCM. The
DA has now approved over-the-counter sales of AEDs.
.5.3. Wearable Automatic Defibrillator
he wearable automatic defibrillator is a vestlike device
orn under the clothing that continuously monitors heart
hythm and automatically delivers an electric shock when
F is detected. This device is worn continuously on a
4-h-a-day basis, except when the wearer is bathing or
howering. The wearable automatic defibrillator has been
pproved in the United States by the FDA for cardiac
atients with a transient high risk for VF such as those
waiting cardiac transplantation, those at very high risk after
recent MI or an invasive cardiac procedure, or those
equiring temporary removal of an infected implanted defi-
rillator for antibiotic therapy.
.6. Ablation
ecommendations
lass I
. Ablation is indicated in patients who are otherwise at
low risk for SCD and have sustained predominantly
monomorphic VT that is drug resistant, who are drug
intolerant, or who do not wish long-term drug ther-
apy. (Level of Evidence: C)
. Ablation is indicated in patients with bundle-branch
reentrant VT. (Level of Evidence: C)
. Ablation is indicated as adjunctive therapy in patients
with an ICD who are receiving multiple shocks as a
result of sustained VT that is not manageable by
reprogramming or changing drug therapy or who do
not wish long-term drug therapy (206,278). (Level of
Evidence: C)
. Ablation is indicated in patients with WPW syn-
drome resuscitated from sudden cardiac arrest due to
AF and rapid conduction over the accessory pathway
causing VF (279). (Level of Evidence: B)
lass IIa
. Ablation can be useful therapy in patients who are
otherwise at low risk for SCD and have symptomatic
nonsustained monomorphic VT that is drug resis-
tant, who are drug intolerant or who do not wish
long-term drug therapy. (Level of Evidence: C)
. Ablation can be useful therapy in patients who are
otherwise at low risk for SCD and have frequent
symptomatic predominantly monomorphic PVCs
that are drug resistant or who are drug intolerant or
who do not wish long-term drug therapy. (Level of
Evidence: C)
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WPW syndrome who have accessory pathways with
refractory periods less than 240 ms in duration (279).
(Level of Evidence: B)
lass IIb
. Ablation of Purkinje fiber potentials may be consid-
ered in patients with ventricular arrhythmia storm
consistently provoked by PVCs of similar morphol-
ogy (280). (Level of Evidence: C)
. Ablation of asymptomatic PVCs may be considered
when the PVCs are very frequent to avoid or treat
tachycardia-induced cardiomyopathy (281). (Level of
Evidence: C)
lass III
Ablation of asymptomatic relatively infrequent PVCs
is not indicated. (Level of Evidence: C)
.6.1. Catheter Ablation—Background
he specific application of radiofrequency (RF) ablation to
T has evolved as the technology has developed. RF
blation can be applied in the treatment of VT in patients
ith LV dysfunction due to prior MI, cardiomyopathy,
undle-branch reentry, and various forms of idiopathic VT
282–294).
.6.2. No Apparent Structural Heart Disease
pecific mapping and ablation techniques that are used
iffer depending on the type of VT. While patients with no
vert structural heart disease account for a small percentage
f patients with VT, they are of particular interest for
blation therapy as this technique may be curative
295,296). These typically present as a single VT arising
rom the RV with an LBBB inferior axis morphology or
rom the LV with a right bundle-branch block (RBBB)
orphology and, in general, are associated with a good
rognosis (289,297–300).
.6.3. Bundle-Branch Reentrant VT
undle-branch reentrant VT is often associated with car-
iomyopathy (279). RF catheter ablation of the bundle
ranches is curative of the arrhythmia but not of the
nderlying structural abnormality (301). Because of the
everity of underlying heart disease and the high prevalence
f conduction abnormalities, adjunct device therapy should
e strongly considered in these patients (301).
.6.4. Structural Heart Disease
T is a common complication of structural heart disease
nd carries significant risk for mortality in CHD patients
ith low EF. In those with extensive structural abnor-
alities, especially those with prior MI, multiple mor-
hologies of VT are often present. As a result, ablation of
single VT morphology can provide palliation but not Aliminate the need for device or antiarrhythmic therapy.
n these patients, VT can originate in, or involve,
xtensive areas of the myocardium and standard RF
elivery carries a relatively low success rate (302–304).
iven the inhomogeneous scarring present in ischemic
T, mapping techniques have evolved that take into
ccount the complex nature of the circuits, including
ystander regions of abnormal conduction. The newer
-dimensional mapping systems permit anatomical re-
onstructions and correlation of EP characteristics with
natomy (190,305–308). These systems have led to an
pproach whereby circuits can be mapped during sinus
hythm and can facilitate ablation in the ischemic patient
ho often does not tolerate VT well (303,309 –312). Use
f these techniques may result in better long-term success
ates (313).
.6.5. Additional Ablation Tools
epending on the arrhythmic substrate, VT circuits can be
lose to the endocardium or exist deeper within the myo-
ardium. The focal lesion of traditional RF delivery systems
ay not create lesions deep enough to penetrate intramyo-
ardial circuits. As a result, saline-irrigated cooled-tip cath-
ters have been developed and used in VT ablation. Cooling
he tip of the catheter permits deeper tissue heating.
reliminary results are promising, but further data are
eeded (314). Another novel technique involves transtho-
acic pericardial access for mapping and ablation. This
echnique was developed to address VTs that are extremely
eep within the myocardium or actually epicardial. It
nvolves inserting a sheath into the pericardial space and
erforming mapping from the epicardium (206,315,316).
ew centers have taken on this approach. This technique
ust be performed with surgical support available if needed,
nd caution must be taken to avoid the epicardial coronary
rteries (317,318). Another novel technique, not used re-
ently, is transcoronary chemical ablation of incessant VT
nd VF (319,320). A more recent technique involves spinal
ord modulation to suppress ventricular arrhythmias (255–
57). Additional studies have suggested that catheter abla-
ion of VF in structurally normal hearts may be feasible by
argeting dominant triggers from the distal Purkinje system.
hese techniques are still considered highly experimental
280,317,318,321).
.7. Surgery and Revascularization Procedures
urgical therapy for the management of ventricular arrhyth-
ias may involve ablation or surgical resection of an
rrhythmogenic focus, cardiac sympathectomy, or aneurysm
esection. Surgical or percutaneous coronary revasculariza-
ion with improved coronary blood flow and reduction in
yocardial ischemia has favorable antiarrhythmic effects.
See the ACC/AHA 2004 Guideline Update for Coronary
rtery Bypass Graft Surgery [322]).
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n patients with recurrent VT refractory to drugs, implanted
efibrillators, and RF catheter ablation, direct surgical
blation or resection of the arrhythmogenic focus is an
pproach that continues to be used in experienced centers.
urgery requires accurate preoperative and intraoperative
apping to determine the site or sites of the tachycardia.
ome centers use a scar-based approach to resecting ar-
hythmogenic sites. The short- and long-term success rates
f map-guided surgical therapy for recurrent-refractory VT
re based mostly on the older literature, and few reports are
vailable to evaluate risk-to-benefit considerations in the
urrent era in patients refractory to catheter ablation and
mplanted defibrillators (323).
Left cervicothoracic sympathetic ganglionectomy was
ntroduced in 1971 for the treatment of adrenergically
riggered life-threatening ventricular arrhythmias associated
ith the LQTS (324). This procedure, performed through
limited supraclavicular approach, involves resection of the
ower half of the left stellate ganglion and removal of at least
he second and third thoracic sympathetic ganglia on the
eft side (325). This surgical therapy is associated with
eduction in the frequency of arrhythmogenic syncope in
his syndrome and may be useful as adjunctive therapy in
igh-risk LQTS patients who have recurrent syncope
nd/or aborted cardiac arrest despite combined ICD and
eta-blocker therapy or in LQTS patients who cannot
olerate beta blockers (326).
Large myocardial aneurysms secondary to MI are associ-
ted with hemodynamic compromise and are frequently
ccompanied by major ventricular arrhythmias. In selected
atients, aneurysm resection can improve cardiac function
nd, along with map-guided EP mapping and resection of
rrhythmogenic ventricular myocardium, may reduce or
liminate the accompanying ventricular arrhythmias (327).
.7.2. Revascularization for Arrhythmia Management
n patients with ventricular arrhythmias, assessment for the
resence of obstructive coronary disease and active ischemia
s essential. Coronary revascularization involving either
ercutaneous balloon/stent angioplasty or bypass surgery is
ffective anti-ischemic therapy. A review of coronary revas-
ularization studies reveals improved survival and reduction
n SCD during long-term follow-up (328,329). If obstruc-
ive CHD is complicated by ventricular arrhythmias, espe-
ially in patients with left main and proximal left anterior
escending coronary artery disease, there is a reasonable
ikelihood that revascularization will reduce the frequency
nd complexity of the arrhythmias and, in some patients,
ill eliminate such arrhythmias. No controlled trials have
valuated the effects of myocardial revascularization on VT
r VF. However, observational studies suggest that:
Sustained monomorphic VT in patients with prior MI is
unlikely to be affected by revascularization (330).Myocardial revascularization is unlikely to prevent recur-
rent cardiac arrest in patients with markedly abnormal
LV function, even if the original arrhythmia appeared to
result from transient ischemia (331).
urther discussion can be found in Section 8.7.
Because ventricular arrhythmias are not always reduced
y revascularization (332,333) and may in fact be exacer-
ated by unrecognized procedure-related MI, careful post-
rocedure monitoring for arrhythmia suppression is indi-
ated. Suppression of ischemia-mediated ventricular
rrhythmias and improvement in survival associated with
oronary revascularization may have contributed to the lack
f ICD efficacy in the Coronary Artery Bypass Graft
CABG) Patch Trial (265). In patients undergoing revas-
ularization surgery following aborted cardiac arrest unre-
ated to an AMI, it is reasonable to implant a defibrillator
fter revascularization surgery in view of the assumed
igh-risk state. However, it is reasonable not to implant an
CD if there was direct, clear evidence of myocardial
schemia immediately preceding the onset of VF and there
as no evidence for prior MI (see also Sections 8.1 and 8.3).
. ACUTE MANAGEMENT OF SPECIFIC ARRHYTHMIAS
.1. Management of Cardiac Arrest
ardiac arrest is characterized by an abrupt loss of effective
lood flow, sufficient to cause immediate loss of conscious-
ess, leading immediately to death if untreated. The most
ommon electrical mechanisms for cardiac arrest are VF and
ulseless VT (see Section 3), but substantial numbers of
ardiac arrests begin as severe bradyarrhythmias, asystole, or
ulseless electrical activity. Survival probabilities are better
or victims presenting with VT/VF than for those with
radyarrhythmic or asystolic mechanisms. A rapid response
ime is the major determinant of survival.
ecommendations
lass I
. After establishing the presence of definite, suspected,
or impending cardiac arrest, the first priority should
be activation of a response team capable of identify-
ing the specific mechanism and carrying out prompt
intervention. (Level of Evidence: B)
. Cardiopulmonary resuscitation (CPR) should be im-
plemented immediately after contacting a response
team. (Level of Evidence: A)
. In an out-of-hospital setting, if an AED is available,
it should be applied immediately and shock therapy
administered according to the algorithms contained
in the documents on CPR (334,335) developed by the
AHA in association with the International Liaison
Committee on Resuscitation (ILCOR) and/or the
European Resuscitation Council (ERC). (Level of
Evidence: C)
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346. For victims with ventricular tachyarrhythmic mech-
anisms of cardiac arrest, when recurrences occur after
a maximally defibrillating shock (generally 360 J for
monophasic defibrillators), intravenous amiodarone
should be the preferred antiarrhythmic drug for at-
tempting a stable rhythm after further defibrillations.
(Level of Evidence: B)
. For recurrent ventricular tachyarrhythmias or non-
tachyarrhythmic mechanisms of cardiac arrest, it is
recommended to follow the algorithms contained in
the documents on CPR (334,335) developed by the
AHA in association with ILCOR and/or the ERC.
(Level of Evidence: C)
. Reversible causes and factors contributing to cardiac
arrest should be managed during advanced life sup-
port, including management of hypoxia, electrolyte
disturbances, mechanical factors, and volume deple-
tion. (Level of Evidence: C)
lass IIa
For response times greater than or equal to 5 min, a
brief (less than 90 to 180 s) period of CPR is
reasonable prior to attempting defibrillation. (Level
of Evidence: B)
lass IIb
A single precordial thump may be considered by
health care professional providers when responding
to a witnessed cardiac arrest. (Level of Evidence: C)
A number of strategies for responding to unexpected
ardiac arrest have resulted in improved survival probabili-
ies for cardiac arrest victims (336). Nonetheless, the abso-
ute number and proportion of survivors remain low (337),
xcept in unique circumstances where there is an extraordi-
arily rapid response time to victims in VF or VT. A
ecrease in cardiac arrest survival occurs at about 7% to 10%
er minute if no CPR is initiated and at 3% to 4% per
inute with bystander CPR. In contrast, when immediate
efibrillation in highly protected environments is available,
uch as in monitored intensive care units and EP laborato-
ies, where response times of less than 30 s are usually
chievable, survival from VF is greater than 90%, the
xception being patients with pathophysiological conditions
hat favor the persistence of this potentially fatal arrhythmia.
urvivability falls off rapidly after the initial 2 min from the
nset of cardiac arrest, so that by 4 to 5 min survivability
ay be 25% or less, and by 10 min it is less than 10%.
tudies have suggested that while immediate defibrillation
s the preferred method within 1 to 2 min after the onset of
ardiac arrest, a brief period of CPR to provide oxygenation
f the victim improves survivability when time to defibril-
ation is longer (338–340).
Advanced life support activities, other than those directly
elated to electrical methods for control of tachyarrhyth- lias, led to the generation of complex protocols to guide
esponders. These documents, published by the AHA (334)
nd the ERC (335), cover the broad expanse of clinical
ircumstances and considerations of mechanisms. They
rovide management information, stratified for special cir-
umstances such as age of the victim (from infancy to the
lderly), pathophysiological status, and survival probabili-
ies. The response algorithms to these various circumstances
re complex and the reader is referred to the source
ocuments for details (334,335). As management guide-
ines, these documents are classified as Level of Evidence:
, but they are derived from a combination of varied studies
nd opinion that range from Level of Evidence: A, B, or C.
bbreviated versions for tachyarrhythmias and nontachy-
rrhythmic mechanisms are shown in Figure 3.
Consistent with the AHA/ERC 2005 guidelines, the
mount of energy and timing of shocks for treatment of VT
n patients with pulses are determined by the patient’s
ondition and the morphological characteristics of the VT.
nstable monomorphic VT is treated with synchronized
ardioversion, while unstable polymorphic VT is treated as
F using high-energy unsynchronized shocks at defibrilla-
ion doses. Monomorphic VT in patients with pulses
enerally responds well to monophasic waveform cardiover-
ion synchronized shocks at initial energies of 100 J or
igher. More data are needed before specific comparative
ecommendations can be made for energy doses of biphasic
evices. Synchronized cardioversion is generally not recom-
ended to treat unstable polymorphic VT because of
nreliable synchronization to a QRS complex and high-
nergy unsynchronized shock at defibrillation doses is rec-
mmended. If there is any doubt whether monomorphic or
olymorphic VT is present in the unstable patient, shock
elivery should not be delayed for detailed rhythm analysis.
he initial recommended shock energy with a biphasic
efibrillator is 150 to 200 J (use recommended device-
pecific dose; in absence of a recommended dose, 200 J
hould be used) and an equal or higher dose is recom-
ended for second and subsequent shocks. If a monophasic
efibrillator is used, 360 J is used for all shocks. Lower
nergy levels should not be used for unsynchronized shocks
ecause they can provoke VF when given in an unsynchro-
ized mode. After shock delivery, the health care provider
hould be prepared to provide immediate CPR and follow
he advanced cardiac life support (ACLS) pulseless arrest
lgorithm if pulseless arrest develops (Fig. 3).
The general goals of advanced life support are to establish
emodynamically effective cardiac rhythm, to optimize ven-
ilation, and to maintain and support the restored circula-
ion. While 3 successive (“stacked”) shocks were recom-
ended in the previous version of the ECC guidelines
341), a 1-shock strategy is now recommended to minimize
ime between chest compressions and shock delivery and
esumption of chest compressions (6,334,335) (see Fig. 3).
pinephrine, 1 mg intravenously, is administered and fol-owed by repeated defibrillation attempts at 360 J. Epineph-
F
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesigure 3. Advanced cardiac life support pulseless arrest algorithm. Reprinted with permission from Circulation 2005;112:IV57–66. AED  automated external
efibrillator; BLS  basic life support; CPR  cardiopulmonary resuscitation; IV/IO  intravenous/intraosseous; PEA  pulseless electrical activity; VF  ventricular
brillation; VT  ventricular tachycardia.
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346ine may be repeated at 3- to 5-min intervals with defibril-
ator shocks in-between doses (334), but high-dose
pinephrine does not appear to provide added benefit (342).
Intravenous amiodarone has replaced intravenous lido-
aine and other antiarrhythmic medications for the man-
gement of resistant ventricular tachyarrhythmias causing
epeated episodes of ventricular tachyarrhythmias (343).
miodarone need not be given routinely to the individual
ho responds to initial defibrillation with a stable rhythm. If
here is sufficient clinical evidence that a cardiac arrest was
eralded by the onset of an ACS, intravenous lidocaine may
till be used for resistant arrhythmias. Beta blockers may be
referred for ACSs if not already being taken. For pharma-
ological hemodynamic support during cardiac arrest man-
gement, vasopressin has been suggested as an alternative to
pinephrine (344), but the evidence for superiority is not
learly established. Responses to nontachyarrhythmic car-
iac arrest largely focus on control of metabolic and tran-
ient factors that may precipitate bradyarrhythmic events or
ulseless electrical activity (Fig. 3).
Simultaneously, the rescuer should focus on ventilation to
orrect the chemistry of the blood, efforts that render the
eart more likely to reestablish a stable rhythm (i.e.,
mproved oxygenation, reversal of acidosis, and improve-
ent of the underlying EP condition). Although adequate
xygenation of the blood is crucial in the immediate
anagement of the metabolic acidosis of cardiac arrest,
dditional correction can be achieved if necessary by intra-
enous administration of sodium bicarbonate. This is rec-
mmended for circumstances of known or suspected preex-
sting bicarbonate-responsive causes of acidosis, certain drug
verdoses, and prolonged resuscitation runs (334). The
ore general role for bicarbonate during cardiac arrest has
een questioned; but in any circumstance, much less sodium
icarbonate than was previously recommended is adequate
or treatment of acidosis in this setting. Excessive quantities
an be deleterious.
In patients in whom acute hyperkalemia is the triggering
vent for resistant VF, or who have hypocalcemia or are
oxic from Ca2 entry–blocking drugs, 10% calcium glu-
onate, 5 mL to 20 mL infused at a rate of 2 to 4 mL/min,
ay be helpful (334). Calcium should not be used routinely
uring resuscitation, even though ionized Ca2 levels may
e low during resuscitation from cardiac arrest. Some
esistant forms of polymorphic VT or torsades de pointes,
apid monomorphic VT or ventricular flutter (rate greater
han or equal to 260/min), or resistant VF may respond to
ntravenous beta-blocker therapy (propranolol, 1-mg intra-
enous boluses to a total dose of up to 15 to 20 mg;
etoprolol, 5 mg intravenously, up to 20 mg) or intravenous
gSO4 (1 to 2 g intravenously given over 1 to 2 min).
The approach to the patient with bradyarrhythmic or
systolic arrest or pulseless electrical activity differs from the
pproach to patients with tachyarrhythmic events of VT/VF
334). Once this form of cardiac arrest is recognized, efforts
hould focus first on establishing control of the cardiorespi- batory status (i.e., continue CPR, intubate, and establish
ntravenous access), then on reconfirming the rhythm (in 2
eads if possible), and finally on taking actions that favor the
mergence of a stable spontaneous rhythm or attempt to
ace the heart. Possible reversible causes, particularly for
radyarrhythmia and asystole, should be considered and
xcluded (or treated) promptly. These include pulmonary
mbolus, AMI, hypovolemia, hypoxia, cardiac tamponade,
ension pneumothorax, preexisting acidosis, drug overdose,
ypothermia, and hyperkalemia. Cardiac pacing for brady-
rrhythmic or asystolic arrests is usually ineffective (345),
ut reversal of hypoxemia, acidosis, or electrolyte imbal-
nces may help in some instances. Epinephrine (1.0 mg
ntravenously every 3 to 5 min) is commonly used in an
ttempt to elicit spontaneous electrical activity or increase
he rate of a bradycardia. For asystole and pulseless electrical
ctivity, atropine as 1.0 mg intravenously/intraosseously,
epeated every 3 to 5 min up to a total of 3 doses or 0.03 to
.04 mg/kg is recommended. For bradycardia, atropine 0.5
g intravenously/intraosseously, repeated every 3 to 5 min
p to a total dose of 0.04 mg/kg, is recommended. Sodium
icarbonate, 1 mEq/kg, may be tried for known or sus-
ected preexisting hyperkalemia or bicarbonate-responsive
cidosis.
.1.1. Arrhythmias Associated With Acute
oronary Syndromes
or recommendations, see Section 7.1 in these guidelines
nd refer to the current guidelines on ACLS (334,335).
ACS can give rise to a life-threatening arrhythmia that
ay be the first manifestation of ischemia. The mechanisms
f these arrhythmias may be different from those seen in
hronic stable ischemic heart disease. Arrhythmias during
cute ischemia may be related to re-entry, abnormal auto-
aticity, or triggered activity and are affected by a variety of
ndogenous factors such as potassium levels and autonomic
tates. These arrhythmias may cause many of the reported
udden deaths in patients with ischemic syndromes. VF or
ustained VT has been reported in up to 20% of AMIs
346,347).
The incidence of VF (occurring within 48 h of the onset
f the ACS) may be decreasing owing to aggressive revas-
ularization limiting infarct size and to increased beta-
locker use (348). VF occurring early in the ACS has been
ssociated with an increase in hospital mortality but not
ith increased long-term mortality (346). Prophylaxis with
idocaine may reduce the incidence of VF in the ACS but
ppears to be associated with increased mortality likely
wing to bradycardia and this treatment has largely been
bandoned (349). Use of prophylactic beta blockers in the
etting of AMI reduces the incidence of VF, and this
ractice is encouraged when appropriate. Similarly, correc-
ion of hypomagnesemia and hypokalemia is encouraged
ecause of the potential contribution of electrolyte distur-
ances to VF (350).
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice GuidelinesMore recent data showed the benefit of the eplerenone,
n aldosterone antagonist, in reducing the risk of SCD
ortality by 37% (p  0.051) 30 d after randomization in
atients after AMI (when initiated at a mean of 7.3 d after
MI) in addition to conventional therapy in patients with
n LVEF less than or equal to 40% and signs of HF (351).
.1.1.1. Pulseless Ventricular
achycardia/Ventricular Fibrillation
In the event of pulseless VT or VF in ACS, the standard
CLS protocol is initiated including unsynchronized elec-
ric shock following basic assessment of airway and initia-
ion of CPR. Energy delivery consists of 1 or more
onophasic shocks at 360 J or biphasic shocks at a dose
ange demonstrated by manufacturer to be effective. If not
vailable, a dose of 200 J is recommended for the first shock
nd an equal or higher dose for subsequent shocks. The
ptimal dose for biphasic shocks has not been determined,
nd no waveform or escalating energy levels recommenda-
ions can be made for biphasic defibrillators at this time. If
eturn to normal rhythm is not accomplished by defibrilla-
ion, the ACLS protocol for pulseless VT or VF is followed.
his includes epinephrine (1 mg intravenously every 3 to 5
in) or vasopressin (40 U intravenously once only; 1 dose of
asopressin intravenously/intraosseously may replace either
he first or second dose of epinephrine), and amiodarone
300-mg or 5-mg/kg intravenous push, with a possible
epeat 150-mg intravenous push once only), or as a second
ier, lidocaine (1.0 to 1.5 mg/kg with repeat dose of 0.5 to
.75 mg intravenously/intraosseously up to a total dose of 3
g/kg). Additional second-tier therapy includes intrave-
ous magnesium (1 to 2 g) or procainamide (30 mg/min up
o 17 mg/kg). The latter is considered acceptable but is no
onger recommended (334).
Following resuscitated VF, prophylactic drug infusion,
ypically with amiodarone plus a beta blocker, may be
ontinued. The antiarrhythmic should be withdrawn as
ppropriate to assess the presence of ongoing arrhythmias.
.1.1.2. Idioventricular Rhythm and
onsustained Ventricular Tachycardia
Neither idioventricular rhythm nor NSVT (lasting less
han 30 s) occurring in the setting of ACS serves as a
eliably predictive marker for early VF. In fact, accelerated
dioventricular rhythm has been associated with reperfusion
352). As such, these arrhythmias do not warrant prophy-
actic antiarrhythmic therapy. However, sustained and/or
emodynamically compromising VT in ACS requires sup-
ressive therapy (2). Management of pulseless VT follows
he ACLS guidelines for pulseless VT/VF.
.1.1.3. Unstable Sustained Ventricular Tachycardia
For recurrent VT, if VT is monomorphic and the EF is
ormal, either procainamide, sotalol, amiodarone, or lido-
aine can be used. Alternately, if the EF is low, amiodarone
r lidocaine is recommended (amiodarone 150 mg intrave-
ously over 10 min or lidocaine 0.5 to 0.75 mg/kg intrave- bous push). If the VT is polymorphic and the baseline QT
s normal, correction of underlying ischemia and electrolyte
bnormalities is emphasized. This may be followed by, or
erformed concurrently with, administration of a beta
locker or lidocaine or amiodarone or procainamide or
otalol. If the VT is polymorphic and the EF is low,
reatment with amiodarone 150 mg intravenously over 10
in or lidocaine 0.5 to 0.75 mg/kg intravenous push is
ecommended. In polymorphic VT, if the baseline QT is
rolonged, correction of electrolytes is emphasized and
ther treatments may include magnesium, overdrive pacing,
soproterenol, phenytoin, or lidocaine.
.1.1.4. Bradycardia and Heart Block
Bradycardia and heart block can occur as a result of MI.
he likelihood of developing complete heart block compli-
ating MI increases in the presence of underlying conduc-
ion system disease. Occurrence of heart block as a result of
I has been associated with an increase in hospital mor-
ality but does not predict long-term mortality in those
urviving to discharge (353). The increase in hospital
ortality is related to the extensive amount of myocardial
amage required to develop heart block rather than to the
eart block itself. While pacing has not been shown to
ncrease long-term survival post-MI, it is still indicated in
ymptomatic bradyarrhythmias associated with AMI, and
acing guidelines are as stated in the 2004 ACC/AHA
uidelines for the Management of Patients With ST-
levation Myocardial Infarction (2) and the ACC/AHA/
ASPE 2002 Guidelines Update for Implantation of Car-
iac Pacemakers and Antiarrhythmia Devices (1).
.1.2. Ventricular Tachycardia Associated
ith Low Troponin Myocardial Infarction
ecommendations
lass I
Patients presenting with sustained VT in whom low-
level elevations in cardiac biomarkers of myocyte injury/
necrosis are documented should be treated similarly to
patients who have sustained VT and in whom no
biomarker rise is documented. (Level of Evidence: C)
Prolonged episodes of sustained monomorphic VT may
e associated with rise in cardiac biomarkers due to myo-
ardial metabolic demands exceeding supply, especially in
atients with CHD. Such patients usually have a history of
I. It is reasonable to evaluate for myocardial ischemia in
atients exhibiting these findings. When sustained VT is
ccompanied by a modest elevation in cardiac enzymes, it
hould not be assumed that a new MI occurred to cause the
achycardia. In the absence of other data, it should be
ssumed that patients experiencing sustained monomorphic
T are at risk for recurrent VT and should be treated for
his arrhythmia in the same manner as are patients without
iomarker release accompanying VT.
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ecommendations
lass I
. Wide-QRS tachycardia should be presumed to be VT
if the diagnosis is unclear. (Level of Evidence: C)
. Direct current cardioversion with appropriate seda-
tion is recommended at any point in the treatment
cascade in patients with suspected sustained mono-
morphic VT with hemodynamic compromise. (Level
of Evidence: C)
lass IIa
. Intravenous procainamide (or ajmaline in some Eu-
ropean countries) is reasonable for initial treatment
of patients with stable sustained monomorphic VT.
(Level of Evidence: B)
. Intravenous amiodarone is reasonable in patients
with sustained monomorphic VT that is hemody-
namically unstable, refractory to conversion with
countershock, or recurrent despite procainamide or
other agents. (Level of Evidence: C)
. Transvenous catheter pace termination can be useful
to treat patients with sustained monomorphic VT
that is refractory to cardioversion or is frequently
recurrent despite antiarrhythmic medication. (Level
of Evidence: C)
lass IIb
Intravenous lidocaine might be reasonable for the ini-
tial treatment of patients with stable sustained mono-
morphic VT specifically associated with acute myocar-
dial ischemia or infarction. (Level of Evidence: C)
lass III
Calcium channel blockers such as verapamil and
diltiazem should not be used in patients to terminate
wide-QRS-complex tachycardia of unknown origin,
especially in patients with a history of myocardial
dysfunction. (Level of Evidence: C)
Electrical cardioversion is always indicated for hemo-
ynamically unstable tachycardia. Managing the patient
resenting with well-tolerated, wide-QRS tachycardia is
acilitated by differentiating between VT, SVT with
berrant conduction, and preexcited tachycardia (354).
his can usually be accomplished by consideration of the
istory and examination of the 12-lead ECG during
achycardia. The hemodynamic status of the patient is not
elpful in distinguishing these mechanisms. A working
iagnosis of VT is appropriate when the diagnosis is
nclear because VT is more prevalent, especially in the
atient with structural heart disease, and therapy directed
nappropriately at SVT may have adverse consequences r355,356). Monomorphic VT is usually related to a
tructural abnormality such as MI scarring but is mech-
nistically heterogeneous. Some “idiopathic” VTs re-
pond well and terminate with intravenous verapamil or
denosine, and those expert in arrhythmia management
ay choose to treat the acute episode with these agents
357,358). If these unique VT entities cannot be recog-
ized with confidence, it is prudent to assume that one is
ealing with VT related to structural heart disease.
Correction of potentially causative or aggravating condi-
ions such as hypokalemia and ischemia is an early priority.
imely termination is usually desirable even if VT is well
olerated. This can be achieved with cardioversion, antiar-
hythmic medications, or pacing techniques. DC cardiover-
ion even at early stage or as “first line” is reasonable
359,360). Advantages include the absence of proarrhyth-
ia and high efficacy in a timely fashion. Cardioversion
oes not prevent recurrence, and a major disadvantage is the
eed for deep sedation or anesthesia. Caution needs to be
xercised if the patient also has concurrent AF (e.g., double
achycardia). If such is the case, the ACC/AHA/ESC 2006
uidelines for the Management of Patients With Atrial
ibrillation need to be followed when feasible (361).
Initial treatment often includes the administration of
ntravenous antiarrhythmic medication. The advantages in-
lude the lack of necessity for anesthesia and ready avail-
bility. Disadvantages include delay in termination, failure
o terminate in some patients, and adverse effects including
ypotension and proarrhythmia. Although drugs such as
ecainide, propafenone, and sotalol are available in intrave-
ous preparations in some countries, only intravenous pro-
ainamide, lidocaine, and amiodarone are widely available.
ntravenous ajmaline is used frequently in some European
ountries. Intravenous amiodarone loading has proved use-
ul in unstable and recurrent VT, especially when VT is
ecurrent after countershock and other antiarrhythmic mea-
ures (362–366). It is also reasonable in patients in whom
ral amiodarone is required after the intravenous phase. It
as proved superior to lidocaine in improving survival to
ospital in patients with cardiac arrest and shock-resistant
F (343). Although intravenous amiodarone has an early
ffect on AV nodal conduction and early antiadrenergic
ffects, the effects on myocardial conduction and refractori-
ess are gradual in onset and maximum effect may not be
een for weeks or months (367–369). Intravenous amioda-
one is not ideal for early conversion of stable monomorphic
T. Intravenous procainamide is more appropriate when
arly slowing of the VT rate and termination of monomor-
hic VT are desired (370,371). Close monitoring of blood
ressure and cardiovascular status is recommended in the
resence of congestive HF or severe LV dysfunction as
ntravenous procainamide can cause transient hypotension
372). Lidocaine is effective when VT is thought to be
elated to myocardial ischemia (373,374).
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ecommendations
lass IIa
Intravenous amiodarone, beta blockers, and intrave-
nous procainamide (or sotalol or ajmaline in Europe)
can be useful for treating repetitive monomorphic VT
in the context of coronary disease (375) and idio-
pathic VT. (Level of Evidence: C)
Repetitive monomorphic VT is characterized electrocar-
iographically by frequent ventricular ectopy and salvos of
SVT with intervening sinus rhythm. It typically occurs at
est and is self-terminating although the arrhythmia can be
resent for much of the time (376). Although this termi-
ology can refer to mechanistically diverse arrhythmias, it
enerally refers to idiopathic VT, most frequently the RV
utflow type (377–379). This tachycardia can cause palpi-
ations or, rarely, tachycardia-related cardiomyopathy (380).
any patients have no symptoms related to the arrhythmia.
n some patients, tachycardia is provoked by exercise (297).
n electrocardiographically similar presentation is less fre-
uent in patients with structural heart disease and, specifi-
ally, previous MI (375).
Treatment is rarely required on an urgent basis, and
hronic management should be based on symptoms and
requency of tachycardia. Tachycardia-induced cardiomyop-
thy is unusual in this entity, and there is usually no need to
reat asymptomatic patients with preserved LV function.
or patients with mild symptoms, reassurance may be the
nly treatment necessary. Repetitive monomorphic VT is
sually an issue of chronic management (pharmacologically
r by ablation), and the strategy will vary considerably
ependent on the clinical situation and etiology of the VT.
eta-blocking agents or calcium channel blockers are often
ffective. Ablation is generally successful in problematic RV
utflow tachycardia (381). When acute therapy is required,
ntiarrhythmic drug selection will depend on etiology and
nderlying ventricular function, with drug selection consid-
rations similar to that described for sustained monomor-
hic VT (see Section 7.2 for further discussion).
.4. Polymorphic VT
ecommendations
lass I
. Direct current cardioversion with appropriate seda-
tion as necessary is recommended for patients with
sustained polymorphic VT with hemodynamic com-
promise and is reasonable at any point in the treat-
ment cascade. (Level of Evidence: B)
. Intravenous beta blockers are useful for patients with
recurrent polymorphic VT, especially if ischemia is
suspected or cannot be excluded. (Level of Evidence: B)
. Intravenous loading with amiodarone is useful for
patients with recurrent polymorphic VT in the ab-sence of abnormal repolarization related to congeni-
tal or acquired LQTS. (Level of Evidence: C)
. Urgent angiography with a view to revascularization
should be considered for patients with polymorphic VT
when myocardial ischemia cannot be excluded. (Level of
Evidence: C)
lass IIb
Intravenous lidocaine may be reasonable for treatment
of polymorphic VT specifically associated with acute
myocardial ischemia or infarction. (Level of Evidence: C)
Polymorphic VT may be sustained, generally requiring
rgent electrical cardioversion, or self-terminating with inter-
udes of sinus rhythm. It is useful to distinguish polymorphic
achycardia associated with normal repolarization from that
ssociated with abnormal repolarization (e.g., prolonged QT
nterval). Both VTs may be similar with gross irregularity of
ate and QRS morphology with phasic increase and decrease of
RS amplitude often described as “torsades de pointes” (see
ection 7.5. for further discussion).
Polymorphic VT with a normal QT interval during inter-
ening sinus rhythm is most frequently seen in the context of
cute ischemia or MI, but the QRS pattern during VT is not
pecific and may be seen with other cardiac disease states such
s cardiomyopathy or HF or in the absence of overt cardiac
isease (e.g., idiopathic polymorphic VT, catecholaminergic
T) (15,382,383). Intravenous beta blockers are useful in this
ontext and improve mortality in the setting of recurrent
olymorphic VT with AMI (384). Intravenous loading with
miodarone is also useful (341,385,386). Urgent coronary
ngiography should be considered in the setting or recurrent
olymorphic VT when ischemia is suspected or cannot be
xcluded (387). In all instances, treatment of HF and associ-
ted correctable conditions and repletion of potassium and
agnesium should be done concurrently with the above.
.5. Torsades de Pointes
ecommendations
lass I
. Withdrawal of any offending drugs and correction of
electrolyte abnormalities are recommended in patients
presenting with torsades de pointes. (Level of Evidence: A)
. Acute and long-term pacing is recommended for pa-
tients presenting with torsades de pointes due to heart
block and symptomatic bradycardia. (Level of Evidence: A)
lass IIa
. Management with intravenous magnesium sulfate is
reasonable for patients who present with LQTS and
few episodes of torsades de pointes. Magnesium is
not likely to be effective in patients with a normal QT
interval. (Level of Evidence: B)
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346. Acute and long-term pacing is reasonable for patients
who present with recurrent pause-dependent torsades
de pointes. (Level of Evidence: B)
. Beta blockade combined with pacing is reasonable acute
therapy for patients who present with torsades de
pointes and sinus bradycardia. (Level of Evidence: C)
. Isoproterenol is reasonable as temporary treatment in
acute patients who present with recurrent pause-
dependent torsades de pointes who do not have
congenital LQTS. (Level of Evidence: B)
lass IIb
. Potassium repletion to 4.5 to 5 mmol/L may be
considered for patients who present with torsades de
pointes. (Level of Evidence: B)
. Intravenous lidocaine or oral mexiletine may be
considered in patients who present with LQT3 and
torsades de pointes. (Level of Evidence: C)
Marked QT interval prolongation and the morphologically
istinctive polymorphic VT torsades de pointes occur in 3 com-
on settings: in congenital LQTS, in a drug-associated form, and
n patients with advanced conduction system disease that has
rogressed to heart block (see Section 11.1.1 for further discus-
ion). Torsades de pointes complicating heart block is managed
ith temporary pacing followed by permanent pacing. Other
auses, such as severe electrolyte abnormalities alone or central
ervous system injury, are less common. Presentation with fre-
uently recurring torsades de pointes in the congenital syndrome
s unusual. In this setting, catecholamines should be avoided.
owever, other maneuvers useful in the drug-associated form
magnesium, potassium, pacing) can be used, and pacing along
ith beta blockade or lidocaine may be considered (388).
.6. Incessant Ventricular Tachycardia
ecommendations
lass I
Revascularization and beta blockade followed by
intravenous antiarrythmic drugs such as procain-
amide or amiodarone are recommended for patients
with recurrent or incessant polymorphic VT due to
acute myocardial ischemia. (Level of Evidence: C)
lass IIa
Intravenous amiodarone or procainamide followed by
VT ablation can be effective in the management of
patients with frequently recurring or incessant mono-
morphic VT. (Level of Evidence: B)
lass IIb
. Intravenous amiodarone and intravenous beta block-
ers separately or together may be reasonable in pa-
tients with VT storm. (Level of Evidence: C) l. Overdrive pacing or general anesthesia may be con-
sidered for patients with frequently recurring or
incessant VT. (Level of Evidence: C)
. Spinal cord modulation may be considered for some
patients with frequently recurring or incessant VT.
(Level of Evidence: C)
.6.1. Clinical Features
he syndrome of very frequent episodes of VT requiring
ardioversion has been termed “VT storm” (see Section 13.5
or further discussion). Frequent appropriate ICD shocks
epresent another variant. While a definition of greater than 2
pisodes in 24 h has been used (389,390), much more frequent
pisodes can also occur. Hemodynamically stable VT lasting
ours has been termed “incessant.” Management guidelines for
hese syndromes rely on anecdotal evidence because they are
are, there are multiple potential underlying mechanisms, and
o randomized trials have been conducted.
Severe underlying heart disease is frequently present. More
arely, VT storm can occur (e.g., in Brugada syndrome, LQTS,
atecholaminergic VT, or in drug overdose) in patients who
ave a structurally normal heart. “VT storm” can be mono-
orphic or polymorphic. Polymorphic VT storm in a patient
ith coronary disease is strongly suggestive of acute myocardial
schemia; pauses may occur prior to polymorphic VT even in
he absence of QT prolongation. Pause-dependent VT with
arked QT prolongation should be managed as torsades de
ointes (see Section 7.5), although acute ischemia can also
resent in this fashion (391). Frequent appropriate ICD shocks
ay represent part of the natural history of advanced heart
isease and may or may not portend a serious deterioration in
nderlying prognosis (392).
.6.2. Management
he first step in VT storm is to identify and correct inciting
actors, commonly including drugs, electrolyte disturbances,
nd acute myocardial ischemia (see Sections 13.5 and 13.6
or further discussion). With frequent ICD shocks, electro-
rams and programming should be reviewed to determine if
evice reprogramming is desirable (393,394).
Intravenous beta blockade should be considered for a
olymorphic VT storm as it is the single most effective
herapy. Revascularization procedures may be urgently
eeded. It is of utmost importance to try and understand the
ubstrate of incessant arrhythmias, because if a diagnosis is
stablished, a targeted treatment may be possible. For
xample, in Brugada syndrome, quinidine or isoproterenol
ay terminate incessant arrhythmias (139,395). In acute
schemia, intravenous amiodarone seems more effective than
ther antiarrhythmic drugs (396). Intra-aortic balloon
ounterpulsation can be tried. Pacing may be useful espe-
ially if the tachycardia onset is pause dependent. Other
otential therapies include ablation (397) or general anes-
hesia (398). Autonomic alternative via spinal cord modu-
ation may be tried.
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice GuidelinesMonomorphic VT storm can be managed by intravenous
ntiarrhythmics (e.g., amiodarone, procainamide) to slow
he rate but may aggravate the tachycardia by promoting
requent or incessant episodes. Ablation can also be effec-
ive. ICD therapy may eventually be needed.
. VENTRICULAR ARRHYTHMIA AND SUDDEN
ARDIAC DEATH RELATED TO SPECIFIC PATHOLOGY
.1. Left Ventricular Dysfunction Due to
rior Myocardial Infarction
ecommendations
lass I
. Aggressive attempts should be made to treat HF that
may be present in some patients with LV dysfunction
due to prior MI and ventricular tachyarrhythmias.
(Level of Evidence: C)
. Aggressive attempts should be made to treat myocardial
ischemia that may be present in some patients with
ventricular tachyarrhythmias. (Level of Evidence: C)
. Coronary revascularization is indicated to reduce the risk
of SCD in patients with VF when direct, clear evidence of
acute myocardial ischemia is documented to immediately
precede the onset of VF. (Level of Evidence: B)
. If coronary revascularization cannot be carried out and
there is evidence of prior MI and significant LV dysfunc-
tion, the primary therapy of patients resuscitated from VF
should be the ICD in patients who are receiving chronic
optimal medical therapy and those who have reasonable
expectation of survival with a good functional status for
more than 1 y. (Level of Evidence: A)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with LV dysfunction due to prior MI who
are at least 40 d post-MI, have an LVEF less than or
equal to 30% to 40%, are NYHA functional class II or
III, are receiving chronic optimal medical therapy,
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: A) (See Section 1.2.)
. The ICD is effective therapy to reduce mortality by a
reduction in SCD in patients with LV dysfunction
due to prior MI who present with hemodynamically
unstable sustained VT, are receiving chronic optimal
medical therapy, and who have reasonable expecta-
tion of survival with a good functional status for more
than 1 y. (Level of Evidence: A)
lass IIa
. Implantation of an ICD is reasonable in patients with
LV dysfunction due to prior MI who are at least 40 d
post-MI, have an LVEF of less than or equal to 30% to
35%, are NYHA functional class I on chronic optimal
medical therapy, and who have reasonable expectation rof survival with a good functional status for more than
1 y. (Level of Evidence: B) (See Section 1.2.)
. Amiodarone, often in combination with beta block-
ers, can be useful for patients with LV dysfunction
due to prior MI and symptoms due to VT unrespon-
sive to beta-adrenergic–blocking agents. (Level of
Evidence: B)
. Sotalol is reasonable therapy to reduce symptoms
resulting from VT for patients with LV dysfunction
due to prior MI unresponsive to beta-blocking
agents. (Level of Evidence: C)
. Adjunctive therapies to the ICD, including cathe-
ter ablation or surgical resection, and pharmaco-
logical therapy with agents such as amiodarone or
sotalol are reasonable to improve symptoms due to
frequent episodes of sustained VT or VF in pa-
tients with LV dysfunction due to prior MI. (Level
of Evidence: C)
. Amiodarone is reasonable therapy to reduce symp-
toms due to recurrent hemodynamically stable VT for
patients with LV dysfunction due to prior MI who
cannot or refuse to have an ICD implanted. (Level of
Evidence: C)
. Implantation is reasonable for treatment of recurrent
ventricular tachycardia in patients post-MI with normal
or near normal ventricular function who are receiving
chronic optimal medical therapy and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: C)
lass IIb
. Curative catheter ablation or amiodarone may be
considered in lieu of ICD therapy to improve symp-
toms in patients with LV dysfunction due to prior MI
and recurrent hemodynamically stable VT whose
LVEF is greater than 40%. (Level of Evidence: B)
. Amiodarone may be reasonable therapy for patients
with LV dysfunction due to prior MI with an ICD
indication, as defined above, in patients who cannot
or refuse to have an ICD implanted. (Level of Evi-
dence: C)
lass III
. Prophylactic antiarrhythmic drug therapy is not in-
dicated to reduce mortality in patients with asymp-
tomatic nonsustained ventricular arrhythmias. (Level
of Evidence: B)
. Class IC antiarrhythmic drugs in patients with a past
history of MI should not be used. (Level of Evidence: A)
Considerations taken by the Writing Committee in
ormulating recommendations for this section are discussed
n detail in the Introduction.
Patients with chronic CHD manifest 3 general types of
entricular tachyarrhythmias: NSVT (defined as 3 or more
epetitive ventricular beats in a row lasting up to 30 s in
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346uration at a rate greater than 100 beats per minute),
ustained VT, and cardiac arrest resulting from VT or VF.
he cardiac mortality of patients with all types of ventricular
achyarrhythmias is high. The high mortality results from
onsudden, as well as sudden, cardiac death. These arrhyth-
ias may result from myocardial ischemia, or effects of HF,
n addition to primary electrical abnormalities. Aggressive
ttempts should be made to treat HF and to search for and
orrect myocardial ischemia in patients with ventricular
achyarrhythmias. In some cases, appropriate treatment of
schemia and HF will abolish the arrhythmia (primarily
olymorphic VT, VF, and NSVT). Even if specific antiar-
hythmic therapy is necessary, the frequency and tolerance
f arrhythmias may be improved with appropriate therapy
or ischemia and HF.
.1.1. Nonsustained Ventricular Tachycardia
ost NSVT in patients with chronic CHD is brief and
oes not cause symptoms. There is no evidence that
uppression of asymptomatic NSVT prolongs life. Thus,
here is no indication to treat NSVT, except in the relatively
ncommon circumstances where frequent (incessant) or
ery rapid episodes compromise hemodynamic stability. In
uch cases, NSVT may be treated with pharmacological
ntiarrhythmic therapy, catheter ablation, or surgical resec-
ion. When NSVT causes symptoms that require therapy,
ttempts should be made to characterize the NSVT elec-
rocardiographically, in order to determine whether the
SVT is related to prior MI or arises by a distinct
echanism that may be especially amenable to RF catheter
blation, such as tachycardia arising from the ventricular
utflow tract. Initial pharmacological therapy of symptom-
tic NSVT should consist of beta adrenergic–blocking
gents, if they are not already being used at an adequate
osage. Pharmacological therapy in patients with symptom-
tic NSVT unresponsive to beta adrenergic–blocking agents
ould most appropriately be amiodarone or sotalol.
.1.2. Sustained Ventricular Tachycardia
he treatment of sustained VT in patients with chronic CHD
hould be tempered by the clinical manifestations produced by
he tachycardia, as well as the frequency of episodes. Patients
ho present with sustained monomorphic VT that does not
recipitate cardiac arrest or cause severe hemodynamic insta-
ility are usually, but not always, at relatively low risk for SCD
2% yearly) (399,400). Twelve-lead ECGs should be obtained
uring episodes of sustained VT, and the morphology assessed
o be certain that it is consistent with location of prior MI(s).
he possibility should be considered that patients with prior
I may develop sustained VT unrelated to the infarction, due
o other mechanisms such as bundle-branch reentry or idio-
athic VT. If episodes are relatively infrequent, the ICD alone
ay be the most appropriate initial therapy, because antitachy-
ardia pacing therapies or high-energy shock therapy may
educe the need for hospitalization and pharmacological anti-
rrhythmic therapy. Suitable adjunctive therapies include cath- gter ablation, surgical resection, and pharmacological therapy
ith agents such as sotalol or amiodarone.
Curative therapy of sustained VT using either surgical
esection or catheter ablation should be considered in patients
ith frequent recurrences of VT unresponsive to antiarrhyth-
ic drugs. Patients in whom the tachycardia is hemodynam-
cally stable may be considered for curative catheter ablation.
he major limitation to catheter ablation is the fact that most
atients with sustained VT resulting from prior MI have
ultiple tachycardias, and it is often difficult to ablate all
achycardias completely, using currently available RF ablation
echnology. Some patients have only 1 or 2 tachycardia circuits
nd may be cured of their arrhythmia by catheter ablation.
owever, they may develop new VT in the future using a
ifferent circuit. Although all morphologically distinct tachy-
ardias may not be cured by catheter ablation, the tachycardia
ubstrate may be modified sufficiently to decrease the frequency
f arrhythmia episodes. Ablation of the tachycardia using
urgery to resect or modify the arrhythmia substrate is an
lternative therapy that may be suitable for patients in whom
atheter ablation is unsuccessful.
Following correction of ischemia, patients who present
ith sustained VT that causes severe hemodynamic com-
romise may benefit from EP testing. Such testing will
ccasionally reveal curable arrhythmias such as bundle-
ranch reentry. In addition, the results of testing often help
n appropriate programming of implantable defibrillators.
he ICD is the primary therapy for such patients.
.1.3. Treatment of Ventricular
ibrillation and Cardiac Arrest Survivors
atients experiencing cardiac arrest due to VF that does not
ccur within the first 24 to 48 h of AMI may be at risk for
ecurrent cardiac arrest. As is the case for patients presenting
ith sustained VT, such patients should be evaluated and
reated for myocardial ischemia. If there is direct, clear evi-
ence of acute myocardial ischemia immediately preceding the
nset of VF and there is no evidence of prior MI, the primary
herapy should be complete coronary revascularization. If
oronary revascularization cannot be carried out and there is
vidence of prior MI and significant LV dysfunction, the
rimary therapy of patients resuscitated from VF should be the
CD.
.1.4. Primary Prevention of Sudden Cardiac Death
ll patients with CHD are at risk for SCD, and most SCD
ccurs in patients without severe LV dysfunction. However,
n the absence of symptomatic arrhythmias, patients with-
ut prior MI and even those with prior MI whose LVEF is
reater than 40% are at such low risk that prophylactic
herapy is not indicated. Nevertheless, the risk for SCD in
atients who do not have symptomatic arrhythmias, without
rior MI, and those with prior MI whose LVEF is greater
han 40% is sufficiently low that prophylactic therapy is not
ndicated at the present time. In addition, when EF is
reater than 40%, the risk of SCD is low enough that
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesrophylactic antiarrhythmic therapy is not indicated for
atients with asymptomatic arrhythmias, such as NSVT.
Subpopulations of patients remain at risk for SCD for
ears after the AMI. Multiple factors in addition to reduced
F have been demonstrated to contribute to the risk for
CD after MI; these include the presence of NSVT,
ymptomatic HF, and sustained monomorphic VT induc-
ble by EP testing. The only specific antiarrhythmic treat-
ent proved consistently effective to reduce risk of both
CD and total mortality is the ICD. ICD therapy is
ndicated to reduce the risk of SCD in 2 patient groups:
atients whose LVEF is less than or equal to 40% as a result
f prior MI and who have spontaneous NSVT and sus-
ained monomorphic VT inducible by EP testing (267), and
atients whose LVEF is less than 30% as a result of an MI
hat occurred greater than or equal to 40 d earlier when HF
NYHA functional class II or III symptoms) is present
248,268). The rationale for recommending that an ICD be
sed in patients with symptomatic HF, in addition to
educed EF, is that the evidence for ICD benefit is strongest
n such patients; most patients enrolled in primary preven-
ion trials had symptomatic HF (8). Evaluation of the need
or an ICD and implantation should be deferred until at
east 3 mo after revascularization procedures (i.e., surgical
ypass grafting or percutaneous angioplasty) to allow ade-
uate time for recovery of ventricular function following
evascularization. In general, ICD implantation should be
eferred until at least 40 d after AMI in patients meeting
he above criteria in order to allow time for recovery of
entricular function and because ICD therapy has not been
emonstrated to improve survival when implanted within
0 d after MI (152,248,401–403). In cases of doubt, an EP
tudy could be considered.
Amiodarone therapy has been thought to be relatively
afe in patients with prior MI who had symptomatic
rrhythmias that required suppression. Although random-
zed trials have not demonstrated a survival benefit when
mpiric amiodarone is initiated early after MI, mortality was
ot increased, and arrhythmic deaths showed a consistent
rend toward reduction with amiodarone treatment
404,405). However, in patients with advanced HF (NYHA
unctional class III), amiodarone may not be beneficial
8,248). Thus, amiodarone should not be used routinely
fter MI but is probably the safest agent to use to suppress
ymptomatic arrhythmias.
.1.5. Use of Implantable Cardioverter-Defibrillator
or Ventricular Tachycardia in Patients With Normal
r Near Normal Left Ventricular Ejection Fraction
ecurrent sustained VT is usually treated by management of
he underlying condition, prevention of predisposing and
rigger factors, and the use of antiarrhythmic therapies such
s class I and class III antiarrhythmic drugs. The use of
ntiarrhythmic agents may predispose the patient to proar-
hythmic complications that might pose significant threats
o life. Increasingly, the ICD is being used effectively to mreat these arrhythmias, which in themselves may not be
ife-threatening, in order to avoid the relative ineffectiveness
nd adverse complications of pharmaceutical therapy. In the
ase of monomorphic VT, antitachycardia pacing is often
pplied successfully without provocation of untoward symp-
oms. On the other hand, polymorphic VT or VF, whether
r not related to antiarrhythmic drug treatment, may require
hock therapy. In any event, the strategy of using devices to
anage such arrhythmias appears to be clinically successful,
lthough expensive.
.2. Valvular Heart Disease
ecommendations
lass I
Patients with valvular heart disease and ventricular
arrhythmias should be evaluated and treated follow-
ing current recommendations for each disorder.
(Level of Evidence: C)
lass IIb
The effectiveness of mitral valve repair or replace-
ment to reduce the risk of SCD in patients with
mitral valve prolapse, severe mitral regurgitation, and
serious ventricular arrhythmias is not well estab-
lished. (Level of Evidence: C)
Ventricular arrhythmias occurring in patients with valvu-
ar heart disease can be caused by any of the mechanisms
esponsible for ventricular arrhythmias in other cardiac
iseases. These patients can have associated CHD, myocar-
ial dysfunction, severe LVH, adrenergic-dependent
hythm disturbances, or an inherited molecular abnormality.
alve abnormalities are not likely to cause ventricular
rrhythmias but may contribute by virtue of their effect on
he myocardium. Although SCD in patients with significant
alvular lesions is frequently caused by a serious ventricular
rrhythmia, it is uncertain whether the event is triggered by
reexisting ventricular arrhythmias. In general, there is
ore knowledge on the risk for SCD in patients with aortic
alve disease compared with other valvular lesions. Al-
hough the overall risk is small, sudden arrhythmic death
ppears to be more frequent in aortic stenosis than in other
esions: approximately 0.4% per year for aortic stenosis, less
han 0.2% per year for regurgitation, and less than 0.2% per
ear for mitral valve disease (406,407).
Most patients who die suddenly have been symptomatic
rom their valvular disease (406). Although recurrent NSVT
ay place a patient with severe aortic stenosis at risk for
yncope, the management of such a patient is usually guided
y the severity of the valvular lesion. To date, there are
nsufficient data demonstrating reduction in ventricular
rrhythmias as a result of valve repair or replacement in
ost patients with valvular disease. For these reasons,
atients with valvular heart disease and ventricular arrhyth-
ias should be evaluated and treated following current
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346ecommendations for each disorder (406). The presence
f a ventricular arrhythmia alone does not constitute an
ndication for valve repair or replacement. An exception
o this general guideline has been suggested for patients
ith myxomatous mitral valve prolapse (MVP) and
erious ventricular arrhythmias, in whom there may be an
ncreased risk for SCD, particularly in the subgroup that
lso has a flail leaflet (408,409). For this reason, the
requent occurrence of ventricular arrhythmias in patients
ith severe myxomatous mitral regurgitation has been
onsidered a class IIb indication for surgery (406),
lthough its effectiveness in reducing SCD has not been
stablished. The role of QT prolongation in subgroups of
atients with MVP remains unclear (3,410).
Patients with mild valvular lesions who have no LV
nlargement, LVH or depressed function should be man-
ged as if they had no structural heart disease.
.3. Congenital Heart Disease
ecommendations
lass I
. ICD implantation is indicated in patients with
congenital heart disease who are survivors of car-
diac arrest after evaluation to define the cause of
the event and exclude any reversible causes. ICD
implantation is indicated in patients who are re-
ceiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of
Evidence: B)
. Patients with congenital heart disease and spontane-
ous sustained VT should undergo invasive hemody-
namic and EP evaluation. Recommended therapy
includes catheter ablation or surgical resection to
eliminate VT. If that is not successful, ICD implan-
tation is recommended. (Level of Evidence: C)
lass IIa
Invasive hemodynamic and EP evaluation is reason-
able in patients with congenital heart disease and
unexplained syncope and impaired ventricular func-
tion. In the absence of a defined and reversible cause,
ICD implantation is reasonable in patients who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: B)
lass IIb
EP testing may be considered for patients with
congenital heart disease and ventricular couplets or
NSVT to determine the risk of a sustained ventricu-
lar arrhythmia. (Level of Evidence: C) olass III
Prophylactic antiarrhythmic therapy is not indicated
for asymptomatic patients with congenital heart dis-
ease and isolated PVCs. (Level of Evidence: C)
Congenital heart disease represents a diverse spectrum of
natomical and physiological defects with significant differ-
nces in respect to natural history, preoperative and post-
perative physiology, and the risk of arrhythmias and late
CD. Overall, congenital heart defects are the leading cause
f infant mortality (less than 1 y of age) in the industrialized
orld. However, with advances in cardiovascular medicine,
his mortality rate has been reduced from 105 to 59 deaths
er 100 000 live births between 1980 and 1995 (411).
early all defects can now be repaired or palliated, with
stimates of greater than 1 million worldwide long-term
urvivors of surgery for congenital heart disease (412).
lthough the short- and long-term survival of these patients
s a matter of ongoing study, it is apparent that patients with
ertain defects have an increased risk of late sudden and
otal cardiac mortality (413). Given the overall low inci-
ence of late SCD in postoperative congenital heart disease
atients, no prospective randomized clinical trials have been
erformed to define either risk factors for SCD or the role
f primary prevention therapies. Therefore, the level of
vidence for most recommendations is class C.
During infancy and childhood, greater than 75% of
eaths in patients with congenital heart disease are in-
ospital events, most occurring during the perioperative
eriod (414). The remaining deaths occur as out-of-hospital
r emergency department events, often in patients with
ther congenital anomalies or sepsis. Therefore, the number
f very young patients with congenital heart disease who are
ictims of arrhythmic SCD is quite small.
Beyond 20 y of age, there is a progressive increase in the
ncidence of sudden and total cardiac mortality in postoperative
ongenital heart disease patients (413). Hence, most studies of
udden death in congenital heart disease have evaluated ado-
escents and young adults (415). Five congenital heart defects
ave been associated with the greatest risks of late SCD:
etralogy of Fallot, D- and L-transposition of the great arteries,
ortic stenosis, and functional single ventricle (413,416,417).
The largest number of late SCD studies in postoperative
atients with congenital heart disease have been for tetral-
gy of Fallot. A meta-analysis of 39 studies including 4627
atients showed that the combination of ventricular dys-
unction and complex ventricular ectopy was the primary
orrelate of late SCD (418). Although more than 20 risk
actors for SCD have been proposed (419), volume overload
ue to pulmonary insufficiency and QRS duration greater
han 160 ms appear to be the additional factors most likely
o be associated with an increased risk of SCD due to
entricular arrhythmias (420,421). The results of EP testing
or risk stratification in these patients have been inconsis-
ent, in part due to variable study protocols and definitions
f response to such testing (422–424).
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice GuidelinesPostoperative patients with D-transposition of the great
rteries appear to have a differing risks for late SCD, based
n whether they have undergone an atrial (Mustard or
enning) or arterial switch procedure. A very high incidence
f late atrial arrhythmias has been noted in patients follow-
ng atrial switch procedures, complicated by profound sinus
radycardia (425,426). The mechanism of SCD appears to
e atrial flutter with 1:1 AV conduction, followed by
yocardial ischemia resulting in polymorphic VT or VF
427). In both D- and L-transposition, progressive ventric-
lar dysfunction may also result in ventricular arrhythmias
s the cause of SCD (416,428).
In general, postoperative patients with unexplained syn-
ope should undergo both hemodynamic and EP evalua-
ion. A high incidence of inducible sustained ventricular
rrhythmias has been reported in syncopal postoperative
atients who have complex ventricular ectopy (429,430).
urthermore, a positive response to EP testing, independent
f the clinical indication, may identify patients with a
igh-risk of late SCD (423). Conversely, isolated ventricu-
ar ectopy is common in older postoperative congenital heart
isease patients. In the absence of ventricular dysfunction or
ymptoms, isolated ventricular ectopy has minimal prognos-
ic significance, and the risks of antiarrhythmic drug treat-
ent can exceed any potential benefit (431). There remain
any patients with simple or complex ventricular ectopy,
ith vague symptoms, or modest impairment of ventricular
unction who require individual judgment regarding the
eed for evaluation and treatment (432). Also, there are
onarrhythmic causes of late sudden death in postoperative
atients, including cerebral or pulmonary embolism, endo-
arditis, and aneurysm rupture (413,416).
Another class of congenital anomalies that may result in
CD is coronary artery abnormalities. The most common
ongenital coronary artery anomaly causing SCD in the
oung is anomalous origin of the left coronary artery from
he right sinus of Valsalva. The proposed mechanism of
CD is that either acute angulation of the coronary ostium
r compression of the left coronary artery as it traverses the
egion between the aortic wall and RVOT results in acute
yocardial ischemia and the development of VT or VF.
he risk of SCD appears greatest during the first 3 decades
f life. Diagnosis may be difficult as only one third of
atients have a prior history or exertional syncope or angina.
efinitive diagnosis by coronary angiography is an indica-
ion for surgical revascularization. Similar risks for SCD
ave also been reported for anomalous origin of the right
oronary artery from the left sinus of Valsalva (433).
Anomalous origin of the left coronary artery from the
ulmonary artery generally presents during the first month
f life. With the normal decline in pulmonary vascular
esistance, myocardial ischemia and dysfunction develop as
oronary perfusion is shunted to the pulmonary circulation.
hen the diagnosis is established by echocardiography
uring infancy, surgical reimplantation of the left coronary
stium is generally associated with recovery of ventricular cunction. However, a small percentage of these patients may
urvive an early MI and subsequently develop extensive right
o left coronary artery collateral circulation. These patients
ay present years or decades later with angina, HF, or
entricular arrhythmias (434).
.4. Metabolic and Inflammatory Conditions
lthough disorders in this category are important causes of
ife-threatening ventricular arrhythmias, the occurrence of
T/SCD is relatively rare and hence, in most cases, there
re few trial data as to how the arrhythmias should best be
anaged. Data relating to the prevention of life-threatening
entricular arrhythmias are even more sparse. All recom-
endations in this section therefore have Level of Evidence
or C.
Acute emergencies, as a consequence of any underlying
ilment in this section, should be managed conventionally.
.4.1. Myocarditis, Rheumatic Disease,
nd Endocarditis
ecommendations
lass I
. Temporary pacemaker insertion is indicated in pa-
tients with symptomatic bradycardia and/or heart
block during the acute phase of myocarditis. (Level of
Evidence: C)
. Acute aortic regurgitation associated with VT should
be treated surgically unless otherwise contraindi-
cated. (Level of Evidence: C)
. Acute endocarditis complicated by aortic or annular
abscess and AV block should be treated surgically unless
otherwise contraindicated. (Level of Evidence: C)
lass IIa
. ICD implantation can be beneficial in patients with
life-threatening ventricular arrhythmias who are not
in the acute phase of myocarditis, as indicated in the
ACC/AHA/NASPE 2002 Guideline Update for Im-
plantation of Cardiac Pacemakers and Antiarrhyth-
mia Devices (1), who are receiving chronic optimal
medical therapy, and who have reasonable expecta-
tion of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
. Antiarrhythmic therapy can be useful in patients with
symptomatic NSVT or sustained VT during the acute
phase of myocarditis. (Level of Evidence: C)
lass III
ICD implantation is not indicated during the acute
phase of myocarditis. (Level of Evidence: C)
.4.1.1. Myocarditis
Myocarditis is an inflammatory process affecting theardiac myocardium and is most often related to infection.
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ion, chemicals, and other physical agents, can lead to
ardiac inflammation. The most common infectious agents
eading to myocarditis are viruses (435,436). Other infective
gents causing myocarditis include bacteria, fungi, protozoa,
etazoa, spirochete, and rickettsia (435,437–453). Immu-
osuppression does not appear to reliably influence progno-
is significantly and is not recommended at this time (453).
The acute course of myocarditis varies, as does its
resentation (454). Presentation ranges from an asymptom-
tic finding detected because of transient ST-T changes
oted on an ECG to a fulminant and life-threatening
ondition with symptoms that mimic ischemia. Acute
anagement is largely supportive but may be quite aggres-
ive depending on the presentation (455). Cardiac arrhyth-
ias associated with acute myocarditis can range from
onduction abnormalities to difficult to suppress life-
hreatening ventricular arrhythmias. Death can occur re-
ated to HF and arrhythmias including heart block
444,445,455–460). Patients with arrhythmias or syncope
ay require antiarrhythmic drugs and/or device therapy
461). Temporary pacemaker insertion is indicated in pa-
ients with acute myocarditis who present with symptomatic
eart block as it would be in other causes of acute symp-
omatic heart block. Pacing is indicated in patients with
ymptomatic sinus node dysfunction or AV block as a
equela of myocarditis as it would be in other causes of sinus
r AV node dysfunction.
Acute myocarditis can lead to chronic cardiomyopathy
hrough a variety of mechanisms (455). In patients with
esidual severe cardiomyopathy and ventricular arrhythmias,
efibrillators and/or biventricular devices are implanted for
he same indications as recommended in the sections on HF
nd cardiomyopathy.
Idiopathic giant cell myocarditis is fairly uncommon but
s of particular note as it typically affects young individuals
nd is usually fatal if untreated (462–467). The diagnosis is
onfirmed by endomyocardial biopsy. Patients may develop
eart block, requiring temporary or permanent pacemakers.
n ICD and antiarrhythmic drugs such as amiodarone may
e needed for VT (462).
Lyme carditis is a complication of Lyme disease affecting
etween 0.3% and 8% of those infected with Borrelia burgdor-
eri (468–471). Patients can develop varying degrees of AV
onduction abnormalities. Junctional rhythm and asystolic
auses can occur. LV dysfunction is generally mild, and the
rocess is usually self-limiting when treated with antibiotics
468). Persistent heart block is rare, but in such cases perma-
ent pacing may be needed (469,472). VT, usually nonsus-
ained, has been reported infrequently (473–475).
Cardiac involvement has been frequently reported in
atients with acquired immunodeficiency syndrome (AIDS)
nd is also seen in patients with human immunodeficiency
irus (HIV) infection without AIDS (476–479). SCD has
een reported with primary myocardial HIV involvement d480,481). QT prolongation and arrhythmias have been
ttributed to drug therapy (482–484).
Chagas disease is caused by the protozoan Trypanosoma
ruzi; it is transmitted by an insect vector and is common in
entral and South America. Acute myocarditis is rare but
ver one third develop late myocardial damage with pro-
ressive HF and have poor survival. Conduction defects
ith progression to complete heart block are common.
ife-threatening ventricular arrhythmias are common.
miodarone appears to be effective in treating ventricular
achyarrhythmias, and death occurs as a result of either
efractory HF or arrhythmias (485). Device therapy includ-
ng the ICD is frequently used in the late phase (486). In
hose with good functional status (e.g., NYHA functional
lass I and II), SCD is a rare event when patients are
reated with amiodarone. However, VT recurrence rate is
igh at 30% per year. RF ablation from the epicardial
urface has been reported to be useful therapy in this
ndication. In those with advanced HF, drug therapy is of
ittle benefit and arrhythmia recurrence rates approach
00%. Mortality is high in these patients, on average 40%
ortality in 1 y (487).
.4.1.2. Rheumatic Disease
Acute rheumatic fever causes a pancarditis involving the
ericardium, myocardium, and endocardium. Sinus tachy-
ardia and PR prolongation are common. Bundle-branch
lock, nonspecific ST-T wave changes, and atrial and
entricular premature complexes may occur. Complete heart
lock and ventricular arrhythmias are rare (488–490). It has
een associated with prolonged QT interval and torsades de
ointes (489).
.4.1.3. Endocarditis
Infective endocarditis can occur as subacute bacterial
ndocarditis or acute bacterial endocarditis. Subacute bac-
erial endocarditis is most often related to infections with
treptococcal species and less commonly with Staphylococcus
ureus, S. epidermidis, and fastidious Haemophilus sp. Typi-
ally, it will develop on abnormal valves after asymptomatic
acteremias from infected gums or the genitourinary or
astrointestinal tract. Acute endocarditis more often is
elated to infections with S. aureus, group A hemolytic
treptococci, pneumococci, or gonococci and with less
irulent microorganisms. It can develop on normal valves
491). Untreated endocarditis is almost always fatal. Pros-
hetic valve endocarditis comprises a substantial proportion
f all cases of infective endocarditis. Although the overall
ncidence of infective endocarditis has not changed over the
ast 3 decades, the age of presentation has increased. Where
ight-sided endocarditis occurs, it is often related to intra-
enous drug abuse.
Endocarditis of the aortic and mitral valves has been
ssociated with rapid death owing to acute valvular
isruption, emboli to the coronary arteries, or abscesses in
he valvular rings or the septum (492,493). While these
eaths are often rapid, they typically are not classified as
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesudden deaths. Uncommonly, endocarditis has been as-
ociated with SCD related to tamponade secondary to
upture (494,495). The development of cardiac rhythm
isturbances portends poorly in infective endocarditis
496). Abscess formation in the valve annulus can result
n first- or second-degree heart block. This occurs more
ften in aortic than mitral valve endocarditis (497). More
dvanced heart block can occur if the abscess erodes into
he septum and disrupts the conduction system. New-
nset heart block in a patient with endocarditis is highly
pecific for abscess (498). Patients with perivalvular
bscess are at higher risk for other complications such as
mbolization and death (499).
Antimicrobial therapy will be given as appropriate to the
pecific causative organism (500). Surgery is recommended
n those with recurrent emboli or refractory HF or those
ho do not respond to antimicrobial therapy. Most physi-
ians believe that abscess formation or fungal endocarditis is
n indication for surgery (501,502). The acute hemody-
amic compromise related to acute aortic regurgitation
econdary to endocarditis can result in VT and is an
ndication for early surgery (498,499,503). Drug treatment
f arrhythmias does not differ from generally accepted
linical principles. Surgery may be indicated in the presence
f documented myocardial involvement or abscess forma-
ion (504).
.4.2. Infiltrative Cardiomyopathies
ecommendations
lass I
In addition tomanaging the underlying infiltrative cardio-
myopathy, life-threatening arrhythmias should be treated
in the same manner that such arrhythmias are treated in
patients with other cardiomyopathies, including the use of
ICDandpacemakers in patientswho are receiving chronic
optimal medical therapy and who have reasonable expec-
tation of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
The association between the infiltrative cardiomyopathies
nd VT/SCD is well documented. In all cases, where
ppropriate, treatment of the underlying condition must
ccompany management of cardiac manifestations.
.4.2.1. Sarcoidosis
One quarter of patients with sarcoidosis have cardiac
esions, but there is a poor correlation between symptoms
nd myocardial involvement even in the most advanced
ases, and hence SCD may be the first manifestation (505).
n proven cases of cardiac sarcoidosis, supraventricular and
entricular arrhythmias occur frequently (73%) and bundle-
ranch block is present in about two thirds of patients.
Approximately one quarter of these patients develop
omplete heart block; a similar proportion has congestive
ardiac failure. The ECG and Holter monitor are not
ensitive or specific enough for detecting myocardial in- tolvement but can be useful for the identification of rhythm
isturbances once the diagnosis has been confirmed by other
eans (e.g., thallium-201 and gallium-67 SPECT or
RI). Myocardial biopsy, although insensitive, has a high
pecificity for the diagnosis of myocardial sarcoidosis. Cor-
icosteroid therapy may reduce the number of premature
entricular complexes and episodes of tachycardia, render-
ng the arrhythmia easier to treat (506); the danger of SCD
ay also be diminished and an improvement may also be
een in conduction defects. The use of immunosuppression
y no means eliminates the risk of further occurrence of
rrhythmias. The resolution of granulomas may leave a
ubstrate for arrhythmogenesis. Prospective trial data do not
xist, but spontaneous VT, severe LV dysfunction, and
evere intraventricular conduction disturbance warrant ICD
nd/or pacemaker therapy as appropriate (507).
.4.2.2. Amyloidosis
Cardiac involvement in amyloidosis, irrespective of the
ubtype or chemotherapeutic intervention, carries a very
oor prognosis. In the AL subtype, the median survival is 6
o with a 6% 3-y survival rate (508,509). Progressive HF is
sually the mode of death, but bradyarrhythmia and espe-
ially VT may be the terminal event. Complex ventricular
rrhythmias are common, affecting 57% of patients; 29%
ave couplets and 18% have NSVT (510). Cardiac tro-
onins, especially troponin T (511); the presence of couplets
n Holter recordings (510); LV wall thickness, especially
reater than 12 to 15 mm on 2-dimensional echocardiog-
aphy (512); the presence of late potentials on SAECG
513); and prolonged infra-His (HV) conduction time on
P studies (514) may all be independent predictors of
ortality. Elevated cardiac troponins may influence the final
ecision as median survival in patients with detectable
alues is 6 to 8 mo compared with 21 to 22 mo in those with
ndetectable levels (511). QTc is prolonged in patients with
ardiac amyloid, but this does not seem to correlate with
ife-threatening arrhythmias (515). The use of permanent
acemakers and ICD devices may not influence long-term
utcome but in familial cases may be used as a bridge to
ransplantation (516).
.4.2.3. Fabry Disease
Fabry disease is an X-linked recessive lysosomal storage
isorder caused by deficiency of lysosomal alpha-
alactosidase. Fabry cardiomyopathy has a prevalence of 3%
o 6% in male patients with unexplained LVH (517,518).
emale carriers with low alpha-1 galactosidase activity may
lso exhibit cardiac manifestations (519). Although cardiac
nvolvement causes a range of ECG abnormalities and
onduction disturbances with AV block, ventricular ar-
hythmias and SCD appear to be very rare (520–525).
mprovements of cardiac hypertrophy and conduction ab-
ormalities have been obtained with enzyme replacement
herapy (526).
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Up to one third of homozygotes with hemochromatosis
ave cardiac involvement. Although the natural course of
ntreated cardiac involvement is progressive HF, ventricular
rrhythmias have been reported (527,528); their incidence
nd that of SCD are however, unknown. Early detection
nd appropriate management of hemochromatosis are es-
ential for a favorable outcome as cardiac and liver involve-
ent may be reversible in the early stages of the disease
529). Arrhythmias are managed conventionally.
.4.3. Endocrine Disorders and Diabetes
ecommendations
lass I
. The management of ventricular arrhythmias secondary
to endocrine disorders should address the electrolyte
(potassium, magnesium, and calcium) imbalance and
the treatment of the underlying endocrinopathy. (Level
of Evidence: C)
. Persistent life-threatening ventricular arrhythmias
that develop in patients with endocrine disorders
should be treated in the same manner that such
arrhythmias are treated in patients with other dis-
eases, including use of ICD and pacemaker implan-
tation as required in those who are receiving chronic
optimal medical therapy and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
. Patients with diabetes with ventricular arrhythmias
should generally be treated in the same manner as
patients without diabetes. (Level of Evidence: A)
.4.3.1. Introduction
Endocrine disorders can induce VT/SCD by excess or
nsufficient hormone activity on myocardial receptors (e.g.,
heochromocytoma, hypothyroidism). The endocrinopathy
an also cause myocardial changes (e.g., acromegaly) or
lectrolyte disturbances produced by hormone excess (e.g.,
yperkalemia in Addison disease and hypokalemia in Conn
yndrome), and certain endocrine disorders can accelerate
he progression of conditions such as underlying structural
eart disease secondary to dyslipidemia or hypertension,
ncreasing the risk of serious arrhythmias.
.4.3.2. Thyroid Disorders
Thyrotoxicosis commonly causes atrial arrhythmias; cases
f VT/SCD are extremely uncommon but may occur with
oncomitant electrolyte disturbances (530). VT/SCD are
ore common in hypothyroidism, the basic underlying
echanism being possibly related to prolongation of the
T interval (531,532). Thyroxin replacement therapy usu-
lly corrects this abnormality and prevents any further
rrhythmias, but antiarrhythmic drugs, such as procain-
mide, have been used successfully in an emergency (531). r.4.3.3. Pheochromocytoma
Pheochromocytoma may present with VT/SCD, but
here are no data to quantify its incidence, best mode of
anagement, or response to treatment. The incidence is
ikely to be low and possibly exacerbated by reversible
atecholamine-induced HCM/DCM (533). Not only will
onventional antagonism of catecholamine excess with al-
ha receptor blockers followed by beta blockade help control
ypertension and reverse or prevent any further structural
eterioration (534), but there is anecdotal evidence that it
revents recurrence of ventricular arrhythmia (535). Early
efinite surgical treatment of the pheochromocytoma
hould be a priority, especially in cases with documented
ife-threatening arrhythmias. In some patients with VT
ssociated with pheochromocytoma, a long QT interval has
een identified (536,537).
.4.3.4. Acromegaly
SCD is an established manifestation of acromegaly, and
ife-threatening arrhythmias are likely to be an important cause
538). Up to one half of all acromegalic patients have complex
entricular arrhythmias on 24-h Holter recordings, and of
hese, approximately two thirds are repetitive (539). There is a
trong correlation between these ventricular arrhythmias and
V mass and duration of the disease but not hormone levels
539). Appropriate surgical management of the pituitary tumor
s paramount for improved long-term outcome, as cardiac
hanges are reversible, especially in the young (540,541).
omatostatin analogues such as octreotide and lanreotide have
oth been shown to reduce LVH and improve the ventricular
rrhythmia profile (542–544).
.4.3.5 Primary Aldosteronism, Addison Disease,
yperparathyroidism, and Hypoparathyroidism
Severe electrolyte disturbances form the basis of arrhyth-
ogenesis and VT/SCD associated with the previously
entioned endocrinopathies. ECG changes including pro-
ongation of QRS and QTc intervals can accompany the
lectrolyte disturbance. Electrolyte imbalance requires im-
ediate attention before definitive treatment of the under-
ying cause (545–549).
.4.3.6. Diabetes
Diabetes is a major risk factor for premature and accel-
rated atherosclerosis, resulting in an increased incidence of
I, stroke, and death compared with a similar age- and
ender-matched population without diabetes (95). The
anagement of atherosclerotic complications that predis-
ose to ventricular arrhythmias and SCD in patients with
iabetes is similar to that in patients with diabetes (550).
In addition to atherosclerosis and hyperglycemia that
redispose the patient with diabetes to ventricular arrhyth-
ias and SCD, autonomic neuropathy, transient hypogly-
emic episodes that may occur with drug therapy, and target
nd-organ damage, such as renal failure, that results in
yperkalemia and occasionally hypokalemic episodes as a
esult of treatment, augment the risk of SCD (551–557).
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesestrictive cardiomyopathy may be a late complication in
ome patients with diabetes.
Hypoglycemic episodes increase sympathetic tone. The
ikelihood of ventricular arrhythmias is enhanced, particularly
hen they occur in a patient with autonomic neuropathy.
evere hypoglycemia is associated with ventricular repolariza-
ion abnormalities, prolongation of the QT interval, and
entricular arrhythmias (551,552). Beta blockers have been
hown to reduce the magnitude of these abnormalities during
xperimental hypoglycemia (558). Although they may mask
ymptoms of hypoglycemia, beta blockers significantly improve
urvival rates in patients with diabetes, and indications for their
se are similar to those for patients with diabetes (559). In a
respecified diabetic subgroup of patients with diabetes and
VH enrolled in the Losartan Intervention for Endpoint
eduction in Hypertension (LIFE) trial, losartan appeared to
fford better protection against SCD than atenolol (560). ACE
nhibitors or angiotensin-2 blockers are recommended in all
atients with vascular complications of diabetes if no contra-
ndications exist.
.4.4. End-Stage Renal Failure
ecommendations
lass I
. The acute management of ventricular arrhythmias in
end-stage renal failure should immediately address
hemodynamic status and electrolyte (potassium,
magnesium, and calcium) imbalance. (Level of Evi-
dence: C)
. Life-threatening ventricular arrhythmias, especially
in patients awaiting renal transplantation, should be
treated conventionally, including the use of ICD and
pacemaker as required, in patients who are receiving
chronic optimal medical therapy and who have rea-
sonable expectation of survival with a good func-
tional status for more than 1 y. (Level of Evidence: C)
Cardiovascular causes account for at least 40% of deaths
n patients with end-stage renal failure and 20% of these are
udden. Arrhythmias often occur during hemodialysis ses-
ions and for at least 4 to 5 h afterward. During this period,
emodynamic status and fluctuations in electrolytes, espe-
ially potassium, magnesium, and calcium, are likely to play
crucial role in triggering events and should be monitored
arefully. LQTS has been reported occasionally, sometimes
elated to therapy with sotalol (561). Risk factors predis-
osing to ventricular arrhythmias include LVH, hyperten-
ion, anemia, cardiac dysfunction, and underlying CHD
562). Of these, systolic blood pressure and myocardial
ysfunction have been suggested to be the more important
eterminants of complex arrhythmia (563). Unfortunately,
here are few data on how individuals at highest risk might
e identified and treated. Restricted vascular access may
nfluence the choice of therapy. i.4.5. Obesity, Dieting, and Anorexia
ecommendations
lass I
Life-threatening ventricular arrhythmias in patients
with obesity, anorexia, or when dieting should be
treated in the same manner that such arrhythmias are
treated in patients with other diseases, including
ICD and pacemaker implantation as required. Pa-
tients receiving ICD implantation should be receiv-
ing chronic optimal medical therapy and have rea-
sonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: C)
lass IIa
Programmed weight reduction in obesity and care-
fully controlled re-feeding in anorexia can effectively
reduce the risk of ventricular arrhythmias and SCD.
(Level of Evidence: C)
lass III
Prolonged, unbalanced, very low calorie, semistarva-
tion diets are not recommended; they may be harmful
and provoke life-threatening ventricular arrhythmias.
(Level of Evidence: C)
Extreme disorders of eating, and overzealous methods of
ectifying them quickly, are all associated with SCD. In
verweight individuals, this risk is particularly evident in the
everely obese with a 40 to 60 times higher incidence
ompared with that in the aged-matched general population
564,565). This is most likely to be related to life-
hreatening ventricular arrhythmias, but changes in the
onduction system of young obese victims of SCD have also
een reported (566). Some obese individuals have prolonged
Tc intervals (567,568) and studies have also documented
n increased QT dispersion in these individuals (569).
ardiomyopathy of obesity (e.g., cardiomegaly, LV dilata-
ion, and myocyte hypertrophy in the absence of interstitial
brosis) is the most common association with SCD (92),
nd this can occur in normotensive individuals (570).
entricular premature complexes are 30 times more com-
on in obese patients with LVH compared with lean
ubjects. The complexity of the ventricular ectopy correlates
ith ventricular diastolic diameter and LV mass (571).
bstructive sleep apnea may play a role in the genesis of
rrhythmias and HF in obese individuals (572).
The risk of SCD in obesity can be significantly reduced
y weight loss. Cardiomyopathy of obesity is reversible, at
east in the early stages of the disease (573,574), as are most
CG changes including prolonged QTc intervals
568,569,575). Weight reduction strategies must therefore
e advocated in all obese patients at risk, but these must
nvolve well-balanced low-calorie diets. Prolonged, unbal-
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iquid protein diets) have been reported to cause cardiac
rrhythmias and SCD by a variety of mechanisms. Such
iets must be avoided especially in those with underlying
ardiac abnormalities (576–580).
Reported mortality rates in anorexia nervosa fluctuate
rom 5% to 20%, but the actual rate is likely to be around 6%
581). Up to one third of these deaths, including those
ccurring during re-feeding, are said to be due to cardiac
auses but no precise data exist on SCD. Prolonged periods
f starvation result in not only anatomical abnormalities
uch as cardiac muscle atrophy and pericardial effusions
582), but also ECG abnormalities, including sinus brady-
ardia and prolongation of the QTc interval, an effect that is
ikely to be compounded by the presence of concurrent
lectrolyte disturbances (582–584). SCD is therefore a
requent cause of mortality in this cohort. Low weight, low
ody mass index, and rapid weight loss immediately pre-
eding assessment are the most important independent
redictors of QTc interval prolongation (582). Most of the
ardiac manifestations of anorexia nervosa are completely
eversible by appropriate re-feeding (582). The “re-feeding
yndrome” is characterized by cardiac, neurological, and
ematological complications triggered by fluid and electro-
yte disturbances during the re-feeding of chronically
tarved individuals (585). Cardiac complications of this
yndrome usually occur within the first week of re-feeding
nd are typically associated with severe degrees of malnu-
rition (less than 70% ideal body weight) (586), hypophos-
hatemia (587), and total parenteral nutrition (588).
.5. Pericardial Diseases
ecommendations
lass I
Ventricular arrhythmias that develop in patients with
pericardial disease should be treated in the same
manner that such arrhythmias are treated in patients
with other diseases including ICD and pacemaker
implantation as required. Patients receiving ICD
implantation should be receiving chronic optimal
medical therapy and have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: C)
SCD can occur in the course of pericardial disease
esulting from a variety of pathological processes; these
nclude both constrictive and restrictive processes, resulting
rom trauma, inflammation, neoplastic, and infectious eti-
logies. There is no evidence linking specific ventricular
rrhythmias with these diseases. Reports of SCD in patients
ith pericardial diseases suggest that primary hemodynamic
rocesses (i.e., acute tamponade, herniation of myocardium
hrough pericardium) are responsible for the vast majority of
CD in such patients (589–592)..6. Pulmonary Arterial Hypertension
ecommendations
lass III
Prophylactic antiarrhythmic therapy generally is not
indicated for primary prevention of SCD in patients
with pulmonary arterial hypertension (PAH) or other
pulmonary conditions. (Level of Evidence: C)
SCD is responsible for 30% to 40% of mortality in
atients with PAH. It appears more commonly in patients
ith primary PAH than in those with thromboembolic
AH (593). Patients experiencing SCD have lower partial
ressure of oxygen than do those free of sudden death (594).
CD in patients with severe PAH appears to occur not only
s a result of (presumed) ventricular arrhythmias but also as
result of pulmonary artery rupture or dissection (595,596).
ardiac arrhythmias may also result from ischemia. Marked
ilatation of the main pulmonary artery has been reported to
ause myocardial ischemia as a result of compression of the
eft main coronary artery (597). Cardiac catheterization is
ssociated with increased risk of death, including docu-
ented VF in this population (598). In addition to patients
ith PAH, ventricular arrhythmias occur in persons with
leep disordered breathing and may be responsible for SCD
n patients with sleep apnea (599).
No trials of prophylactic antiarrhythmic therapy have been
onducted in patients with PAH or other pulmonary condi-
ions. Antiarrhythmic therapy is not indicated for prevention of
CD in patients with PAH or other pulmonary conditions
600,601). Good clinical judgment should be used in the
anagement of asymptomatic arrhythmias in such patients, as
hey may be prone to proarrhythmic effects of antiarrhythmic
gents. Furthermore, such patients may be at high risk during
urgical procedures, such as ICD implantation.
.7. Transient Arrhythmias of Reversible Cause
ecommendations
lass I
. Myocardial revascularization should be performed,
when appropriate, to reduce the risk of SCD in
patients experiencing cardiac arrest due to VF or
polymorphic VT in the setting of acute ischemia or
MI. (Level of Evidence: C)
. Unless electrolyte abnormalities are proved to be the
cause, survivors of cardiac arrest due to VF or poly-
morphic VT in whom electrolyte abnormalities are
discovered in general should be evaluated and treated
in a manner similar to that of cardiac arrest without
electrolyte abnormalities. (Level of Evidence: C)
. Patients who experience sustained monomorphic VT
in the presence of antiarrhythmic drugs or electrolyte
abnormalities should be evaluated and treated in a
manner similar to that of patients with VT without
electrolyte abnormalities or antiarrhythmic drugs
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malities should not be assumed to be the sole cause of
sustained monomorphic VT. (Level of Evidence: B)
. Patients who experience polymorphic VT in associa-
tion with prolonged QT interval due to antiarrhyth-
mic medications or other drugs should be advised to
avoid exposure to all agents associated with QT
prolongation. A list of such drugs can be found on
the Web sites www.qtdrugs.org and www.torsades.
org. (Level of Evidence: B)
The mortality of cardiac arrest survivors is high, even when
he cause of the initial arrest appears to be a transient or
orrectable abnormality, and much of the mortality appears due
o recurrent cardiac arrest (33,602). The most common puta-
ive reversible causes of arrest are acute ischemia and electrolyte
mbalance. Other common potential causes to which cardiac
rrest is attributed include proarrhythmic effects of antiarrhyth-
ic drugs (603). No controlled trials have evaluated the effects
f myocardial revascularization on VT or VF. However,
bservational studies suggest that:
Sustained monomorphic VT in patients with prior MI is
unlikely to be affected by revascularization (330).
Myocardial revascularization is sufficient therapy only in
patients surviving VF in association with myocardial
ischemia when ventricular function is normal and there is
no history of MI (604).
The short-term (hospital) mortality of patients in whom
rimary VF complicates the acute phase of MI is high.
owever, patients who survive the initial hospitalization
fter Q-wave MI have survival virtually identical to patients
ithout VF in the acute phase of infarction (605). The low
isk for late cardiac arrest appears to apply only to patients
xperiencing Q-wave infarction; patients with an infarction
efined by biomarker elevations without development of
ew Q waves have a significantly higher risk of late cardiac
rrest (606,607). Transient ischemia resulting from coro-
ary artery spasm may cause polymorphic VT or VF (608).
n such cases, treatment of coronary spasm is may be
ufficient to prevent recurrent arrhythmia (609,610). Coro-
ary artery spasm may increase the risk of ventricular
rrhythmias and SCD.
Electrolyte abnormalities, including hypokalemia and
ypomagnesemia, facilitate development of VT in predis-
osed patients receiving antiarrhythmic agents and other
rugs associated with the LQTS. However, hypokalemia
an also result from cardiac arrest and should not otherwise
e assumed to be the cause of cardiac arrest, except under
nusual circumstances (611). Correction of hypokalemia
oes not affect inducibility of monomorphic VT occurring
fter MI. Electrolyte abnormalities should not be assumed
o be the cause of cardiac arrest, except in the presence of
rug-induced LQTS.
In patients who develop polymorphic VT in associationith drug-induced QT prolongation, withdrawal of theffending antiarrhythmic or other agent is usually sufficient
o prevent arrhythmia recurrence. If ventricular function is
ormal, no therapy beyond drug withdrawal, avoidance of
uture drug exposure, and correction of electrolyte abnor-
alities is necessary. However, if ventricular function is
bnormal, cardiac arrest or syncope should not be attributed
olely to antiarrhythmic drugs, and evaluation and treatment
hould be similar to patients experiencing such events in the
bsence of antiarrhythmic drugs.
Occasionally, patients develop monomorphic sustained
T only in the presence of antiarrhythmic drugs without
T prolongation. In such cases, it may appear that the
evelopment of spontaneous VT is dependent on drug
dministration. In most patients exhibiting this behavior,
he monomorphic VT is inducible by EP testing in the
bsence of antiarrhythmic drugs (612,613).
. VENTRICULAR ARRHYTHMIAS
SSOCIATED WITH CARDIOMYOPATHIES
.1. Dilated Cardiomyopathy (Nonischemic)
ecommendations
lass I
. EP testing is useful to diagnose bundle-branch reen-
trant tachycardia and to guide ablation in patients
with nonischemic DCM. (Level of Evidence: C)
. EP testing is useful for diagnostic evaluation in
patients with nonischemic DCM with sustained pal-
pitations, wide-QRS-complex tachycardia, presyn-
cope, or syncope. (Level of Evidence: C)
. An ICD should be implanted in patients with non-
ischemic DCM and significant LV dysfunction who
have sustained VT or VF, are receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: A)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with nonischemic DCM who have an LVEF
less than or equal to 30% to 35%, are NYHA func-
tional class II or III, who are receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: B) (See Section
1.2.)
lass IIa
. ICD implantation can be beneficial for patients with
unexplained syncope, significant LV dysfunction, and
nonischemic DCM who are receiving chronic opti-
mal medical therapy and who have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346. ICD implantation can be effective for termination of
sustained VT in patients with normal or near normal
ventricular function and nonischemic DCM who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: C)
lass IIb
. Amiodarone may be considered for sustained VT or
VF in patients with nonischemic DCM. (Level of
Evidence: C)
. Placement of an ICDmight be considered in patients
who have nonischemic DCM, LVEF of less than or
equal to 30% to 35%, who are NYHA functional class
I receiving chronic optimal medical therapy, and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: C) (See Section 1.2.)
Considerations taken by the Writing Committee in
ormulating recommendations for this section are discussed
n detail in the Introduction.
.1.1. Risk Stratification
he 5-y mortality for DCM has been recently estimated at
0% with SCD accounting for approximately 30% (8% to
1%) of deaths (614,615). Ventricular arrhythmias, both
ymptomatic and asymptomatic, are common, but syncope
nd SCD are infrequent initial manifestations of the disease
616,617). The incidence of SCD is highest in patients with
ndicators of more advanced cardiac disease who are also at
ighest risk of all cause mortality. Although VT and/or VF
s considered the most common mechanism of SCD,
radycardia, pulmonary embolus, electromechanical disso-
iation and other causes account for up to 50% of SCDs in
atients with advanced HF (107,618,619). Risk stratifica-
ion is difficult in DCM. SCD occurs less frequently in
atients with less advanced cardiac disease but the propor-
ion of SCD to all-cause death is higher in this group
617,618,620). Predictors of overall outcome also predict
CD and generally reflect severity of disease (EF, end-
iastolic volume, older age, hyponatremia, pulmonary cap-
llary wedge pressure, systemic hypotension, AF) (614).
nfortunately, they do not specifically predict arrhythmic
eath and are not useful in the patient with less severe
isease (3,621). Even a low EF (less than 20%) may not
ave high positive predictive value for SCD (622–624).
yncope has been associated with a higher risk of SCD
egardless of the proven etiology of the syncope (223,625)
nd patients with ICD implantation receive appropriate
hocks comparable to a secondary prevention cohort
223,625,626). Premature ventricular complexes and NSVT
orrelate with the severity of cardiac disease and occur in the
ajority of patients with severe LV dysfunction619,627,628). This limits the utility of ventricular arrhyth- mias as risk stratifiers as they would be expected to be
ensitive but not specific. It has been suggested that the
resence of NSVT may be more specific in the individual
ith better LV function (3). Induction of VT by EP testing
as been shown to predict SCD (625) but unfortunately
ailure to induce VT misses most individuals destined to die
uddenly (129,627,629,630). Microvolt TWA has been
uggested to predict SCD in a cohort study of 137 patients
ith DCM (151). The study included 37 patients with an
ndication for ICD and most endpoints occurred in this
roup. Nonetheless, the positive predictive value was rela-
ively modest (0.22), as was EF less than 35% (0.15).
diopathic DCM has heterogeneous etiologies but is famil-
al in at least 40% of cases, being usually autosomal
ominant with variable penetrance but also X-linked (631–
34). Unfortunately, genetic information is not currently
seful for risk stratification.
.1.2. Electrophysiological Testing
n DCM, EP testing plays a minor role in the evaluation
nd management of VT. This is related to low inducibility,
ow reproducibility of EP testing, and low predictive value
f induced VT (203,204). The multicenter CAT trial
ncluded 104 patients with DCM and LVEF less than 30%
ithout sustained VT/VF (635). NSVT during Holter
onitoring was recorded in 52%. With use of a complete
P testing protocol, only 2.9% of patients had sustained VT
nd 9.6% had VF induced. However, symptomatic patients
ay have various supraventricular tachyarrhythmias, typical
nd atypical atrial flutter or AF, requiring EP testing for
iagnostic purposes or to guide ablation. Bundle-branch
eentry may be suspected in patients with DCM, intraven-
ricular conduction defects during sinus rhythm, and LBBB
attern tachycardia (636).
.1.3. Management
he treatment of DCM is often based on individual patient
resentation and local physician experience. Pharmaceuti-
als that have improved overall mortality in patients with
F, such as beta blockers and ACE inhibitors, have also
educed SCD (622,637–640). Amiodarone is generally
referred to treat patients with symptomatic arrhythmias
ecause of the absence of significant negative hemodynamic
ffects and low proarrhythmic potential, although controlled
omparative trials of drugs are not available. Amiodarone
as been suggested to improve mortality in uncontrolled
rials (641). In controlled trials, amiodarone reduced the
ncidence of SCD in a population of patients with predom-
nately nonischemic DCM (637) but not in a study of HF
atients where the majority had CHD (638). The ICD has
een shown to be superior to amiodarone for secondary
revention of VT and VF in studies where the majority of
atients had CHD (266,642,643). The subgroup with
onischemic DCM in these studies benefited from the ICD
ore than did those with CHD (644).
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice GuidelinesThe role of the ICD in primary prophylaxis has been
ontroversial. The Cardiomyopathy Trial (CAT) enrolled
atients with recently diagnosed DCM and was discontin-
ed early due to futility largely because of a lower-than-
xpected incidence of all-cause mortality (635). This was a
elatively small study (50 patients in the ICD arm and 54 in
he control group), although the 5-y follow-up showed
ewer deaths in the ICD group versus control (13 vs. 17,
espectively). In the AMIOVERT study (645), 103 patients
ith DCM, EF less than 35%, and NSVT were randomized
o amiodarone or ICD. The primary endpoint was total
ortality, and the study was stopped prematurely due to
utility. The Defibrillators in Nonischemic Cardiomyopathy
reatment Evaluation (DEFINITE) (646–648) random-
zed 458 patients with nonischemic cardiomyopathy, EF
ess than 35%, and frequent PVCs or NSVT to receive best
edical therapy with or without ICD. There was a trend
oward reduction of mortality with ICD therapy, but this
as not significant.
The DEFINITE patients were randomized to receive
est medical therapy with or without an ICD, and the
rimary endpoint was all-cause mortality. After 2 y, mor-
ality was 13.8% in the standard therapy group versus 8.1%
mong those receiving an ICD, amounting to a 5.7%
bsolute reduction and a 35% relative risk reduction with
CD implantation. This failed to reach statistical signifi-
ance (p  0.06), but the findings are comparable to those
f other similar trials (647,648). The SCD-HeFT com-
ared amiodarone, ICD, and best medical therapy in 2521
atients with CHD or nonischemic cardiomyopathy who
ere in NYHA functional class II or III HF with EF less
han 35%. The drug arm (amiodarone) was double blinded
nd placebo controlled. The median follow-up was 45.5 mo.
he total mortality in the medical group was 7.2% per year
ver 5 y with a risk reduction of 23% in the ICD group
ersus placebo (CI 0.62 to 0.96, p  0.007). Relative risk
eduction was comparable for LV dysfunction due to prior
I and nonischemic groups, but absolute mortality was
ower in the nonischemic group, resulting in a greater
umber to treat per life saved. There was no mortality
ifference between the amiodarone and placebo groups (8).
urther risk stratification may decrease the number of
ndividuals needed to treat to save a life in this population
649). With the exception of DEFINITE (25% in the ICD
rm), trials assessing ICD in primary prophylaxis of DCM
id not generally include asymptomatic patients with
YHA functional class I and therefore the efficacy of ICD
n this population is not fully known (650). Because mor-
ality is low in this subgroup, the benefit of ICD therapy is
t best moderate.
.1.4. Genetic Analysis
he clinical applicability of genetic analysis to DCM is still
imited as knowledge in this area does not allow genotyping
f most individuals clinically affected by the disease. Patients
ith DCM and AV block and patients with DCM and vkeletal muscle diseases have a higher probability of being
uccessfully genotyped. When a pathogenetic mutation is
dentified, it becomes possible to establish a presymptomatic
iagnosis of the disease among family members and to
rovide them with genetic counseling to monitor progres-
ion of the disease and to assess the risk of transmitting the
isease to offspring. Based on current knowledge, genetic
nalysis does not contribute to further risk stratification in
CM.
.2. Hypertrophic Cardiomyopathy
ecommendations
lass I
ICD therapy should be used for treatment in patients
with HCM who have sustained VT and/or VF and
who are receiving chronic optimal medical therapy
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: B)
lass IIa
. ICD implantation can be effective for primary pro-
phylaxis against SCD in patients with HCM who
have 1 or more major risk factor (see Table 7) for
SCD and who are receiving chronic optimal medical
therapy and in patients who have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
. Amiodarone therapy can be effective for treatment in
patients with HCM with a history of sustained VT
and/or VF when an ICD is not feasible. (Level of
Evidence: C)
lass IIb
. EP testing may be considered for risk assessment for
SCD in patients with HCM. (Level of Evidence: C)
able 7. Risk Factors for Sudden Cardiac Death in
ypertrophic Cardiomyopathy
Major Risk Factors
Possible in
Individual Patients
ardiac arrest (VF) AF
pontaneous sustained VT Myocardial ischemia
amily history of premature sudden death LV outflow obstruction
nexplained syncope High-risk mutation
V thickness greater than or equal to 30 mm Intense (competitive)
physical exertionbnormal exercise BP
onsustained spontaneous VT
odified with permission from Maron BJ, McKenna WJ, Danielson GK, et al.
merican College of Cardiology/European Society of Cardiology clinical expert
onsensus document on hypertrophic cardiomyopathy. A report of the American
ollege of Cardiology Foundation Task Force on Clinical Expert Consensus
ocuments and the European Society of Cardiology Committee for Practice
uidelines. J Am Coll Cardiol 2003;42:1687–713.
AF  atrial fibrillation; BP  blood pressure; LV  left ventricular; VF 
entricular fibrillation; VT  ventricular tachycardia.
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phylaxis against SCD in patients with HCM who
have 1 or more major risk factor for SCD (see
Table 7) if ICD implantation is not feasible. (Level
of Evidence: C)
.2.1. Risk Stratification
ost individuals with HCM are asymptomatic and the first
anifestation may be SCD (651–657). SCD is usually
elated to ventricular arrhythmia with varying contribution
f triggers such as ischemia, outflow obstruction, or AF
653–656,658). SCD is less frequently due to bradycardia
659). The annual mortality from HCM has been estimated
s high as 6% from tertiary centers (653,660,661), but
ommunity-based studies suggest a more benign disease in
he majority of individuals, with an annual mortality in the
ange of 1% or less (662–667). This relatively low incidence
reates a challenge for risk stratification because the false-
ositive values for any stratifier may overwhelm the true-
ositive values (668). Features suggesting higher risk of
CD have been derived from observational studies
98,662,669–677). In one study, 23 of 480 patients died
uddenly over a mean follow-up of 6.5 y (678). The risk of
CD was directly related to LV wall thickness with essen-
ially no mortality over 20 y with wall thickness less than 20
m and mortality of almost 40% for wall thickness greater
han or equal to 30 mm. Patients with such extreme wall
hickness were the youngest and frequently asymptomatic.
ive of 12 patients in this category under the age of 18 died
uddenly. Others have suggested that patients with extreme
eptal hypertrophy also have other risk factors, and the
ndependent value of extreme septal hypertrophy is less clear
98,679). The degree of outflow obstruction has been shown
o predict cardiovascular death (674,678) but not SCD
678). Athletes with HCM should not participate in most
ompetitive sports with the possible exception of sports of
ow dynamic and low static intensity (680–682). Participa-
ion in low-to-moderate athletic activities may be allowed in
elected low-risk patients (683).
Cardiac MRI (684) and CT (685) have been suggested to
e helpful in assessing extent of disease and predicting
CD. A history of SCD in one or more family members has
een considered to signify higher risk (653,660,686). This is
ntuitively logical and related closely to the suggestion that
ertain specific genetic abnormalities have been associated
ith increased risk of SCD (687–691); the role of genetic
esting as a predictor of SCD is likely to increase (687).
yncope has been associated with increased risk of SCD
657,692–695). The severity of other symptoms such as
yspnea, chest pain, and effort intolerance has not been
orrelated with increased risk of SCD (695,696). A flat or
ypotensive response to upright or supine exercise testing in
atients younger than 40 y has been shown to be a risk
actor for SCD, although the positive predictive value of this
nding is low (658). A normal blood pressure responsedentifies a low-risk group (658,697–699). The presence of aT on Holter monitoring (665,696,700–702) has been
ssociated with a higher risk of SCD, although the positive
redictive accuracy is relatively low. The absence of VT
ppears to have good negative predictive value. VT induced
n the EP laboratory (97) has also been associated with a
igher risk of SCD, although others have suggested that VT
nduced in this setting with aggressive stimulation tech-
iques is not specific (703,704).
A consensus document on HCM from the American
ollege of Cardiology and European Society of Cardiology
ategorized known risk factors for SCD as “major” and
possible in individual patients” (705) (see Table 7).
It is clear that many of the risk factors listed in Table 7 are
nterdependent, and the major independent risk factors may
rove to be the extent of disease and the genetic abnormal-
ty. The absence of risk factors identifies a low-risk group,
ut the positive predictive value of any single risk factor is
imited. Risk stratification based on incorporation of mul-
iple risk factors would likely improve positive predictive
ccuracy (693).
.2.2. Electrophysiological Testing
he value of EP testing in HCM has been controversial
706). In 1989, Fananapazir et al. (707) showed by using 2
remature stimuli that only 16% of patients with cardiac
rrest or syncope in the setting of HCM had inducible
ustained VT. In a later study, the same group published
ata on 230 patients, including 155 patients reported earlier
97,707). Patients with inducible VT had a poorer prognosis
han those without inducible VT. Induced VT was often
olymorphic. The response to EP testing was considered to
e an important predictive factor for outcome, together with
history of syncope or cardiac arrest. In a prospective study
f 29 patients with HCM, 8 of them presenting with
yncope, EP testing with up to 3 extrastimuli at 3 cycle
engths including LV stimulation failed to distinguish
atients with from those without syncope (224). In patients
ho received an ICD for primary prevention, the estimated
ppropriate discharge rate was 5% per year (708).
.2.3. Management
he mainstay of pharmacological management for the
ymptomatic patient has been beta blockers or verapamil,
hich probably exert their effect by reducing heart rate and
ecreasing contractility (653,660). Disopyramide has been
imilarly used presumably for its negative inotropic effect
709). AF can be especially problematic (710,711), with
udden clinical deterioration as a result of high ventricular
ates and loss of atrial filling. In addition, it is associated
ith increased risk of embolism, HF, and death. The high
ate of embolism warrants anticoagulation with warfarin
ven though this has not been validated in this group of
atients by a large randomized trial. Amiodarone is widely
sed and considered the most effective antiarrhythmic
gent, although large controlled comparative trials are not
vailable (710,712). Medical therapy has not been proved to
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinese beneficial in the prevention of disease progression in the
symptomatic individual and is generally not indicated.
onetheless, treatment with beta blockers and/or calcium
ntagonists is tempting even in asymptomatic individuals if
hey are younger and have severe hypertrophy or significant
radients (660). It is intuitively reasonable that optimal
edical therapy and control of comorbidities will also
educe the risk of SCD, although this has not been rigidly
emonstrated.
Although no randomized studies are available, the ICD
as been used in patients with cardiac arrest, sustained VT,
r VF, with a high percentage of patients receiving appro-
riate discharge during follow-up at a rate of 11% per year
708). The ICD implanted in a subgroup of patients for
rimary prophylaxis on the basis of perceived high risk for
CD (syncope, family history of SCD, NSVT, inducible
T, septal thickness greater than or equal to 30 mm)
esulted in a lower rate of appropriate discharge of 5% per
ear (708). Amiodarone has been shown useful in preven-
ion of SCD in nonrandomized studies (712,713), while
ther studies have suggested symptomatic improvement but
ave not shown complete prevention of SCD (714,715).
lacebo-controlled studies or studies that compared ICD
ith amiodarone are not available, and the role of amioda-
one in prevention of SCD is unclear. Amiodarone is
nlikely to be superior to the ICD for this purpose, and a
omparative study may never be done (716). The ICD is not
ndicated in the majority of asymptomatic patients with
CM, who will have a relatively benign course. Its role is
ndividualized in the patient considered to be at high risk for
CD (3,717,718). Although precise risk stratification has
ot been validated, patients with multiple risk factors
especially severe septal hypertrophy, greater than or equal
o 30 mm) and those with SCD (especially multiple SCDs)
n close relatives appear to be at sufficiently high risk to
erit consideration of ICD therapy.
.2.4. Genetic Analysis
enetic analysis is useful in families with HCM because
henever a pathogenetic mutation is identified, it becomes
ossible to establish a presymptomatic diagnosis of the
isease among family members and to provide them with
enetic counseling to assess the risk of disease development
nd transmission of the disease to offspring. Genetic anal-
sis may contribute to risk stratification in selected circum-
tances.
.3. Arrhythmogenic Right Ventricular Cardiomyopathy
ecommendations
lass I
ICD implantation is recommended for the preven-
tion of SCD in patients with ARVC with docu-
mented sustained VT or VF who are receiving
chronic optimal medical therapy and who have rea- usonable expectation of survival with a good func-
tional status for more than 1 y. (Level of Evidence: B)
lass IIa
. ICD implantation can be effective for the prevention
of SCD in patients with ARVC with extensive dis-
ease, including those with LV involvement, 1 or more
affected family member with SCD, or undiagnosed
syncope when VT or VF has not been excluded as the
cause of syncope, who are receiving chronic optimal
medical therapy, and who have reasonable expecta-
tion of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
. Amiodarone or sotalol can be effective for treatment of
sustained VT or VF in patients with ARVC when ICD
implantation is not feasible. (Level of Evidence: C)
. Ablation can be useful as adjunctive therapy in
management of patients with ARVC with recurrent
VT, despite optimal antiarrhythmic drug therapy.
(Level of Evidence: C)
lass IIb
EP testing might be useful for risk assessment of
SCD in patients with ARVC. (Level of Evidence: C)
.3.1. Risk Stratification
RVC (“dysplasia”) is suspected in patients, typically a
oung man, with RV arrhythmias or in relatives of individ-
als with known ARVC. Syncope, presyncope, and, less
requently, biventricular failure are also observed (719,720).
he ventricular arrhythmias have LBBB morphology that
pans the spectrum of simple ventricular ectopy, sustained
nd NSVT, or VF. ARVC needs to be considered along
ith idiopathic RV outflow VT in the individual with
entricular ectopy and VT coming from the RV outflow
egion. In contrast to ARVC, idiopathic RV outflow VT is
sually not associated with the ECG abnormalities seen
ith ARVC, is more common in women, and is initiated by
soproterenol infusion instead of by EP testing (721,722).
he ECG in ARVC frequently shows precordial T-wave
nversion, usually over V1 to V3, and QRS duration greater
han 110 ms (721). Low voltage potentials following the
RS (epsilon waves) are characteristic but seen relatively
nfrequently, and late potentials are observed on the
AECG in greater than 50% of individuals (721,723,724).
Unfortunately, SCD is frequently the first manifestation
f the disease (96,725,726). A standardized diagnostic
cheme has been formulated to establish a clinical diagnosis
n a point score basis (727). The annual incidence of SCD
as varied, ranging from 0.08% to 9% (720,728–730). In an
utopsy series, 24 of 27 patients were determined to have
ied suddenly and 3 to have died of congestive HF (731).
CD occurs relatively frequently during exercise or during
tress, but SCD with no apparent provocation is not
ncommon (732). In one Italian series, up to 25% of SCD
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sually occurs in individuals with grossly visible RV abnor-
alities, it can occur in those with only microscopic
bnormalities and no obvious RV enlargement (734). RV
ilation, precordial repolarization abnormalities, and LV
nvolvement have been associated with risk of sudden death
730,735,736). Certain genetic types may be associated with
igher risk of SCD (737). SCD in 1 or more family
embers intuitively suggests a higher risk of SCD in an
ffected individual, but this has not been well quantified
170).
.3.2. Electrophysiological Testing
he arrhythmic manifestations of the disease are variable
96). The prognostic role of EP testing in patients present-
ng with isolated PVCs or NSVT is not known. The
esponse to EP testing may be influenced by the severity of
he disease. Progression of disease has to be considered. EP
esting has been evaluated in a limited number of patients
or risk stratification. Di Biase et al. (738) used EP testing
n 17 patients with “mild” dysplasia and induced VT only in
atients with spontaneous sustained VT. VT was induced in
0% of 12 patients with spontaneous sustained VT (739).
he positive predictive value for recurrent VT was only
5%. Sustained VT could not be induced in 20 patients
resenting with NSVT (736). In this study, inducibility was
8% in 24 of 27 patients presenting with sustained VT. EP
esting, in general, is used to reproduce clinical VT and to
uide ablation (740,741).
.3.3. Management
he treatment of ARVC is often based on individual patient
resentation and local physician experience. The ICD has been
sed in patients with unexplained syncope, sustained VT, or
F with a high incidence of appropriate shocks (742). Al-
hough there are no specific large randomized trials in ARVC
o support this, the situation is sufficiently “similar” to those
isease states such as previous MI where these indications are
ell established (266,718,741,743). ICD treatment in individ-
als with a known family history of SCD or unexplained
yncope is intuitively compelling but not rigidly proved. The
mpact of medical therapy on mortality is not established. RF
blation has been used in selected patients for VT in medically
efractory patients (744). Elimination of 1 or more clinical
achycardias by RF ablation is useful for management of
ymptoms but may not be sufficient to prevent SCD. Operative
herapy in the form of total electrical RV disconnection has
roved successful in medically refractory patients with normal
V function but does carry a risk of postoperative right HF
745). Heart transplantation and ventricular assist devices are
n option in patients with biventricular failure.
.3.4. Genetic Analysis
enetic analysis is useful in families with RV cardiomyopathy,
ecause whenever a pathogenetic mutation is identified, it
ecomes possible to establish a presymptomatic diagnosis of the disease among family members and to provide them with
enetic counseling to monitor the development of the disease
nd to assess the risk of transmitting the disease to offspring.
ased on current knowledge, genetic analysis does not con-
ribute to risk stratification in RV cardiomyopathy.
.4. Neuromuscular Disorders
ecommendations
lass I
Patients with neuromuscular disorders who have
ventricular arrhythmias should generally be treated in
the same manner as patients without neuromuscular
disorders. (Level of Evidence: A)
lass IIb
Permanent pacemaker insertion may be considered
for neuromuscular diseases such as myotonic muscu-
lar dystrophy, Kearns-Sayre syndrome, Erb dystro-
phy, and peroneal muscular atrophy with any degree
of AV block (including first-degree AV block) with or
without symptoms, because there may be unpredict-
able progression of AV conduction disease. (Level of
Evidence: B)
The inherited neuromuscular disorders may predispose to
trial arrhythmias, conduction defects, advanced AV block,
onomorphic VT, polymorphic VT, and SCD (746–755).
n exhaustive list of the inherited neuromuscular disorders
s beyond the scope of this guideline. Table 8 lists some of
he more common disorders associated with cardiovascular
anifestations, produced in some cases by degeneration of
he specialized conduction tissue and in others by degener-
tive changes in atrial and myocardial tissue predisposing to
ardiomyopathy and ventricular arrhythmias. In many cases,
he resting ECG is abnormal, with first-degree AV block,
undle-branch block, Q waves, ST-T abnormalities, or
VCs (753,754).
The clinical presentation, indicating the potential sub-
trate for SCD, is quite variable, ranging from asymptom-
tic to the symptoms of syncope, lightheadedness, and
alpitations. There are no large series of asymptomatic
atients treated with devices and the timing of pacemaker/
CD implantation is not clear based on the available
iterature. In general, the more advanced the cardiac in-
olvement is (conduction or structural), the more likely it is
hat a serious arrhythmia will occur. SCD is a well-
ecognized complication of some of the neuromuscular
iseases and progression of the conduction abnormalities
ay be unpredictable (756–762). Once cardiac involvement
ccurs, particularly with the muscular dystrophies, the
linician should maintain a low threshold for investigating
ymptoms or ECG findings to determine the need for
acemaker insertion, invasive EP studies, or ICD implan-
ation. Screening for underlying cardiovascular manifesta-
ions with a resting 12-lead ECG or echocardiogram to
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesetermine cardiac involvement should be part of the routine
linical assessment, independent of symptom status. The
elative likelihood of a patient with an inherited neuromus-
ular disorder developing a conduction disturbance, ventric-
lar arrhythmia, or cardiomyopathy is listed in Table 8. In
eneral, the indications for device therapy in patients with
uchenne, Becker, X-linked cardiomyopathies, limb-girdle
C to 2F, and Friedreich ataxia should follow standard
acing/ICD guidelines as for patients with dilated cardio-
yopathies. The reader is referred to the ACC/AHA/
ASPE 2002 Guidelines Update for Implantation of Car-
iac Pacemakers and Antiarrhythmic Devices for a
omprehensive listing of indications (1). In an asymptom-
tic subject with normal ECG and no cardiovascular man-
festations, pacemaker or ICD implantation is generally not
ndicated.
Indications for pharmacological or device therapy in
atients with myasthenia gravis, Guillain-Barre syndrome,
r an acute cerebrovascular event are quite different than
hose for the above-mentioned inherited neuromuscular
isorders. Treatment is often temporary to manage the
cute event and not usually required on a long-term basis.
0. HEART FAILURE
ecommendations
lass I
. ICD therapy is recommended for secondary preven-
tion of SCD in patients who survived VF or hemo-
dynamically unstable VT, or VT with syncope and
who have an LVEF less than or equal to 40%, who are
receiving chronic optimal medical therapy, and who
have a reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: A)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with LV dysfunction due to prior MI who
are at least 40 d post-MI, have an LVEF less than or
Table 8. Frequency of Events in Neuromuscul
Muscular dystrophies
Duchenne
Becker
X-linked dilated CM
Limb-girdle 1B
Limb-girdle 2C-2F
Myotonic MD
Emery-Dreifuss MD and associated disorders
Other conditions
Friedreich’s ataxia
Kearns-Sayre syndrome
 to  represents a comparison between the various m
AD  autosomal dominant; AR  autosomal recessive
dystrophy; VA  ventricular arrhythmias;   low-fre
high-frequency event.equal to 30% to 40%, are NYHA functional class II orIII receiving chronic optimal medical therapy, and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: A) (See Section 1.2.)
. ICD therapy is recommended for primary prevention
to reduce total mortality by a reduction in SCD in
patients with nonischemic heart disease who have an
LVEF less than or equal to 30% to 35%, are NYHA
functional class II or III, are receiving chronic opti-
mal medical therapy, and who have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: B) (See Section
1.2.)
. Amiodarone, sotalol, and/or other beta blockers are
recommended pharmacological adjuncts to ICD
therapy to suppress symptomatic ventricular tachyar-
rhythmias (both sustained and nonsustained) in oth-
erwise optimally treated patients with HF. (Level of
Evidence: C)
. Amiodarone is indicated for the suppression of acute
hemodynamically compromising ventricular or su-
praventricular tachyarrhythmias when cardioversion
and/or correction of reversible causes have failed to
terminate the arrhythmia or prevent its early recur-
rence. (Level of Evidence: B)
lass IIa
. ICD therapy combined with biventricular pacing can
be effective for primary prevention to reduce total
mortality by a reduction in SCD in patients with
NYHA functional class III or IV, are receiving
optimal medical therapy, in sinus rhythm with a QRS
complex of at least 120 ms, and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: B)
. ICD therapy is reasonable for primary prevention to
reduce total mortality by a reduction in SCD in
patients with LV dysfunction due to prior MI who
are at least 40 d post-MI, have an LVEF of less than
sorders Associated With Heart Disease
Inheritance HB VA CM
nked   
nked   
nked —  
  
  
  
nked, AD, AR   
—  
—   
conditions and the relative frequency of an event.
 cardiomyopathy; HB  heart block; MD  muscular
event;   intermediate-frequency event;  ar Di
X-li
X-li
X-li
AD
AR
AD
X-li
AR
edical
; CMor equal to 30% to 35%, are NYHA functional class I,
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have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evi-
dence: B) (See Section 1.2.)
. ICD therapy is reasonable in patients who have
recurrent stable VT, a normal or near normal LVEF,
and optimally treated HF and who have a reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
. Biventricular pacing in the absence of ICD therapy is
reasonable for the prevention of SCD in patients
with NYHA functional class III or IV HF, an LVEF
less than or equal to 35%, and a QRS complex equal
to or wider than 160 ms (or at least 120 ms in the
presence of other evidence of ventricular dyssyn-
chrony) who are receiving chronic optimal medical
therapy and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: B)
lass IIb
. Amiodarone, sotalol, and/or beta blockers may be
considered as pharmacological alternatives to ICD
therapy to suppress symptomatic ventricular tachyar-
rhythmias (both sustained and nonsustained) in op-
timally treated patients with HF for whom ICD
therapy is not feasible. (Level of Evidence: C)
. ICD therapy may be considered for primary preven-
tion to reduce total mortality by a reduction in SCD
in patients with nonischemic heart disease who have
an LVEF of less than or equal to 30% to 35%, are
NYHA functional class I receiving chronic optimal
medical therapy, and who have a reasonable expecta-
tion of survival with a good functional status for more
than 1 y. (Level of Evidence: B) (See Section 1.2.)
Considerations taken by the Writing Committee in
ormulating recommendations for this section are discussed
n detail in the Introduction.
Ventricular arrhythmias and SCD are common in pa-
ients with symptomatic acute and chronic HF and LV
ystolic dysfunction. The cause of HF likely influences the
echanisms and types of ventricular arrhythmias. The
uidelines and comments in this section refer to patients
ith the symptomatic HF; not just abnormal LVEF (refer
o the ACC/AHA Guideline Update for the Diagnosis and
anagement of Chronic Heart Failure in the Adult for
efinitions (6).
Arrhythmia management in the setting of acute HF takes
lace concurrently with attempts at hemodynamic stabiliza-
ion. Evaluation of arrhythmias in the setting of acute HF
ecessitates a search for correctable mechanical problems
uch as catheters placed for hemodynamic monitoring that
re causing ventricular or supraventricular arrhythmias. In
ddition, meticulous attention needs to be given to such
actors as pharmacological agents used in the management Ef acute heart failure and electrolyte and oxygen status.
iven its relatively rapid onset of action and its superior
afety profile in patients with HF, the use of intravenous
miodarone for the management of life-threatening ar-
hythmias during acute HF has gained widespread accep-
ance.
In the acutely ill patient with HF, SVT and AF or atrial
utter may impose hemodynamic decompensation, and
ggressive therapy may be needed. Vagotonic measures
arely work in the setting of acute HF. Poorly tolerated SVT
ay be better treated acutely by synchronous cardioversion,
hich may be accomplished at relatively low energies (e.g.,
0 to 100 J biphasic). Verapamil may be effective at
uppressing reentrant SVTs that are dependent on the AV
ode. Care should be taken to avoid excessive myocardial
uppression related to the negative inotropic effects of
erapamil. Intravenous amiodarone may be more effective at
ate control of AF or atrial flutter and may restore sinus
hythm. In HF patients, amiodarone either alone or with
lectrical cardioversion is effective at slowing the heart rate
nd achieving cardioversion (763,764).
In the setting of acute HF, ventricular arrhythmias may
e especially poorly tolerated and early cardioversion should
e performed, rather than attempting pharmacological ter-
ination of arrhythmia. Patients with advanced myocardial
isease often have intraventricular conduction delays, mak-
ng the distinction of ventricular from supraventricular
rrhythmias challenging. Regardless of the origin of an
nstable arrhythmia, cardioversion is appropriate. Amioda-
one is preferred for longer-term administration and is
enerally well tolerated hemodynamically (765). Catheter
blation may be an appropriate adjunctive therapy in se-
ected patients.
NSVT can be documented on 24-h ambulatory ECG
onitoring in 30% to 80% of chronic HF patients without
rrhythmia symptoms (25,766,767). Although NSVT is
ssociated with increased mortality risk in this population,
he weight of evidence does not show a specific link between
SVT and SCD (25,766,768), although one trial has
uggested a link (767). There is no evidence that suppres-
ion of NSVT has a favorable effect on prognosis in patients
ith HF (638). Thus, asymptomatic NSVT should not be
reated by antiarrhythmic medication. If NSVT causes
ymptoms that require therapy, amiodarone is probably the
afest agent to use for treatment, although amiodarone
reatment in NYHA functional class III patients in the
CD-HeFT trial was associated with possibly increased
ortality (8,248).
Polymorphic VT in association with or not in associ-
tion with QT prolongation may occur during exacerba-
ion of HF. These arrhythmias may resolve with the
reatment of HF.
SCD accounts for approximately 50% of deaths in pa-
ients with HF. However, there is little evidence that
mpiric antiarrhythmic therapy can reduce the risk of SCD.
arlier trials of empiric therapy with amiodarone have
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesielded conflicting results, with some demonstrating re-
uced mortality and others showing no improvement in
urvival (637,638). The SCD-HeFT trial showed no sur-
ival benefit to patients with HF (NYHA functional class II
nd III) and LVEF less than or equal to 35% treated with
miodarone empirically (8).
ICD therapy did not improve the survival of patients with
F due to nonischemic DCM in 2 small trials (635,645).
owever, the SCD-HeFT trial demonstrated a 23% reduc-
ion in total mortality with ICD treatment in comparison to
lacebo (8). These results are consistent with the results of
EFINITE and earlier trials of patients with CHD and LV
ysfunction, some of whom had symptomatic HF
192,267,268). ICD in combination with biventricular pac-
ng may improve survival and improve symptoms of patients
ith advanced HF (NYHA functional class III and IV) over
hort-term follow-up (1 to 2 y).
Biventricular pacing may be used to synchronize the
ontraction of the LV in patients with abnormal ventricular
ctivation. Cardiac resynchronization therapy has been
hown to improve hemodynamics, increase LVEF, extend
xercise tolerance, and improve quality of life (769,770). In
atients with a poor functional status (NYHA functional
lass III or IV), reduced ventricular function (LVEF less
han or equal to 35%), and a wide-QRS complex (at least
20 ms), biventricular pacing without ICD therapy has
onsistently led to a reduction of mortality and hospital
dmissions for the treatment of HF (771,772). It has
herefore been strongly recommended (class I) elsewhere (6)
hat biventricular pacing should be considered for the
reatment of such patients. This guideline considers thera-
ies for the management of ventricular arrhythmias and
CD. In 1 recent study (772) that recruited patients with
YHA class III through IV HF, an EF equal to or less than
5%, and a QRS complex equal to or greater than 160 ms
or at least 120 ms in the presence of other evidence of
entricular dyssynchrony), sudden death was also signifi-
antly reduced when biventricular pacing was applied.
owever, in another study (771) that recruited similar
atients, except that the QRS complex had simply to equal
r exceed 120 ms, sudden death was not prevented by
esynchronization therapy alone. The value of biventricular
acing without additional ICD support for the reduction of
udden death remains controversial (773,774).
1. GENETIC ARRHYTHMIA SYNDROMES
1.1. General Concepts for Risk Stratification
QTS, Brugada syndrome, and catecholaminergic poly-
orphic ventricular tachycardia (CPVT) (Online Mende-
ian Inheritance in Man [OMIM] Nos. 192500, 152427,
03830, 600919, 176261, 603796, 601144, and 604772)
775) are inherited arrhythmogenic diseases. They share
enetically determined susceptibility to VT and SCD in the
bsence of recognizable structural abnormalities of the
eart. These syndromes are by definition rare diseases,ecause they have an estimated prevalence below 5 in 10 000
Definition 1295/1999/EC of the European Parliament
770]).
Given the limited number of individuals affected by these
iseases, certain aspects should be considered before devel-
ping recommendations for risk stratification and manage-
ent of patients with these diseases.
Most of the data available for these conditions derive
from large registries that have followed patients over
time, recording outcome information. No randomized
studies are available, and most likely they will never be
conducted in these uncommon conditions. Therefore,
the level of evidence for recommendation in these con-
ditions is B or C depending on the size of the available
registries and on the duration of the follow-up of enrolled
patients. (This Writing Committee has decided to con-
sider Level of Evidence: B for data collected by the
registries on LQTS because they are based on large
number of patients with a long follow-up and to use a
Level of Evidence: C for the Brugada syndrome and
CPVT registries, which have a much shorter observation
time for enrolled patients.)
Data on the natural history of these diseases are poten-
tially biased by the fact that it is more likely that a highly
symptomatic case is referred to a registry. This potential
bias is likely to be more pronounced in the more recent
registries (ARVC, Brugada syndrome, and CPVT) than
in those that have been collecting patient information for
decades (LQTS).
Some concepts applied for risk stratification are common
to the different inherited arrhythmogenic diseases. For
example, the severity of the ECG phenotype is generally
a marker of increased risk of SCD in most of these
diseases. In LQTS, the “severe” phenotype is represented
by the presence of a QTc exceeding 500 ms (103,776), in
the Brugada syndrome by the spontaneous presence of
ST-segment elevation in the right precordial leads
(104,777), and in CPVT by VT induced by exercise
stress testing (105,778).
Because these diseases are characterized by electrical
abnormalities occurring in the structurally intact heart,
the use of the ICD is always indicated with a class I
indication in the secondary prevention of cardiac arrest.
Its use in primary prevention is more debated, consider-
ing the young age of patients at diagnosis. In LQTS and
in CPVT, pharmacological therapy with beta blockers is
effective in reducing the risk of cardiac events. In these
diseases, therefore, beta blockers are recommended as
first-line treatment in all affected individuals, class I
indication, and the use of the ICD is recommended for
higher-risk subgroups (104,105,777,779). In the Brugada
syndrome, no effective pharmacological treatment is
known and therefore the use of prophylactic ICD should
be targeted to high-risk patients (104,777).
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practice and is being integrated in the risk stratification
schemes (103,780).
In general, a family history of SCD has not proved useful
in stratifying risk in affected patients.
Avoidance of competitive sports is recommended by
some, but not others, for all patients affected by inherited
arrhythmogenic disorders even when physical activity is
not considered to be the trigger for arrhythmic episodes,
such as in patients with Brugada syndrome and LQT3
(see Section 13.1).
A concise overview of clinical manifestations and the
ecommendations for risk stratification and management of
he individual diseases is outlined in the following subsec-
ions.
1.1.1. Long QT Syndrome
ecommendations
lass I
. Lifestyle modification is recommended for patients
with an LQTS diagnosis (clinical and/or molecular).
(Level of Evidence: B)
. Beta blockers are recommended for patients with an
LQTS clinical diagnosis (i.e., in the presence of
prolonged QT interval). (Level of Evidence: B)
. Implantation of an ICD along with use of beta
blockers is recommended for LQTS patients with
previous cardiac arrest and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: A)
lass IIa
. Beta blockers can be effective to reduce SCD in
patients with a molecular LQTS analysis and normal
QT interval. (Level of Evidence: B)
. Implantation of an ICD with continued use of beta
blockers can be effective to reduce SCD in LQTS
patients experiencing syncope and/or VT while re-
ceiving beta blockers and who have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: B)
lass IIb
. Left cardiac sympathetic neural denervation may be
considered for LQTS patients with syncope, torsades
de pointes, or cardiac arrest while receiving beta
blockers. (Level of Evidence: B)
. Implantation of an ICD with the use of beta blockers
may be considered for prophylaxis of SCD for pa-
tients in categories possibly associated with higher
risk of cardiac arrest such as LQT2 and LQT3 and
who have reasonable expectation of survival with a rgood functional status for more than 1 y. (Level of
Evidence: B)
1.1.1.1. Causes and Risk Factors
The LQTS is an inherited disease characterized by pro-
onged ventricular repolarization (QT interval) and by ventric-
lar tachyarrhythmias that may manifest as syncopal events.
ardiac arrhythmias are often elicited by stress and emotion,
lthough in some cases they may also occur at rest or during
leep (781). Two patterns of inheritance have been identified:
he more common autosomal dominant Romano-Ward and
imothy syndromes (782,783) and the much rarer autosomal
ecessive cases. The latter are usually more severe, often but not
lways involving consanguineous marriages, and are often
ssociated with congenital deafness (the Jervell Lange-Nielsen
yndrome [784]). Mutations in 8 genes have been identified: 7
f them encode cardiac ion channel subunits (785–790) and 1
ncodes an anchoring protein that has been implicated in
ontrolling ion channel targeting specific membrane sites
791). The distinguishing features of some of the genetic
ariants of the disease have been identified and incorporated in
isk stratification algorithms.
1.1.1.2. Risk Stratification
Even before the identification of the genetic subtypes,
T interval duration was identified as the strongest predic-
or of risk for cardiac events (syncope, SCD) in LQTS
776), and it remains so. A normal QT interval in an
ngenotyped family member portends a good prognosis
792). A QTc exceeding 500 ms (corresponding to the
pper QTc quartile among affected genotyped individuals)
dentifies patients with the highest risk of becoming symp-
omatic by age 40 (103). Patients with the Jervell Lange-
ielsen and other homozygous syndromes and patients with
QTS associated with syndactyly (790,793) are at higher
isk. A family history of SCD has not proved to be a risk
actor for SCD (779, 794).
Genetic testing is often useful in probands with a clinical
iagnosis of LQTS to provide more accurate risk stratifica-
ion and to guide therapeutic strategies.
Symptoms in LQTS range from SCD to syncope and
ear syncope. Patients resuscitated from SCD have an
specially ominous prognosis, with a relative risk of 12.9 of
xperiencing another cardiac arrest (779). In addition,
ffected patients may be identified because of QT prolon-
ation detected incidentally or because they are relatives of
ffected individuals and are found to be mutation carriers in
enetic screening; prognosis in such family members tends
o be better than that for the proband. Risk is increased
uring the immediate postpartum period (795).
It has been shown that the interplay between genetic
efect, QT duration, and gender may provide an algorithm
or risk stratification (103). Patients with the highest risk of
ecoming symptomatic are LQT1 and LQT2 patients with
QTc greater than 500 ms and males with LQT3 irrespec-
ive of QT interval duration (103). LQT3 patients may
epresent a group at higher risk (780). Among LQT2
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesatients, those with a mutation resulting in a change in the
ore region of the protein (796) appear to be at higher risk
f cardiac events than are those with mutations in other
egions of the gene. Beta blockers are highly effective in
QT1, whereas they offer incomplete protection in LQT2
nd LQT3 (797).
1.1.1.3. Ventricular Arrhythmias
Syncope in LQTS patients is usually attributed to severe
entricular arrhythmias (although other causes can occur).
yncopal events are usually associated with stress, emotion,
r exercise; however, gene-specific triggers for cardiac events
ave been identified in the 3 most common genetic variants
f the disease. Individuals affected by the LQT1 form of the
isease (mutations in the KCNQ1 or KvLQT1 gene encod-
ng the ion channel that conducts the potassium current IKs)
re more susceptible to cardiac events occurring during
xercise (798) and particularly during swimming (799,800).
QT2 patients harbor mutations in the KCNH2 (or
ERG) gene encoding the channel conducting the potas-
ium current IKr are susceptible to cardiac events occurring
uring rest or emotion, and characteristically with acoustic
timuli (800,801). Finally, LQT3 patients carrying muta-
ions in the SCN5A gene encoding the cardiac sodium
hannel are susceptible to cardiac events occurring at rest
nd during sleep (798). A description of the long QT
ubtypes is given in Table 9.
The mean age for first manifestation of the disease is 12 y,
ut there is a wide range from the first year of life to as late
s the fifth through sixth decades. Documentation of the
rrhythmia during cardiac events is relatively uncommon in
QTS: when arrhythmias are recorded, the characteristic
olymorphic VT, “torsades de pointes,” is identified
781,802); SCD may be the first manifestation of the
isease.
1.1.1.4. Lifestyle Changes
It is recommended that all patients affected by LQTS
void competitive sports activity (682). For LQT1 pa-
ients, swimming should be specifically limited or per-
ormed under supervision. LQT2 patients should avoid
xposure to acoustic stimuli especially during sleep
avoidance of telephone and alarm clock on the night
tand). All patients with LQTS should avoid drugs
able 9. Long QT Syndrome Subtypes
Variant Gene Chromosome Function
LQT1 KCNQ1 11p15.5 IKs alpha subunit
LQT2 KCNH2 7q35-35 IKr alpha subunit
LQT3 SCN5A 3p21-23 INa alpha subunit
LQT4 ANK2 4q25-2 Targeting protein
LQT5 KCNE1 21p22.1-22-2 IKs beta subunit
LQT6 KCNE2 21p22.1-22-2 IKr beta subunit
LQT7 KCNJ2 17p23.1-24.2 IK1
LQT8 CACNA1C 12p13.3 ICa alpha subunit
JLN1 KCNQ1 11p15.5 IKs alpha subunitmJLN2 KCNE1 21p22.1-22-2 IKr beta subunitnown to prolong the QT interval and those that deplete
otassium and magnesium.
1.1.1.5. Andersen Syndrome
In 1971, Andersen et al. (803) reported the case of an
-y-old with short stature, hypertelorism, broad nasal root,
nd defect of the soft and hard palate. The definition of
ndersen syndrome was used for the first time in 1994 by
awil et al. (804) to describe a clinical disorder consisting of
major features: potassium-sensitive periodic paralysis,
entricular arrhythmias, and dysmorphic features (similar to
hose described by Andersen in 1971). The presence of a
arying degree of QT interval prolongation was pointed out
n the first systematic description of the disease (804).
ubsequently, Sansone et al. (805) strengthened its crucial
iagnostic significance. Besides showing QT interval pro-
ongation, Andersen syndrome patients may also present
ith repolarization abnormalities consisting in a late repo-
arization component resembling an enlarged U wave. Bi-
irectional VT has been also reported as a distinguishing
attern of arrhythmias in Andersen syndrome. Andersen
yndrome is also referred to as LQT7 even if it has been
ebated whether it should be considered part of the spec-
rum of the LQTSs (806). Despite SCD being reported
807), arrhythmias do not appear to be a major cause of
eath in Andersen syndrome and the disease often has a
enign outcome (805,808).
The genetic background of Andersen syndrome was recently
lucidated through genomewide linkage analysis by Plaster et
l. (804), who successfully linked this disorder to the locus
7q23 in a large family. A candidate gene screening was carried
ut in the critical region and a missense mutation was identi-
ed in the KCNJ2 gene. Additional mutations were subse-
uently identified in 8 unrelated individuals, thus providing the
roof that KCNJ2 is the cause of at least some of the Andersen
yndrome cases. KCNJ2 encodes an inwardly rectifier potas-
ium channel, Kir2.1, that is highly expressed in the heart,
here it appears to act as a determinant factor of phase 4
epolarization and of resting membrane potential. Mutations
n KCNJ2 are found in approximately 40% of patients with
ndersen syndrome.
Little is known about risk stratification and management
f patients with Andersen syndrome. Patients seem to have
entricular arrhythmias but not a high incidence of cardiac
rrest. The benefit of prophylactic treatment with beta
lockers has not been defined even if most patients with
rolonged QT are usually treated with these agents on
mpiric grounds. The beneficial role of calcium channel
lockers has also been proposed based on the arrhythmia
uppression observed in a single patient (809).
1.1.1.6. Genetic Analysis
Genetic analysis is very important for identifying all
utation carriers within an LQTS family. Once identified,
ilent carriers of LQTS genetic defects may be treated with
eta blockers for prophylaxis of life-threatening arrhyth-
ias. Furthermore, silent mutation carriers should receive
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QTS to offspring.
In patients affected by LQTS, genetic analysis is useful for
isk stratification (103) and for making therapeutic decisions
810). Although genetic analysis is not yet widely available, it is
dvisable to try to make it accessible to LQTS patients.
1.1.2. Short QT Syndrome
he first report of a clinical condition characterized by
bnormally short repolarization was made by Gussak et al.
n 2000 (140). These authors described 2 siblings and their
other, all with a persistently short QT interval (260 to 275
s) with peaked and narrow T waves in the absence of
tructural heart disease. These authors proposed that a QT
nterval shorter than 300 ms is diagnostic for SQTS. In
003, Gaita et al. (811), reported 2 families with SQTS and
howed that all affected patients had a QTc less than 300 ms
ith a QT interval less than 280 ms. Shortly thereafter, a
ovel form of SQTS in patients with a QTc up to 320 ms
as identified (812). At present, it is still undefined whether
he diagnosis of SQTS should be based on QT or QTc and
hich is the sensitivity and specificity of different QT/QTc
nterval cutoff values.
Morphological T-wave abnormalities accompany the abbre-
iated repolarization in SQTS. Several patients have tall and
eaked T waves or asymmetrical T waves with a normal
scending phase and a very rapid descending limb. Clinical
arameters for diagnosis are not yet known, so genetic analysis
eems useful to confirm diagnosis in suspected cases.
Up to now, only 23 cases of SQTS from 6 different
amilies have been reported (813) and the present experi-
nce suggests that the disease may be highly lethal. It should
e considered, however, that when only a very limited
ohort of patients is available, the severity of a disease tends
o be overestimated, because symptomatic patients are
dentified because of their life-threatening arrhythmias
hile asymptomatic patients remain underdiagnosed. No
nformation is available on whether specific triggers may
recipitate cardiac events, as cardiac arrest has occurred both
t rest and under stress. Mutations in at least 3 genes
ncoding for cardiac ion channel proteins highly expressed
n the cardiac muscle may cause SQTS.
The first identified SQTS gene is KCNH2 (814), which
as found to harbor mutation leading to a remarkable
ncrease in the IKr current. Bellocq et al. (815) reported
nother gain-of-function mutation affecting the KCNQ1
ene in a 70-y-old man presenting with idiopathic VF and
hort QT interval at the ECG. The third gene is KCNJ2,
dentified as the cause of abnormally short ventricular
able 10. Genetic Variants of Short QT Syndrome
Locus
Name
Chromosomal
Locus Inheritance
Gene
Symbol
QTS1 7q3p2135-q36 Autosomal dominant KCNH2
QTS2 11p15.5 Autosomal dominant KCNQ1
QTS3 17q23.1-q24.2 Autosomal dominant KCNJ2 IKepolarization with a peculiar T-wave morphology (ex-
remely fast terminal limb and a quasi-normal ST segment
nd ascending T-wave phase) by Priori et al. (816).
It is interesting to note that all 3 SQTS genes (KCNH2,
CNQ1, and KCNJ2) also cause LQTS. The ECG pheno-
ypes depend on the opposite biophysical consequences of
he underlying mutations, with loss-of-function mutations
eing associated with LQTS and gain-of-function mutation
eing the cause of SQTS.
EP investigations have shown that both atrial and ven-
ricular effective refractory periods are shortened in SQTS
nd programmed electrical stimulation usually induces ven-
ricular tachyarrhythmias. Whether inducibility of ventric-
lar arrhythmias is predictive of adverse clinical outcome
emains unclear (Table 10).
The management of patients with SQTS is still poorly
efined (817). In patients with mutation on the KCNH2
ene, it has been suggested that quidinidine may be effective
n suppressing inducibility at programmed electrical
timulation, but whether this also confers long-term
revention of cardiac arrest is unknown. For the other
enetic forms of SQTS, the efficacy of quinidine is less
lear and the use of the ICD may be considered, even if it
ay be associated with an increased risk of inappropriate
hocks due to T-wave oversensing (817).
1.1.2.1. Genetic Analysis
Genetic analysis may help identify silent carriers of
QTS-related mutations; however, the risk of cardiac
vents in genetically affected individuals with a normal
CG is currently not known. Similarly, given the limited
umber of patients with SQTS so far identified, at present,
enetic analysis does not contribute to risk stratification.
1.1.3. Brugada Syndrome
ecommendations
lass I
An ICD is indicated for Brugada syndrome patients
with previous cardiac arrest receiving chronic optimal
medical therapy and who have reasonable expectation
of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
lass IIa
. An ICD is reasonable for Brugada syndrome patients
with spontaneous ST-segment elevation in V1, V2, or
V3 who have had syncope with or without mutations
demonstrated in the SCN5A gene and who have
Protein Reference
r potassium channel alpha subunit (HERG) Brugada et al. (813)
s potassium channel alpha subunit (KvLQT1) Bellocq et al. (814)IK
IK1 potassium channel (Kir2.1) Priori et al. (815)
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tional status for more than 1 y. (Level of Evidence: C)
. Clinical monitoring for the development of a spon-
taneous ST-segment elevation pattern is reasonable
for the management of patients with ST-segment
elevation induced only with provocative pharmaco-
logical challenge with or without symptoms. (Level of
Evidence: C)
. An ICD is reasonable for Brugada syndrome patients
with documented VT that has not resulted in cardiac
arrest and who have reasonable expectation of sur-
vival with a good functional status for more than 1 y.
(Level of Evidence: C)
. Isoproterenol can be useful to treat an electrical storm
in the Brugada syndrome. (Level of Evidence: C)
lass IIb
. EP testing may be considered for risk stratification in
asymptomatic Brugada syndrome patients with spon-
taneous ST elevation with or without a mutation in
the SCN5A gene. (Level of Evidence: C)
. Quinidine might be reasonable for the treatment of
electrical storm in patients with Brugada syndrome.
(Level of Evidence: C)
1.1.3.1. Causes and Risk Factors
The Brugada syndrome is associated with a characteris-
ically abnormal ECG and a high risk of SCD in individuals
ith a structurally normal heart (818). The Brugada pattern
CG shows J-point segment elevation in leads V1 to V3 and
BBB in some patients; the ECG pattern can be present
lways or intermittently. Occasionally, J-point elevation has
een reported in other (e.g., inferior) leads. The disease is
ransmitted with an autosomal dominant pattern of inher-
tance. The clinical expression of the phenotype is modified
y gender as 90% of the affected individuals with a diag-
ostic ECG are male. Only 1 Brugada syndrome disease
ene has been identified so far, the cardiac sodium channel
ene (SCN5A) (819); non-SCN5A loci have also been
eported but the disease gene(s) at these loci remain to be
dentified. Cardiac events (syncope or cardiac arrest) occur
redominantly in males in the third and fourth decades of
ife, although presentation with cardiac arrest in neonates or
hildren have been reported (104,777,820). Fever is a
redisposing factor for cardiac arrest in the Brugada syn-
rome (800,818,821–824).
1.1.3.2. Risk Stratification
Because implantation of an ICD is the only prophylactic
easure able to prevent SCD, risk stratification is of major
mportance in these patients.
1.1.3.3. Family History
As with LQTS, there are no data showing that family
istory predicts cardiac events among family members.
herefore, it should not be assumed that asymptomaticndividuals with the characteristic ECG but without family distory are at low risk or that family members of an
ndividual with SCD are at increased risk (104).
1.1.3.4. Electrocardiography
ST-segment elevation can occur spontaneously or be
xposed by administration of sodium channel blockers such
s flecainide, procainamide, or ajmaline (825). There is
greement that patients with a spontaneous pattern have a
orse prognosis than individuals in whom the typical ECG
s observed only after pharmacological drug challenge
104,777).
1.1.3.5. Clinical Symptoms
Patients with history of syncope and the ECG pattern of
pontaneous ST-segment elevation have a 6-fold higher risk
f cardiac arrest than patients without syncope and the
pontaneous ECG pattern (104).
1.1.3.6. Electrophysiological Testing
The role of EP testing for risk stratification is debated.
rugada et al. (206,207) suggested that EP testing has a
ivotal role in risk stratification: in their large study, EP
esting had a low positive predictive value (23%), but over a
-y follow-up, it had a very high negative predictive value
93%). By contrast, Priori et al. (104,826) reported that EP
esting has a low accuracy in predicting individuals who will
xperience cardiac arrest. Priori et al. (104,208) proposed
hat noninvasive risk stratification based on the ECG and
ymptoms provides an accurate alternative for risk
tratification.
1.1.3.7. Genetic Defect
Because only a single gene has been linked to the Brugada
yndrome, there is still insufficient information about the
ontribution of genetic defects in predicting clinical out-
ome. Mutations in the SCN5A gene do not identify a
ubset of patients at higher risk of cardiac events (104).
1.1.3.8. Ventricular Arrhythmias
SCD is caused by rapid polymorphic VT or VF fre-
uently occurring at rest or during sleep. Patients with
rugada syndrome usually do not have ventricular extrasys-
oles or nonsustained runs of VT at Holter recording.
herefore, the therapeutic approach for these patients is
entered on the prevention of cardiac arrest. Basic science
tudies and clinical studies suggest a role for block of the
ransient outward potassium current by quinidine in reduc-
ng arrhythmia frequency (827,828). Quinidine and isopro-
erenol may be useful in patients with arrhythmia storm
ven in the presence of an ICD (139,395,829).
1.1.3.9. Genetic Analysis
Genetic analysis may help identify silent carriers of
rugada syndrome-related mutations so that they can re-
ain under clinical monitoring to detect early manifesta-
ions of the syndrome. Furthermore, once identified, silent
utation carriers should receive genetic counseling andiscussion of the risk of transmitting the disease to off-
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1.1.4. Catecholaminergic Polymorphic
entricular Tachycardia
ecommendations
lass I
. Beta blockers are indicated for patients who are
clinically diagnosed with CPVT on the basis of the
presence of spontaneous or documented stress-
induced ventricular arrhythmias. (Level of Evidence:
C)
. Implantation of an ICD with use of beta blockers is
indicated for patients with CPVT who are survivors
of cardiac arrest and who have reasonable expectation
of survival with a good functional status for more
than 1 y. (Level of Evidence: C)
lass IIa
. Beta blockers can be effective in patients without
clinical manifestations when the diagnosis of CPVT
is established during childhood based on genetic
analysis. (Level of Evidence: C)
. Implantation of an ICD with the use of beta blockers
can be effective for affected patients with CPVT with
syncope and/or documented sustained VT while re-
ceiving beta blockers and who have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
lass IIb
Beta blockers may be considered for patients with
CPVT who were genetically diagnosed in adulthood
and never manifested clinical symptoms of tachyar-
rhythmias. (Level of Evidence: C)
1.1.4.1. Causes and Risk Factors
CPVT is characterized by ventricular tachyarrhythmias
hat develop during physical activity or acute emotion in the
resence of an unremarkable resting ECG (778). The first
pisodes often manifest during childhood, although late-
nset cases have been described (830).
The disease can be transmitted as an autosomal dominant
s well as an autosomal recessive trait. Half of the autosomal
ominant cases are caused by mutations in the gene encod-
ng the cardiac ryanodine receptor (RyR2), responsible for
alcium release from the stores of the sarcoplasmic reticu-
um (831,832). The recessive form is caused by mutations in
he gene encoding calsequestrin (CASQ2), a calcium-
uffering protein in the sarcoplasmic reticulum (833).
1.1.4.2. Risk Stratification
Too few patients with CPVT have been reported to allow
he definition of a risk stratification scheme. Beta blockers
ppear to be effective. Patients who have had an episode ofF are considered at higher risk and are usually implanted
ith an ICD along with beta-blocker therapy. The recur-
ence of sustained VT or of hemodynamically nontolerated
T while receiving beta blockers is usually considered a
arker of higher risk and an ICD is often recommended in
hese patients. EP testing is not useful for management and
isk stratification because CPVT patients are usually not
nducible (105,778).
1.1.4.3. Ventricular Arrhythmias
Supraventricular and ventricular arrhythmias are usually
eproducibly induced by exercise stress when the heart rate
eaches a threshold of 120 to 130 beats per minute. Isolated
VCs usually develop first and are followed shortly after by
hort runs of NSVT. If the patient continues to exercise, the
uration of VT runs progressively increase and VT may
ecome sustained. A beat-to-beat alternating QRS axis that
otates by 180°, “bidirectional VT,” is the typical pattern of
PVT-related arrhythmias. CPVT patients can also present
ith irregular polymorphic VT or VF (105,778).
Beta blockers prevent recurrences of syncope in the
ajority of patients (105,778), even if VT and SVT usually
an still be elicited during exercise stress test. If syncope
ccurs in a patient taking a beta blocker, the implantation of
n ICD is recommended (105). However, ICD therapy
equires careful programming of the device to prevent
eedless therapy for nonsustained episodes of ventricular
achyarrhythmia.
1.1.4.4. Genetic Analysis
Genetic analysis may help identify silent carriers of
atecholaminergic VT-related mutations; once identified
ilent carriers may be treated with beta blockers to reduce
he risk of cardiac events and may receive appropriate
enetic counseling to assess the risk of transmitting the
isease to offspring. Based on current knowledge, genetic
nalysis does not contribute to risk stratification.
2. ARRHYTHMIAS IN
TRUCTURALLY NORMAL HEARTS
2.1. Idiopathic Ventricular Tachycardia
ecommendations
lass I
Catheter ablation is useful in patients with structur-
ally normal hearts with symptomatic, drug-refractory
VT arising from the RV or LV or in those who are
drug intolerant or who do not desire long-term drug
therapy. (Level of Evidence: C)
lass IIa
. EP testing is reasonable for diagnostic evaluation in
patients with structurally normal hearts with palpita-
tions or suspected outflow tract VT. (Level of Evi-
dence: B)
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelines. Drug therapy with beta blockers and/or calcium
channel blockers (and/or IC agents in RVOT VT)
can be useful in patients with structurally normal
hearts with symptomatic VT arising from the RV.
(Level of Evidence: C)
. ICD implantation can be effective therapy for the
termination of sustained VT in patients with normal
or near normal ventricular function and no structural
heart disease who are receiving chronic optimal med-
ical therapy and who have reasonable expectation of
survival for more than 1 y. (Level of Evidence: C)
2.1.1. Demographics and Presentation
f Outflow Tract Ventricular Tachycardia
T arising from the RV is the most common form of VT in
pparently healthy people and is associated with a good
rognosis in those without overt structural heart disease
291,294,297,377,834–844). This VT usually has a left
undle-branch, inferior-axis morphology. It often presents
s nonischemic exercise-induced and/or repetitive mono-
orphic VT. Symptoms tend to be mild and syncope is rare
722). Left ventricular outflow tract (LVOT) VT can arise
n the absence of overt structural abnormalities and accounts
or a small percentage of the overall cases of VT. The ECG
ecorded during sinus rhythm in patients with RVOT
achycardia helps distinguish it from the more serious
ondition of RV dysplasia where the ECG is more often
bnormal (722). RVOT has long been thought to be
diopathic in nature, but this characterization has relied on
onventional imaging and diagnostic techniques such as
tress testing, echocardiography, and coronary angiography
297,834,835,843,845–847). More recently, MRI has been
pplied to the evaluation of patients with VT arising from
he RV in the absence of defined abnormalities on conven-
ional testing particularly to exclude ARVC (210,262).
VOT VT can be classified by site of origin to either an
ndocardial origin; coronary cusp origin; or epicardial origin
232). VT arising from the LVOT and from the LV septum
ypically presents in the third to fifth decades of life (694).
VOT VT is more common in men than in women. This
T may be incessant and may be provoked by exercise.
2.1.2. Mechanisms
everal EP mechanisms have been associated with RVOT
T, including abnormal automaticity and triggered activity.
he most common form of RVOT VT is related to
riggered activity arising from delayed afterdepolarizations
nd is thought to be dependent on intracellular calcium
verload and cyclic adenosine monophosphate (377,
40,841). RVOT VT is frequently adenosine sensitive, may
erminate with vagal maneuvers, and is facilitated by cat-
cholamines. As such, it is often not easily inducible at
aseline EP testing and may require rapid burst pacing or
timulation by isoproterenol (210,722). LV VT arising from
he outflow tract may be reentrant but can also result from
nhanced automaticity. Incessant LV VT has been related po a triggered mechanism associated with delayed afterde-
olarizations (4,694). Idiopathic LV tachycardia can be
erapamil sensitive, adenosine sensitive, and propranolol
ensitive (697–702).
2.1.3. Electrophysiological Testing
P is motivated by the need to establish precise diagnosis to
uide curative catheter ablation (209,210). Outflow tract VT in
he absence of concomitant cardiac disease does not carry an
dverse prognosis, although syncope can occur (848). The
rognostic value of inducibility of ventricular arrhythmias has
ot been systematically evaluated. Inducibility of 80% has been
eported in 35 patients with RVOT when EP testing was
erformed with up to 3 extrastimuli and isoproterenol infusion
f required (300). In another study, a rate of induction of only
% was observed, but this increased to by 80% with isoproter-
nol infusion alone (210). Induction with burst pacing has also
een useful (297).
VTs arising from the LVOT or aortic cusps have been
escribed. These appear to be mechanistically and prognostically
imilar to RVOT VT. Induction of LVOT VT by EP testing is
ot consistent, although the arrhythmia may be provoked. It can
e provoked during isoproterenol infusion (378).
2.1.4. Management
linical treatment of RVOT or LVOT VT often involves beta
nd calcium channel blockers. Type IC antiarrhythmic drugs
ave been found to be useful in RVOT VT (297,837,849–
52). In patients who remain symptomatic or for whom drug
herapy fails, catheter ablation of the arrhythmia focus in the
VOT should be considered. Acute success rates for RVOT
blation have been reported in excess of 90% (210,722).
owever, long-term success varies and may depend on the
egree or presence of other abnormalities.
2.1.5. Demographics and Presentation
f Other Idiopathic Left Ventricular Tachycardias
o-called idiopathic LV VT can arise from the LVOT or
rom the fascicles of the specialized conduction system.
ascicular VT can be classified into 3 types according to
rigin and QRS morphology during VT. Left posterior
ascicular VT typically has an RBBB and superior axis
orphology and is the more common form of fascicular VT.
T arising from the left anterior fascicle has an RBBB and
ight-axis deviation configuration and is less common.
arely, fascicular VT will arise from fascicular location high
n the septum and has a narrow QRS and normal axis
onfiguration. This VT presents in the third to fifth decades
f life (695) and is equally distributed between the sexes.
2.1.6. Mechanisms and Treatment
eft fascicular VT typically is reentrant and may respond to
eta or calcium channel blockers. However, in patients who
o not tolerate medical treatment or for whom medical
reatment has failed, ablation can be considered. Ablation of
osterior fascicular VT is guided by recording made either
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otential preceding the earliest ventricular electrogram
703,704,709,853). Newer 3-dimensional mapping devices
hat do not require the presence of sustained VT can
acilitate ablation in these patients (710).
2.2. Electrolyte Disturbances
ecommendations
lass I
Potassium (and magnesium) salts are useful in treat-
ing ventricular arrhythmias secondary to hypokale-
mia (or hypomagnesmia) resulting from diuretic use
in patients with structurally normal hearts. (Level of
Evidence: B)
lass IIa
. It is reasonable to maintain serum potassium levels
above 4.0 mM/L in any patient with documented
life-threatening ventricular arrhythmias and a struc-
turally normal heart. (Level of Evidence: C)
. It is reasonable to maintain serum potassium levels
above 4.0 mM/L in patients with acute MI. (Level of
Evidence: B)
. Magnesium salts can be beneficial in the manage-
ment of VT secondary to digoxin toxicity in patients
with structurally normal hearts. (Level of Evidence: B)
Although changes in extracellular potassium, extracellular and
ntracellular magnesium (especially with associated hypokalemia),
nd intracellular calcium are all associated with EP changes that
re arrhythmogenic, life-threatening ventricular arrhythmias in
atients with structural heart disease should not be attributed
olely to changes in these ionic concentrations. Changes in
otassium concentration may occur after cardiac arrest or may
ccompany certain disease states such as periodic paralysis.
A rapid rise in extracellular potassium, hypokalemia (less
han 3.5 mM), and hypomagnesemia are all associated with
entricular arrhythmias and SCD in patients with structur-
lly normal hearts (some of whom may have underlying
hannelopathies) and in an AMI setting (591,854–867).
ypomagnesemia is classically associated with polymorphic
T or torsades de pointes, which together with ventricular
rrhythmias in an AMI setting may respond to intravenous
agnesium (868–871). Hypokalemia with or without hy-
omagnesemia may be responsible for ventricular arrhyth-
ias in subjects with hypertension and congestive cardiac
ailure (precipitated by the use of thiazide and loop diuret-
cs) (855,856,872), acute starvation (873), acute alcohol
oxicity/withdrawal, and those with ventricular arrhythmias
ssociated with digoxin and other Vaughan Williams class 1
ntiarrhythmic drugs (865,874,875). Significant hypocalce-
ia can prolong the QT interval.
Changes in the extracellular ionic concentrations of
alcium required to produce EP changes that may contrib-
te to ventricular arrhythmias are not encountered in clinical aractice. Occasionally, hyperparathyroidism can cause im-
ortant elevations in serum calcium concentrations. Intra-
ellular fluctuations in calcium concentration influenced by
rugs (e.g., digitalis glycosides), exercise (e.g., cat-
cholamines), and reperfusion following myocardial isch-
mia, however, can trigger EP changes that may lead to
ife-threatening arrhythmias. The protective effects of beta
lockade in the latter settings may in part be due to the
nhibition of calcium influx into myocytes.
2.3. Physical and Toxic Agents
2.3.1. Alcohol
ecommendations
lass I
. Complete abstinence from alcohol is recommended
in cases where there is a suspected correlation be-
tween alcohol intake and ventricular arrhythmias.
(Level of Evidence: C)
. Persistent life-threatening ventricular arrhythmias de-
spite abstinence from alcohol should be treated in the
same manner that such arrhythmias are treated in
patients with other diseases, including an ICD, as
required, in patients receiving chronic optimal medical
therapy and who have reasonable expectation of survival
for more than 1 y. (Level of Evidence: C)
The relationship between alcohol ingestion and VT/SCD
s indisputable; what is controversial however, is its exact
ature (876). A number of studies claim a J-shaped rela-
ionship with risk lowest in individuals with low alcohol
ntake (i.e., 2 to 6 drinks per week) compared with those
ho rarely or never consume alcohol (877) and those with a
igh alcohol intake (i.e., more than 3 to 5 drinks per day)
878,879) and binge drinking habits, the “holiday heart
yndrome” (880–883). The reason for this relationship is
robably the protective effects of low to moderate alcohol
onsumption on the risk of CHD (884). This is contested
y a meta-analysis where lower protective and harmful
ffects were found in women, in men living in countries
utside the Mediterranean area, and in studies where fatal
vents were used as the outcome. Furthermore, unlike
ow-risk patients without CHD, in middle-aged men with
stablished CHD, low to moderate alcohol intake (1 to 14
nits per week) was not associated with any significant
enefit (885). Alcohol ingestion may therefore reduce the
ncidence of VT/SCD due to coronary events, but its effect
n life-threatening arrhythmias correlates directly with the
mount and duration of alcohol intake and even small
uantities may be significant in susceptible individuals.
The mechanisms associated with alcohol-induced VT/SCD
re complex and not entirely related to the presence of
lcohol-induced cardiomyopathy. Alcohol has a negative ino-
ropic effect mediated by direct interaction with cardiac muscle
ells, although this action is often masked by the indirect
ctions from enhanced release of catecholamines (886). EP
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinestudies have shown alcohol to induce various arrhythmias
ncluding VT in patients with and without cardiomyopathy
887,888). LVH and remodeling is an early response to heavy
rinking (889); one third of alcoholics demonstrate diastolic
ysfunction correlating with consumption (890) and 20% to
6% develop DCM within 5 y (891). In these patients,
yocyte and nuclear hypertrophy, interstitial fibrosis, and
yocyte necrosis provide the substrate for arrhythmogenesis
892). QTc is prolonged in patients with proved alcoholic liver
isease in the absence of electrolyte disturbances and may act as
he trigger to life-threatening arrhythmias (893).
2.3.2. Smoking
ecommendations
lass I
Smoking should be strongly discouraged in all pa-
tients with suspected or documented ventricular ar-
rhythmias and/or aborted SCD. (Level of Evidence: B)
Cigarette smoking is an independent risk factor for SCD
egardless of underlying CHD (58,894–897). The vast
ajority of these deaths are arrhythmic. In females who
moke 25 or more cigarettes per day, the risk of ventricular
rrhythmia and SCD is increased 4-fold, similar to that
onferred by a history of MI (62). It is a long-term risk
actor (898) and continues to be so in survivors of out-of-
ospital cardiac arrest who fail to give up smoking (74).
essation of smoking significantly reduces risk of SCD.
here are no data available to allow identification of
ndividuals at greatest risk.
2.3.3. Lipids
ecommendations
lass I
Statin therapy is beneficial in patients with CHD to
reduce the risk of vascular events, possibly ventricular
arrhythmias, and SCD. (Level of Evidence: A)
lass IIb
n-3 polyunsaturated fatty acid supplementation
may be considered for patients with ventricular
arrhythmias and underlying CHD. (Level of Evi-
dence: B)
The association of high total, very low-density lipopro-
ein (VLDL), or low-density lipoprotein (LDL) cholesterol
evels, a low HDL cholesterol level together with high
riglyceride and apolipoprotein B levels with increased risk
f VT/SCD is almost entirely due to concurrent CHD.
ppropriate lipid management strategies, especially the use
f statins, reduces the risk of SCD by preventing recurrent
atal MI and ventricular arrhythmia (899–901). The effect
f lipid lowering on SCD in primary prevention has not
een addressed, but a relative risk reduction of 30% to 40% sould be expected in parallel with the reduction in the risk
f CHD death (902,903).
Free fatty acid or nonesterified fatty acid levels are also
n independent risk factors for SCD but not fatal MI
94). However, the widely held belief from clinical
tudies that dietary n-3 PUFA may confer protection
rom arrhythmic death in subjects with and without
ocumented underlying CHD (904,905), in patients who
ave manifest previously (904 –911), has been challenged
y a small multicenter, double-blinded, randomized,
lacebo-controlled trial of n-3 PUFA in 200 patients
ith ICD and a recent episode of ventricular arrhythmia
262). This study showed a trend toward a higher
ncidence of VT/VF in patients randomized to fish oil, a
rend that correlated with n-3 PUFA levels. An actuarial
nalysis of time to recurrent events showed significantly
ore events in patients randomized to fish oil.
3. VENTRICULAR ARRHYTHMIAS AND SUDDEN
ARDIAC DEATH RELATED TO SPECIFIC
OPULATIONS
3.1. Athletes
ecommendations
lass I
. Preparticipation history and physical examination, in-
cluding family history of premature or SCD and specific
evidence of cardiovascular diseases such as cardiomyop-
athies and ion channel abnormalities, is recommended
in athletes. (Level of Evidence: C)
. Athletes presenting with rhythm disorders, structural
heart disease, or other signs or symptoms suspicious
for cardiovascular disorders should be evaluated as
any other patient but with recognition of the poten-
tial uniqueness of their activity. (Level of Evidence: C)
. Athletes presenting with syncope should be carefully
evaluated to uncover underlying cardiovascular dis-
ease or rhythm disorder. (Level of Evidence: B)
. Athletes with serious symptoms should cease compe-
tition while cardiovascular abnormalities are being
fully evaluated. (Level of Evidence: C)
lass IIb
Twelve-lead ECG and possibly echocardiography
may be considered as preparticipation screening for
heart disorders in athletes. (Level of Evidence: B)
It is generally accepted that preparticipation screening for
edical conditions should be a requirement for clearance to
articipate in competitive athletics, but there are no uni-
ormly accepted standards for screening. Because the risk of
CD among athletes appears to exceed the risk in compa-
ably aged populations (912), attention to cardiovascular
creening is of special importance.
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ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346Competitive athletics has been defined as “participation
n an organized team or individual sport that requires
egular competition against others as a central component,
hat places a high premium on excellence and achievement
nd requires some form of systematic training” (913,914).
reparticipation screening of athletes has been discussed in
arious conferences, and policy statements, although
802,915,916) the screening programs vary greatly in differ-
nt countries. The major causes of SCD in athletes are
CM (36%) , coronary artery anomalies (19%), ARVC,
nd myocarditis. In Italy, the incidence of the former as a
ause of SCD has been reduced considerably due to an
CG and echocardiographic screening program (917).
3.1.1. Screening and Management
3.1.1.1. Screening
Preparticipation cardiovascular screening focuses in general on a
oung population group (aged less than 30 y), among whom most
nomalies will be congenital, although some might be acquired
isorders (680,915, 918). The multiple mechanisms and diseases
nvolved in sudden death in young athletes have been reviewed
919). Drug intake may have an important effect on the cardio-
ascular system and may lead to coronary artery spasm (cocaine),
odification of repolarization by drugs in susceptible individuals
i.e., antibiotics, antiarrhythmics, antidepressant agents), and
lunted heart rate response during exercise (beta blockers) (920).
pecial consideration is required in athletes who are middle-aged
nd older (914).
Screening of athletes is a difficult task. The low incidence of
nomalies makes screening not very cost effective, although one
tudy has suggested that ECG screening is more cost effective
han echocardiographic screening (921,922). Routine physical
xamination might not reveal clinically significant anomalies,
nd personal or family histories have limited value. The resting
CG can disclose rhythm disturbances, abnormal repolariza-
ion syndromes such as the LQTS, the Brugada syndrome, the
PW syndrome, and the depolarization and repolarization
bnormalities associated with HCM. However, nonspecific
ariations commonly observed on ECGs recorded from ado-
escents and young athletes may be confounding. Echocardi-
graphy may show structural anomalies but will not disclose
nomalies of the coronary arteries.
Nonetheless, it is recommended that all candidates undergo
creening tests, such as ECG and, when appropriate, echocardi-
graphy (e.g., abnormal ECG, family history), beyond the history
nd physical examination. The impact of additional screening
equires further clarification; the financial burden for subsequent
nvestigation in case of suspected anomalies might be considerable.
3.1.1.2. Management of Arrhythmias, Cardiac
rrest, and Syncope in Athletes
In athletes, risk factors might be aggravated or attenuated
ut not abolished by regular physical activity. For legal and
thical reasons, athletes receiving cardiovascular drugs and
evices such as pacemakers and ICDs are generally not
llowed to participate in high-grade competition. Excep- mions, such as beta adrenergicblocking agents, depend on
egal and regulatory guidelines. According to the World
nti-Doping Code established by the World Anti-Doping
gency (WADA), one of the bodies of the International
lympic Committee and accepted by all international sports
ederations, beta blockers and diuretics are prohibited in
ome particular sports. The list of particular sports can be
ound on the WADA World Wide Web site at www.wada-
ma.org and is available as a downloadable file (923).
Athletes presenting with syncope or presyncope should
ot participate in competitive sports until the cause is
etermined to be both benign and treatable. Increase of
VCs during exercise requires careful evaluation. They
ight be caused by structural anomalies, including coronary
rtery anomalies, abnormal origin of coronary artery, mitral
alve prolapse, ARVC, and HCM or DCM. Endurance
raining is commonly accompanied by sinus bradycardia,
unctional rhythm, and Wenckebach AV conduction on
CG. These are generally adaptive responses in apparently
ormal individuals. The distinction between adaptive LV
hamber enlargement and a mild form of cardiomyopathy
ight be difficult. Athletes with nonsustained and asymp-
omatic exercise-induced ventricular arrhythmias may par-
icipate in low-intensity competitive sports provided that no
tructural heart disease has been demonstrated (924). Rec-
mmendations for disqualification from high-intensity
ports have been stated in an advisory paper (914) and a
ethesda Conference (682,802).
Athletes presenting with rhythm disorders, cardiac
nomalies, or syncope should be treated as any other
atients. One must keep in mind that high-grade physical
ctivity may aggravate the anomaly.
3.2. Gender and Pregnancy
ecommendations
lass I
. Pregnant women developing hemodynamically un-
stable VT or VF should be electrically cardioverted or
defibrillated. (Level of Evidence: B) (See Section 7.)
. In pregnant women with the LQTS who have had
symptoms, it is beneficial to continue beta-blocker
medications throughout pregnancy and afterward,
unless there are definite contraindications. (Level of
Evidence: C)
3.2.1. QT Interval
ypically, women have longer QT intervals than do men,
nd this difference is more pronounced at slower heart rates.
he corrected QT interval in males decreases at puberty and
hen gradually increases as androgen levels fall. By age 50,
ender differences in QT intervals have largely equalized
925). A similar shortening of the QT interval at puberty
as been noted in males genotypically characterized with
QTSs (926). These observations strongly support a hor-
onal effect on QT and hence arrhythmia susceptibility. In
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesomen with the congenital LQTS, the risk of cardiac arrest
s greater during the postpartum period compared with
efore or during pregnancy (795). The relative tachycardia
een during pregnancy may serve to shorten the QT interval
nd be protective. Beta blockers have a major benefit during
he postpartum period when the heart rate naturally falls.
eta blockers can generally be used safely during pregnancy.
ost are excreted in breast milk. Use during pregnancy is
enerally well tolerated by both the mother and the fetus,
lthough a decrease in fetal heart rate can be seen. Several
tudies have demonstrated an increased susceptibility in
omen to torsades de pointes, likely related to the longer
aseline QT interval and perhaps to differences in drug
harmacodynamics (927). The incidence of both congenital
nd acquired forms of long QT intervals and resultant
orsades de pointes is higher in women than in men (776,
28). In the Long QT Registry, 70% of the subjects and
8% of affected family members are women (929). Until
uberty, males in the registry were found to be more likely
han females to have cardiac arrests or syncope, but subse-
uently, the incidence of these potentially fatal events
redominated in females (926). Several studies have shown
hat drug-induced torsades de pointes is more common in
omen than in men (930–933). ICD therapy should be
trongly considered in patients with long-term QT syn-
romes who are drug resistant and those with marked
otential for life-threatening arrhythmias (1).
3.2.2. Pregnancy and Postpartum
ecommendations on management of cardiovascular dis-
ases during pregnancy, including ventricular arrhythmias,
ave been summarized elsewhere (934). Palpitations are
xtremely common during pregnancy, and several studies
ave shown an increase in the symptoms of SVT during
regnancy (935–937). While most palpitations are benign
uring pregnancy, new-onset VT is of concern (938,939).
lthough the presence of structural heart disease should be
ought in these women, often VT occurs in the absence of
vert structural heart disease and may be related to elevated
atecholamines (938). As such, these arrhythmias may be
eta blocker sensitive. In women presenting with new-onset
T during the last 6 wk of pregnancy or in the early
ostpartum period, the possibility of postpartum cardiomy-
pathy should be ruled out (940). In women with non-long
T-related sustained VT during pregnancy, antiarrhythmic
herapy may be indicated with intravenous lidocaine acutely
r procainamide long term. Amiodarone can have deleteri-
us effects on the fetus, including hypothyroidism, growth
etardation, and premature birth. Prophylactic therapy with
cardioselective beta blocker may be effective. Sotalol can be
onsidered if beta-blocker therapy is ineffective (941). For
omen with known structural heart disease, pregnancy may
resent significant risk. Pulmonary edema, stroke, or cardiac
eath can occur in up to 13% of such pregnancies (942).
ndependent predictors of risk in women with heart disease
nclude prior history of arrhythmias, cyanosis, poor func-ional class, LV systolic dysfunction, and LV outflow
bstruction (942). Potentially life-threatening ventricular
achyarrhythmias should be terminated by electrical cardio-
ersion. Beta 1-selective beta blockers alone, amiodarone
lone (noting cautions about birth defects above), or in
ombination may be used, and ICD may be needed as its
resence does not contraindicate future pregnancies.
3.2.3. Special Concerns Regarding Specific
rrhythmias
PW syndrome and orthodromic AV reciprocating tachycardia
re more common in men than in women (943,944). In addition,
n patients with WPW syndrome manifest pathways are more
ommon in men. Conversely, antidromic AV ventricular recipro-
ating tachycardia is more common in women than in men.
owever, AF degenerating to VF is more common in men than
n women (100). For symptomatic WPW syndrome, the treat-
ent of choice is RF ablation. The outcomes are similar in both
exes (945–947). Management of symptomatic WPW during
regnancy may require initiation of antiarrhythmic drugs to block
he accessory pathway and, in some, long-term monitoring.
The incidence of SCD at any age is greater in men than in
omen (948). In part, this may be related to the more common
ccurrence of coronary disease in men. However, even
atched cohorts without CHD show a male preponderance.
lassic predictors such as obesity, LVH, hyperlipidemia, and
obacco use are associated with CHD and VT more in men
han in women (898). For women, hyperglycemia, elevated
ematocrit, and decreased vital capacity are more important
redictors for CHD and VT (898). The impact of diabetes is
een in both sexes but is much more pronounced in women.
hile NSVT and PVCs have been associated with increased
isk of sudden death in men with or without CHD, no such
ssociation has been seen in women (898). Similarly, while
VCs post-MI in men have been associated with increased
ortality, this does not hold true for women (949).
3.3. Elderly Patients
ecommendations
lass I
. Elderly patients with ventricular arrhythmias should
generally be treated in the same manner as younger
individuals. (Level of Evidence: A)
. The dosing and titration schedule of antiarrhythmic
drugs prescribed to elderly patients should be ad-
justed to the altered pharmacokinetics of such pa-
tients. (Level of Evidence: C)
lass III
Elderly patients with projected life expectancy less
than 1 y due to major comorbidities should not
receive ICD therapy. (Level of Evidence: C)
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entricular arrhythmias are common in elderly populations,
nd the incidence increases in the presence of structural heart
isease (404,950–952). It must be noted that the elderly are a
eterogeneous group. In different studies, elderly patients are
efined anywhere from greater than 60 y to greater than 85 y
f age. This lack of uniformity raises concerns regarding the
pplicability of study results to the entire elderly population.
Ventricular arrhythmias can be found in 70% to 80% of
ersons over the age of 60 y and complex ventricular ectopy is
ommon in this age group, although many such persons are
ften asymptomatic (953–956). Complex ventricular arrhyth-
ias often presage new major coronary events and SCD in
atients with CHD and other types of structural heart disease
957,958). The incidence of SCD increases with advancing age
959,960). In elderly patients with CHD, the proportion of
ardiac deaths that are sudden decreases (36,961), whereas the
roportion of “out of hospital” SCD increases progressively
ith advancing age (36,414).
Although greater than 80% of patients who die suddenly
rom cardiac causes have CHD, elderly patients with DCM
nd valvular heart disease are also at risk (957,961). SCD
as also been documented in elderly patients with HCM
662), ARVC (962), and surgically repaired tetralogy of
allot (963), particularly in patients with LV dysfunction.
rugada syndrome and congenital LQTS are uncommon
auses of SCD in elderly patients (929,964).
In the peri-infarction period, cardiac arrest (used as SCD
urrogate) is more common in elderly patients. Data from
he Second National Registry of Myocardial Infarction
NRMI-2) indicate that age greater than 75 y was associated
ith a higher likelihood of in-hospital cardiac arrest with an
dds ratio of 1.6 (CI 1.5 to 1.7) (965).
3.3.2. Pharmacological Therapy
he management of ventricular arrhythmias and the preven-
ion of SCD in elderly patients do not differ appreciably from
hose recommended for the general population. However,
hen prescribing antiarrhythmic drugs to elderly patients, one
ust take into account the physiological changes that occur
ith advancing age and adjust drug regimens accordingly.
uch changes include decreased renal and hepatic clearance
nd altered volume of distribution of pharmacological agents.
dditionally, changes in body composition and the presence of
omorbidities must be considered. Therefore, drug therapy
hould be initiated at lower than the usual dose and titration of
he drug should take place at longer intervals and smaller doses.
The empiric use of most antiarrhythmic drugs to treat NSVT
nd other complex ventricular ectopy has been shown to be
neffective in preventing SCD and is even deleterious under certain
ircumstances (966–970). Advanced age has been found to
ncrease the susceptibility to adverse cardiac events from class IC
ntiarrhythmic drugs (969). Amiodarone is the only antiarrhyth-
ic drug shown to improve prognosis in survivors of cardiac brrest, based on a meta-analysis of 15 randomized trials (971) (see
ection 6.3.1 for further discussion).
Amiodarone, however, is a drug associated with numer-
us side effects particularly in elderly patients who are prone
o develop side effects and who are commonly on multiple
rugs increasing the risk of drug interactions (404,972).
herefore, when considering amiodarone therapy for the
revention of SCD in an elderly patient who is receiving
ultiple drugs for comorbid conditions, the treating physi-
ian must weigh the potential benefit of such therapy
gainst its potential side effects and decide whether amio-
arone, device therapy, or no therapy is most appropriate for
his particular patient.
Beta blockers, along with several agents that do not possess
lassic antiarrhythmic properties (e.g., ACE inhibitors, angioten-
in receptor blockers, statins), have been shown in many studies to
educe all-cause mortality and SCD after AMI in all age groups,
ncluding the elderly (110,973–976). In the Beta Blocker Heart
ttack trial, subgroup analysis demonstrated that the greatest
enefit of beta blockers occurred in the group aged 60 to 69 y
973). The combination of beta blockers and amiodarone may
educe all-cause mortality and SCD to a greater extent than
miodarone alone (404,405), and in a post-hoc analysis of the
AST data, patients treated with an antiarrhythmic drug who
ere also receiving beta blockers had a lower SCD rate than those
reated only with an antiarrhythmic drug (977). Beta blockers have
lso been shown to reduce all-cause mortality and SCD in patients
ith severe HF (978,979). In these studies, subgroup analysis
howed equivalent benefit from beta blocker therapy in younger
nd older patients.
Despite the demonstrated efficacy in reducing all-cause
ortality and SCD, beta blockers are underused in the elderly.
retrospective analysis of the use of beta blockers after MI in
atients greater than age 65 y found that only 21% of 3737
atients without contraindications were so treated. Patients
ho received these agents had a 43% lower 2-y mortality than
atients not so treated (980). Similarly, a study of clinical
ractices and sources of therapeutic variation found a strong,
ndependent negative association between age and odds of
reatment with beta blockers after MI (981). These findings are
matter of great public health concern.
3.3.3. Device Therapy
everal randomized, prospective trials have demonstrated the
fficacy of ICDs in reducing SCD in patients with CHD at
igh risk for SCD (primary prevention) and in patients
esuscitated from SCD (secondary prevention) compared with
ntiarrhythmic drug therapy (192,266–268,642,643).
All of the above-referenced studies included substantial
umbers of patients over the age of 65 y. Subgroup analysis
n AVID and MADIT II trials demonstrated equivalent
enefits from ICD implantation in older and younger
atients (266,268). In the Cardiac Arrest Study Hamburg
CASH) study, patients older than 65 y derived a greater
enefit from ICD implantation than younger patients (643).
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rials are applicable to elderly patients across the board.
Data comparing the efficacy and complications of ICD
herapy in older and younger patients are sparse. In a retro-
pective study comparing the efficacy of ICD therapy in
atients over age 65 with that of patients under 65 (982), no
ignificant difference in surgical morbidity or length of hospital
tay following ICD implantation was noted between the 2
roups. Furthermore, similar survival rates were calculated for
he 2 groups at 1, 2, and 3 y postICD implantation.
Similarly in an observational study (983) of 450 patients
ho received either epicardial (46%) or transvenous (54%)
CDs, the 3-, 5-, and 7-y survival for arrhythmic mortality
as similar for younger and older patients. Perioperative
orbidity was also similar in all patient groups.
Despite these documented benefits of ICD implantation,
any physicians have been hesitant to subject elderly
atients to such interventions and the role of device therapy
n this age group has been controversial. However, several
bservational studies have shown that the invasive approach
n managing patients with life-threatening ventricular ar-
hythmias is equally beneficial in the elderly and in younger
atients (984–986). From 1985 to 1995, the use of ICDs in
lder patients grew from 1% to 13%; this was associated
ith improved medium-term survival (987).
Very elderly patients with multiple comorbidities and limited
ife expectancy may not be appropriate candidates for ICD therapy
ven if they meet standard criteria. In such circumstances, the
linical judgment of the primary treating physician and the desires
f the patient and/or his or her family take precedence over general
uideline recommendations. Nevertheless, there is evidence from
study (988) that octogenarians who die suddenly can be highly
unctional even in the month before their death. This information
upports the concept that SCD often strikes fully functional
lderly patients who could benefit from an ICD implantation if
hey meet appropriate criteria.
3.4. Pediatric Patients
ecommendations
lass I
. An ICD should be implanted in pediatric survivors of
a cardiac arrest when a thorough search for a correct-
able cause is negative and the patients are receiving
optimal medical therapy and have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
. Hemodynamic and EP evaluation should be per-
formed in the young patient with symptomatic, sus-
tained VT. (Level of Evidence: C)
. ICD therapy in conjunction with pharmacological
therapy is indicated for high-risk pediatric patients
with a genetic basis (ion channel defects or cardio-
myopathy) for either SCD or sustained ventricular
arrhythmias. The decision to implant an ICD in a
child must consider the risk of SCD associated with sthe disease, the potential equivalent benefit of med-
ical therapy, as well as risk of device malfunction,
infection, or lead failure and that there is reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
lass IIa
. ICD therapy is reasonable for pediatric patients with
spontaneous sustained ventricular arrhythmias asso-
ciated with impaired (LVEF of 35% or less) ventric-
ular function who are receiving chronic optimal
medical therapy and who have reasonable expectation
of survival with a good functional status for more
than 1 y. (Level of Evidence: B)
. Ablation can be useful in pediatric patients with
symptomatic outflow tract or septal VT that is drug
resistant, when the patient is drug intolerant or
wishes not to take drugs. (Level of Evidence: C)
lass III
. Pharmacological treatment of isolated PVCs in pediat-
ric patients is not recommended. (Level of Evidence: C)
. Digoxin or verapamil should not be used for treatment of
sustained tachycardia in infants when VT has not been
excluded as a potential diagnosis. (Level of Evidence: C)
. Ablation is not indicated in young patients with
asymptomatic NSVT and normal ventricular func-
tion. (Level of Evidence: C)
The incidence of SCD due to cardiovascular disease is
ignificantly less in pediatric than in adult patients. Current
stimates are that deaths due to cardiovascular disease in
ndividuals younger than 25 y of age account for less than 1%
f all cardiac mortality (36). Due to this low event rate,
opulation-based epidemiological studies have been required
o define the incidence of unexpected, sudden death in pedi-
tric patients. These studies have been relatively consistent,
ith an event rate between 1.3 and 4 deaths per 100 000
atient years (49,989–991). A definite or probable cardiac
ause has been estimated in 70% of young, unexpected sudden
eath victims (433). This compares with the estimated SCD
ate of 100 per 100 000 patient years in adult patients (992).
iven the low incidence of events, no randomized clinical trials
ave been performed to define either risk stratification for
CD in the young or the role of primary prevention therapies.
herefore, the level of evidence for most recommendations in
oung patients is class C.
Despite these limitations, several groups of young patients
ave been identified who are at an increased risk of SCD
ompared with the general population. These include patients
ith congenital heart disease, coronary artery anomalies, car-
iomyopathies, and primary arrhythmic diagnoses such as the
QTSs (993). The risk of SCD and significance of ventricular
rrhythmias in these patients are discussed in the individual
ections in this report regarding these topics. This section
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lation and its significance as a risk factor for SCD.
SCD in pediatric patients with WPW syndrome is uncom-
on and occurs primarily in patients with prior syncope,
ultiple accessory pathways, or short refractory periods.
herefore, in selected patients, an EP study may be indicated
nd ablation performed if the patient is symptomatic or the
efractory period of the accessory pathway is equal to or less
han 240 ms (279).
Isolated PVCs are common in infants, with 15% of all
ewborns reported as having some ventricular ectopy during
4-h ambulatory ECG monitoring. The prevalence of
entricular ectopy decreases to less than 5% in children but
hen increases to 10% by 10 y of age and 25% during late
dolescence and early adulthood (994–996). For the vast
ajority of young patients with ventricular ectopy, the
rimary objective is to exclude any associated functional or
tructural heart disease, in which case PVCs may have
rognostic significance (434,997). Simple ventricular ectopy
n the absence of heart disease has not been demonstrated to
ave adverse prognostic significance.
Sustained ventricular arrhythmias may also occur in infants,
ost commonly, it is an accelerated idioventricular rhythm. By
efinition, this is a ventricular rhythm no more than 20% faster
han the sinus rate and occurring in the absence of other heart
isease (998). This arrhythmia typically resolves spontaneously
uring the first months of life. This is in contrast to the rare infant
ith incessant VT, which may be due to discrete myocardial
umors or cardiomyopathy (999,1000). VF and SCD have been
eported in these infants, most often following the administration
f intravenous digoxin or verapamil for a presumptive diagnosis of
VT (1001,1002). These ventricular arrhythmias may respond to
ntiarrhythmic treatment or be amenable to surgical resection.
ustained VT in infants may also be caused by hyperkalemia or
ssociated with one of the LQTSs, particularly those forms with
V block or digital syndactyly (790,1003,1004).
There is considerable debate regarding the sudden infant
eath syndrome (SIDS) and potential role of the LQTS in
ausing some of these deaths (1005,1006). However,
opulation-based studies have demonstrated a 40% decline in
he incidence of SIDS associated with avoidance of sleeping in
he prone position, supporting apnea, or impaired respiratory
egulation as the primary cause of SIDS in most cases (1007).
efinition of the cause(s) of SIDS remains an area of ongoing
nvestigation and includes autonomic dysfunction and ventric-
lar arrhythmias due to genetic causes.
Beyond the first year of life, most children with complex ectopy
r hemodynamically tolerated VT appear to have a good progno-
is (233,1008). The cause of these arrhythmias remains unknown,
nd they often spontaneously resolve. Pharmacological suppres-
ion of these ventricular arrhythmias is generally ineffective and
ay increase the risk of an adverse outcome.
RVOT and LVOT tachycardia and LV septal tachycar-
ia may be diagnosed during childhood or adolescence. The
riteria for diagnoses of these specific arrhythmias are
iscussed in Section 12. The general prognosis for theserrhythmias is mostly benign, with treatment for symptom-
tic patients with catheter ablation offering a high rate of
ure. As with other pediatric arrhythmias, a primary objec-
ive is to exclude any associated cardiovascular disease.
atecholaminergic or exercise-induced polymorphic VT is
ne exception to the benign prognosis for hemodynamically
olerated VT in patients with an otherwise normal heart.
lthough patients with this form of VT may not be overtly
ymptomatic, they are at risk for SCD (105). Also, symp-
omatic ventricular arrhythmias may be the initial presen-
ation of cardiomyopathy in young patients (834,1009).
The role and benefit of ICD implantation for the
revention of SCD in young children with advanced ven-
ricular dysfunction have not been defined. In older children
nd adolescents, prophylactic ICD implantation may be
onsidered, based on data derived from adult randomized
linical trials of similar patients (8,248).
The treatment of potentially life-threatening ventricular ar-
hythmias in children is disease specific (e.g., beta blockade for
QTSs, catheter or surgical ablation for focal VTs, and heart
ransplantation for end-stage cardiomyopathies). When indicated,
CDs with transvenous lead systems are generally feasible in
hildren older than 10 y (1). However, there is concern regarding
he longevity of intravascular leads when potentially used for
ecades of life (1010). The use of ICDs in younger children and
hose with complex congenital heart disease remains challenging
nd often requires the use of epicardial or subcutaneous array
ystems. The higher incidence of lead failure and ICD infection or
rosion in these patients mandates the judicious use of these
evices in young patients (1011).
3.5. Patients With Implantable
ardioverter-Defibrillators
ecommendations
lass I
. Patients with implanted ICDs should receive regular
follow-up and analysis of the device status. (Level of
Evidence: C)
. Implanted ICDs should be programmed to obtain
optimal sensitivity and specificity. (Level of Evi-
dence: C)
. Measures should be undertaken to minimize the
risk of inappropriate ICD therapies. (Level of
Evidence: C)
. Patients with implanted ICDs who present with
incessant VT should be hospitalized for manage-
ment. (Level of Evidence: C)
lass IIa
. Catheter ablation can be useful for patients with
implanted ICDs who experience incessant or fre-
quently recurring VT. (Level of Evidence: B)
. In patients experiencing inappropriate ICD therapy,
EP evaluation can be useful for diagnostic and ther-
apeutic purposes. (Level of Evidence: C)
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ncidence of arrhythmias, although the patient is protected
rom the consequences of the arrhythmias.
3.5.1. Supraventricular Tachyarrhythmias
VT may trigger ICD action due to fulfilling programmed
entricular or SVT detection criteria. The effect of atrial
achyarrhythmia on ventricular rate response is crucial. As
ong as the ventricular rate fits within the tachycardia
etection window, meaningful programming of the detec-
ion algorithms may prevent device action for VT. If
entricular rate falls within the VF detection window,
ppropriate therapy should not be withheld (see Section 7.6
or further discussion). Sophisticated algorithms enhance
pecificity of VT therapy and help to avoid VT therapies
ased on rate criteria alone (1012–1014). Beta blockade is
lso a valuable therapy that will prevent many unwanted
evice interventions due to supraventricular arrhythmias.
dditional investigations such as Holter recordings,
atient-activated loop recorders, and EP studies might be
equired to guide the management of these arrhythmias.
3.5.2. Supraventricular Tachycardia in Patients
ith Ventricular Implantable Cardioverter-Defibrillators
pisode analysis relies mainly on the information from the
entricular lead of the ICD, although in some instances atrial
ctivity is also sensed (see later) (1015). Careful analysis of detected
pisodes, the effects of antitachycardia pacing on the cycle length
ntervals, and the mode of termination or acceleration are impor-
ant for classification of the detected tachycardia. Enhanced
iscrimination algorithms help to reduce inappropriate VT ther-
pies based on the rate criterion alone. AF is the most frequent
ulprit of arrhythmia. Rapid ventricular rate during SVTs may
rovoke ventricular antitachycardia pacing. Device action may be
roarrhythmic, as inappropriate antitachycardia pacing may cause
T or VF (1016).
3.5.3. Dual-Chamber Implantable
ardioverter-Defibrillators
ual-chamber ICDs provide improved atrial diagnostic
eatures with recording of local atrial electrograms, regular-
ty of atrial signals, and cycle lengths. This may provide
dditional features to avoid inappropriate VT/VF therapies,
ut inappropriate ventricular tachyarrhythmia sensing still
ccurs in 10% to 15% of cases (1017). Oversensing of
ar-field signals by the atrial electrodes(s) may prompt
nappropriate therapies for SVTs, such as antitachycardia
acing or automatic cardioversion. In case of programmed
nternal atrial cardioversion therapies, even low-energy
hocks may be painful and compromise quality of life
1018). High-rate atrial antitachycardia pacing may induce
transient) AF. Efficacy of advanced atrial pacing or cardio-
ersion therapies varies greatly in function of episode
uration, atrial cycle length, and atrial tachycardia mecha-
ism (1013,1019,1020). Acute efficacy of atrial antitachy-
ardia pacing may be as high as 40% (1013).3.5.4. Arrhythmia Storm in Implantable
ardioverter-Defibrillator Patients
he term arrhythmia storm refers to a situation when
umerous device discharges occur due to recurrent repetitive
rrhythmias. A vicious cycle between device action and
ardiac dysfunction may lead to further deterioration. The
anagement must address all aspects to correct the situation
see Section 7.6 for further discussion).
3.6. Drug-Induced Arrhythmias
3.6.1. Introduction
ecause the problem of drug-induced arrhythmias is spo-
adic, randomized, double-blind clinical trials have, with
ery few exceptions, not been performed. Specific syn-
romes of drug-induced arrhythmias, with diverse mecha-
isms and management strategies, are described in the
ections that follow. Treatment guidelines focus on avoiding
rug treatment in high-risk patients, recognizing the syn-
romes of drug-induced arrhythmia and withdrawal of the
ffending agent(s). The efficacy of specific therapies is often
nferred from anecdotal evidence or preclinical, mechanism-
ased studies.
High drug concentrations due to overdose or drug inter-
ctions generally increase the risk of drug-induced arrhyth-
ias. The largest increases in concentrations occur when a
rug is eliminated by a single pathway and that pathway is
usceptible to inhibition by the administration of a second
rug. Table 11 lists examples of drug interactions that may
ause arrhythmias through this mechanism. Interactions can
lso reduce plasma concentrations of antiarrhythmic drugs
nd thereby exacerbate the arrhythmia being treated. Addi-
ive pharmacological effects may also result in arrhythmias.
3.6.2. Digitalis Toxicity
ecommendations
lass I
An antidigitalis antibody is recommended for patients
who present with sustained ventricular arrhythmias,
advanced AV block, and/or asystole that are considered
due to digitalis toxicity. (Level of Evidence: A)
lass IIa
. Patients taking digitalis who present with mild car-
diac toxicity (e.g., isolated ectopic beats only) can be
managed effectively with recognition, continuous
monitoring of cardiac rhythm, withdrawal of digi-
talis, restoration of normal electrolyte levels (includ-
ing serum potassium greater than 4 mM/L), and
oxygenation. (Level of Evidence: C)
. Magnesium or pacing is reasonable for patients who
take digitalis and present with severe toxicity (sus-
tained ventricular arrhythmias, advanced AV block,
and/or asystole). (Level of Evidence: C)
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Dialysis for the management of hyperkalemia may be
considered for patients who take digitalis and present
with severe toxicity (sustained ventricular arrhyth-
mias; advanced AV block, and/or asystole). (Level of
able 11. Drug Interactions Causing Arrhythmias
Drug Interacting Drug
Increased Concentratio
igoxin Some antibiotics
igoxin Amiodarone
Quinidine
Verapamil
Cyclosporine
Itraconazole
Erythromycin
uinidine Ketoconazole
isapride Itraconazole
erfenadine, astemizole Erythromycin*
Clarithromycin
Some calcium blockers*
Some HIV protease inhibitors
(especially ritanovir)
eta blockers propafenone Quinidine (even ultra-low dose)
Fluoxetine
lecainide Some tricyclic antidepressants
ofetilide Verapamil
Cimetidine
Trimethoprim
Ketoconazole
Megestrol
Decreased Concentrati
igoxin Antacids
Rifampin
uinidine, mexiletine Rifampin, barbiturates
Synergistic Pharmacologica
T-prolonging antiarrhythmics Diuretics
eta blockers Amiodarone, clonidine, digoxin,
diltiazem, verapamil
igoxin Amiodarone, beta blockers,
clonidine, diltiazem,
verapamil
erapamil Amiodarone, beta blockers,
clonidine, digoxin, diltiazem
iltiazem Amiodarone, beta blockers,
clonidine, digoxin, verapamil
lonidine Amiodarone, beta blockers,
digoxin, diltiazem, verapamil
miodarone Beta blockers, clonidine,
digoxin, diltiazem, verapamil
ildenafil Nitrates
These may also accumulate to toxic levels with co-administration of inhibitor drugs
lancey CE, editors. Handbook of Experimental Pharmacology: vol. 171. Basis andEvidence: C)lass III
Management by lidocaine or phenytoin is not recom-
mended for patients taking digitalis and who present
with severe toxicity (sustained ventricular arrhyth-
mias, advanced AV block, and/or asystole). (Level of
Effect
Arrhythmogenic Drug
liminating gut flora that metabolize digoxin, some antibiotics may
crease digoxin bioavailability. Note: some antibiotics also interfere with
glycoprotein (expressed in the intestine and elsewhere), another effect
at can elevate digoxin concentration
ased digoxin bioavailability, reduced biliary and renal excretion due to
glycoprotein inhibition
xin toxicity
ased drug levels
ased beta blockade
ased beta blockade
ased adverse effects
eased analgesia (due to failure of biotransformation to the active
etabolite morphine)
ased plasma dofetilide concentration due to inhibition of renal excretion
Antiarrhythmic Drug
eased digoxin effect due to decreased absorption
ased P-glycoprotein activity
ced drug metabolism
ivity Causing Arrhythmias
ased torsades de pointes risk due to diuretic-induced hypokalemia
ycardia when used in combination
ased and persistent vasodilation; risk of myocardial ischemia
toconazole. Data are from Roden DM, Anderson ME. Proarrhythmia. In: Kass RS,
ment of Cardiac Arrhythmias. Boston: Springer Verlag, 2006:288–304 (1021).n of
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Certain arrhythmias are typical: enhanced atrial, junc-
ional, or ventricular automaticity (with ectopic beats or
achycardia) often combined with AV block. Overdose of
igitalis causes severe hyperkalemia and cardiac standstill.
he diagnosis is established by the combination of charac-
eristic rhythm disturbances, ancillary symptoms (visual
isturbances, nausea, changes in mentation), and elevated
erum concentrations. Contributing factors may include
ypothyroidism, hypokalemia, or renal dysfunction.
3.6.2.2. Specific Management
In mild cases, management includes discontinuing the
rug, monitoring rhythm and maintaining normal serum
otassium. Occasionally, temporary pacing may be needed.
or more severe intoxication (serum digoxin concentration
reater than 4 to 5 ng/mL, and with serious arrhythmias),
he treatment of choice is digoxin-specific Fab antibody
1022). In one series of 150 severely intoxicated patients,
esponse was rapid (30 min to 4 h), and 54% of patients
resenting with a cardiac arrest survived hospitalization.
ide effects include worsening of the underlying disease
increased ventricular rate during AF, exacerbation of HF)
nd hypokalemia. Digoxin concentration monitoring is
nreliable after antidigoxin antibody. There is little role for
reviously used therapies such as lidocaine or phenytoin.
3.6.3. Drug-Induced Long QT Syndrome
ecommendations
lass I
In patients with drug-induced LQTS, removal of the
offending agent is indicated. (Level of Evidence: A)
lass IIa
. Management with intravenous magnesium sulfate is
reasonable for patients who take QT-prolonging
drugs and present with few episodes of torsades de
pointes in which the QT remains long. (Level of
Evidence: B)
. Atrial or ventricular pacing or isoproterenol is rea-
sonable for patients taking QT-prolonging drugs
who present with recurrent torsades de pointes.
(Level of Evidence: B)
lass IIb
Potassium ion repletion to 4.5 to 5 mmol/L may be
reasonable for patients who take QT-prolonging
drugs and present with few episodes of torsades de
pointes in whom the QT remains long. (Level of
Evidence: C)
3.6.3.1. Clinical Features
Marked QT prolongation, often accompanied by the
orphologically distinctive polymorphic VT torsades deointes, occurs in 1% to 10% of patients receiving QT-
D
2rolonging antiarrhythmic drugs and much more rarely in
atients receiving “noncardiovascular” drugs with QT-
rolonging potential. While many drugs have been associ-
ted with isolated cases of torsades de pointes, Table 12 lists
hose generally recognized as having QT-prolonging poten-
ial. An up-to-date list is maintained at www.torsades.org
nd www.qtdrugs.org.
Most cases of drug-induced torsades de pointes display a
short-long-short” series of cycle length changes prior to
nitiation of tachycardia. QT intervals, uncorrected for rate,
re generally greater than 500 ms, prominent U waves are
ommon, and marked QTU prolongation may be evident
nly on postpause beats. Major risk factors for drug-induced
orsades de pointes are listed in Table 13; often more than
ne is present. Drugs can expose subclinical congenital
QTS; in addition, some studies have implicated com-
oner DNA variants (polymorphisms, with frequencies
anging up to 15% of some populations) (70,1023).
Presentations of drug-induced QT prolongation include
ncidental detection in an asymptomatic patient, palpita-
ions due to frequent extrasystoles and nonsustained ven-
ricular arrhythmias, syncope due to prolonged episodes of
orsades de pointes, or SCD. The extent to which SCD in
atients receiving QT-prolonging therapies represents tor-
ades de pointes is uncertain. The QT-prolonging agent
-sotalol increased mortality in a large randomized clinical
rial (SWORD [Survival With Oral D-sotalol]), an effect
hat may have been due to torsades de pointes (970). In the
anish Investigators of Arrhythmia and Mortality on
ofetilide (DIAMOND) trial, 3.3% of patients with severe
F had torsades de pointes during the first 72 h of
ofetilide therapy (1024). High concentrations of erythro-
ycin achieved by intravenous therapy have been associated
ith torsades de pointes, and a review of SCD in a
able 12. Examples of Drugs Causing Torsades de Pointes*
requent (greater than 1%)
(e.g.,) hospitalization for monitoring recommended during drug
initiation in some circumstances)
● Disopyramide
● Dofetilide
● Ibutilide
● Procainamide
● Quinidine
● Sotalol
● Ajmaline
ess frequent
● Amiodarone
● Arsenic trioxide
● Bepridil
● Cisapride
● Anti-infectives: clarithromycin, erythromycin, halofantrine,
pentamidine, sparfloxacin
● Antiemetics: domperidone, droperidol
● Antipsychotics: chlorpromazine, haloperidol, mesoridazine,
thioridazine, pimozide
● Opioid dependence agents: methadone
See www.torsades.org for up-to-date listing. Adapted with permission from Roden
M. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013–
2. Copyright © 2004 Massachusetts Medical Society (1025).
M
e
i
1
p
s
s
(
p
n
p
s
(
w
r
2
m
s
e
p
(
(
c
w
1
R
C
C
1
2
C
1
a
m
b
s
c
T
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
A
i
S
T
D
Q
S
*
t
e316 Zipes et al. JACC Vol. 48, No. 5, 2006
ACC/AHA/ESC Practice Guidelines September 5, 2006:e247–e346edicaid database implicated the combination of oral
rythromycin and drugs blocking its metabolism as increas-
ng SCD (603).
3.6.3.2. Management
Monitoring high-risk patients during initiation of QT-
rolonging antiarrhythmic drugs and recognition of the
yndrome when it occurs are the first steps. Maintaining
erum potassium between 4.5 and 5 mEq/L shortens QT
1026, 1027); no specific data are available on the efficacy of
otassium repletion to prevent torsades de pointes. Intrave-
ous magnesium can suppress episodes of torsades de
ointes without necessarily shortening QT, even when
erum magnesium is normal (1028). Magnesium toxicity
areflexia progressing to respiratory depression) can occur
hen concentrations reach 6 to 8 mEq/L but is a very small
isk with the doses usually used in torsades de pointes, 1 to
g intravenously. Temporary pacing is highly effective in
anaging torsades de pointes that is recurrent after potas-
ium repletion and magnesium supplementation. Isoproter-
nol can also be used to increase heart rate and abolish
able 13. Risk Factors for Drug-Induced Torsades de Pointes
Female gender
Hypokalemia
Bradycardia
Recent conversion from atrial fibrillation
Congestive heart failure
Digitalis therapy
High drug concentrations (exception: quinidine), often due to drug
interactions
Rapid rate of intravenous drug administration
Baseline QT prolongation
Ventricular arrhythmia
Left ventricular hypertrophy
Congenital long QT syndrome
Certain DNA polymorphisms
Severe hypomagnesemia
Concomitant use of 2 or more drugs that prolong the QT interval
Combination of QT-prolonging drug with its metabolic inhibitor
dapted with permission from Roden DM. Drug-induced prolongation of the QT
nterval. N Engl J Med 2004;350:1013–22. Copyright © 2004 Massachusetts Medical
ociety (1025).
DNA  deoxyribonucleic acid.
able 14. Syndromes of Drug-Induced Arrhythmia and Their M
Drugs Clinical Settin
igitalis Mild cardiac toxicity (isolated arrhythm
Severe toxicity: sustained ventricular ar
block; asystole
T-prolonging drugs Torsades de pointes: few episodes, QT
Recurrent torsades de pointes
odium channel blockers Elevated defibrillation or pacing requir
Atrial flutter with 1:1 AV conduction
Ventricular tachycardia (more frequent
Brugada syndrome
Always includes recognition, continuous monitoring of cardiac rhythm, withdrawal o
han 4 mEq/L), and oxygenation. The order shown is not meant to represent the preferre
AV  atrioventricular; IV  intravenous.ostectopic pauses. Anecdotes have reported that lidocaine
1029), verapamil (1030), and even occasionally amiodarone
1031) have been effective. However, amiodarone may itself
ause torsades de pointes, albeit much less commonly than
ith other QT-prolonging antiarrhythmics (1032).
3.6.4. Sodium Channel Blocker–Related Toxicity
ecommendations
lass I
In patients with sodium channel blocker–related
toxicity, removal of the offending agent is indicated.
(Level of Evidence: A)
lass IIa
. Stopping the drug, reprogramming the pacemaker or
repositioning leads can be useful in patients taking sodium
channel blockers who present with elevated defibrillation
thresholds or pacing requirement. (Level of Evidence: C)
. In patients taking sodium channel blockers who present
with atrial flutter with 1:1 AV conduction, withdrawal of
the offending agent is reasonable. If the drug needs to be
continued, additional A-V nodal blockade with diltiazem,
verapamil, or beta blocker or atrial flutter ablation can be
effective. (Level of Evidence: C)
lass IIb
Administration of a beta blocker and a sodium bolus
may be considered for patients taking sodium chan-
nel blockers if the tachycardia becomes more frequent
or more difficult to cardiovert. (Level of Evidence: C)
3.6.4.1. Clinical Features
Arrhythmias caused by sodium channel-blocking drugs
re included in Table 14. Antiarrhythmic drugs are the
ost common precipitants, although other agents, nota-
ly tricyclic antidepressants and cocaine, may produce
ome of their toxicities through these mechanisms. Sodium
hannelblocking drugs with slower rates of dissociation
ement
Management*
nly)
mias; advanced AV Anti-digitalis antibody
Pacing
Dialysis for hyperkalemia
ins long IV magnesium sulfate (MgSO4)
Replete potassium (K) to 4.5 to 5 mEq/L
Ventricular pacing
Isoproterenol
t Stop drug; reposition leads
Diltiazem, verapamil, beta blocker (IV)
ult to cardiovert) Beta blocker; sodium
Stop drug; treat arrhythmia
ding agents, restoration of normal electrolytes (including serum potassium to greateranag
g
ias o
rhyth
rema
emen
; diffic
f offen
d sequence when more than one treatment is listed.
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September 5, 2006:e247–e346 ACC/AHA/ESC Practice Guidelinesend to generate these adverse effects more commonly; these
nclude agents such as flecainide, propafenone, and quini-
ine that (as a consequence of the slow dissociation rate)
end to prolong QRS durations even at normal heart rates
nd therapeutic dosages (1033).
In large clinical trials, sodium channelblocking drugs have
ncreased mortality among patients convalescing from MI. This
ffect was best demonstrated in CAST (967), but similar trends
ere also seen with earlier trials of mexiletine (1034) and disopyr-
mide (1035). Analysis of the CAST database has indicated that
atients at risk for recurrent myocardial ischemia are especially
usceptible to SCD during sodium channelblocking drugs
1036).
In patients treated for sustained VT, these agents may
rovoke more frequent, and often more difficult to cardiovert,
pisodes of sustained VT. While the drugs generally slow the
ate of VT, occasionally the arrhythmia becomes disorganized
nd may be resistant to cardioversion; deaths have resulted. It
eems likely that at least some of the excess mortality in CAST
nd other trials reflect such provocation or exacerbation of
ustained ventricular arrhythmias. Sodium channelblocking
rugs increase defibrillation energy requirement and pacing
hresholds (1037,1038); as a consequence, patients may require
eprogramming or revision of pacing or ICD systems or
hanges in their drug regimens. Sodium channel blockers can
convert” AF to slow atrial flutter, which can show 1:1 AV
onduction with wide-QRS complexes. This drug-induced
rrhythmia can be confused with VT (1039).
Sodium channel blockers can occasionally precipitate the
ypical Brugada syndrome ECG (1040). This has been
eported not only with antiarrhythmic drugs but also with
ricyclic antidepressants (1041) and cocaine (1042).
hether this represents exposure of individuals with clini-
ally inapparent Brugada syndrome (see Section 11.1.3) or
ne end of a broad spectrum of responses to sodium
hannelblocking drugs is not known. The extent to which
atent Brugada syndrome may have played a role in the
AST result is also unknown.
3.6.4.2. Management
Sodium channel-blocking drugs should not be used in
atients with MI or sustained VT due to structural heart
isease. The extent to which this prohibition on sodium
hannel blockers in patients with structural heart disease
xtends to tricyclic antidepressants that also block sodium
hannels is unknown (1043).
The major indication for these drugs is atrial arrhythmias
n patients without structural heart disease; this excludes at
east those studied in CAST (recent or remote MI) and by
echanistic considerations extends to those with other
orms of ventricular dysfunction. When used for AF, AV
odalblocking drugs should be coadministered to prevent
apid ventricular rates should atrial flutter occur; amioda-
one may be an exception. Patients presenting with atrial
utter and rapid rates (and in whom VT is not a consider-
tion) should be treated by slowing of AV conduction withrugs such as intravenous diltiazem. Ablation of the atrial
utter and continuation of the antiarrhythmic drug may be
n option for long-term therapy (1044).
Animal and clinical anecdotes suggest that administration
f sodium, as sodium chloride or sodium bicarbonate, may
e effective in the reversing conduction slowing or frequent
r cardioversion-resistant VT (1045,1046). Beta blockers
ave also been used successfully (1047).
3.6.5. Tricyclic Antidepressant Overdose
3.6.5.1. Clinical Features
Tricyclic antidepressants are second only to analgesics as a cause
f serious overdose toxicity. Typical cardiac manifestations include
inus tachycardia, PR and QRS prolongation, and occasionally a
rugada syndrome-like ECG (1041). Hypotension, fever, and
oma are other common manifestations of serious toxicity. Tor-
ades de pointes have been associated with tricyclic antidepressant
se, but this seems to be very rare.
3.6.5.2. Management
QRS duration can be shortened in experimental animals and in
umans by administration of NaHCO3 or NaCl boluses (1048).
ntiarrhythmic drugs, including beta blockers, are generally
voided. Supportive measures, such as pressors, activated charcoal,
nd extracorporeal circulation, may be required.
3.6.6. Sudden Cardiac Death and Psychiatric
r Neurological Disease
he incidence of SCD is increased in patients with seizure
isorders (1049) and schizophrenia. It is uncertain whether this
eflects specific abnormalities, such as autonomic dysfunction or
n unusually high prevalence of cardiovascular disease, or the
herapies used to treat the disease (1049–1052). Drug interactions
ay also contribute (1053). Antipsychotic agents well known to
roduce marked QT prolongation and torsades de pointes include
hioridazine and haloperidol. Another group of generally newer
ntipsychotic drugs also prolong the QT interval, but fewer cases
f torsades de pointes have been reported. It is not known whether
his reflects intrinsic differences between drugs producing marked
T prolongation versus those producing lesser degrees of QT
rolongation or differences in patient exposures to newer versus
lder drugs (238,1054).
3.6.7. Other Drug-Induced Toxicity
ecommendations
lass I
. High intermittent doses and cumulative doses exceeding
the recommended levels should be avoided in patients
receiving anthracyclines such as doxorubicin. (Level of
Evidence: B)
. All patients receiving 5-fluorouracil therapy should receive
close supervision and immediate discontinuation of the
infusion if symptoms or signs of myocardial ischemia
occur. Further treatment with 5-fluorouracil must be
avoided in these individuals. (Level of Evidence: C)
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cardiac assessment including echocardiography, which
should be undertaken prior to use of anthracyclines
such as doxorubicin, and regular long-term follow-up
should be considered. (Level of Evidence: C)
Anthracycline cardiotoxicity is dose dependent, with
ntermittent high doses and higher cumulative doses in-
reasing the risk of cardiomyopathy and lethal arrhythmias
1055,1056). Risk factors include younger age, female gen-
er, and use of trastuzimab (1055,1057–1059). This form of
ardiomyopathy can occur acutely soon after treatment,
ithin a few months of treatment (the so-called subacute
orm), or many years later (1056,1060–1066). There is an
ncrease in ventricular ectopy in patients receiving doxoru-
icin during the acute infusion period, but this is very rarely
f any significance (1067,1068). Some studies have sug-
ested reduced HRV, abnormalities in area ratios on
AECG, and increased QTc may be indicators of impend-
ng cardiomyopathy and electrical instability, but these have
et to be substantiated (1066,1069,1070). Long-term inter-
ittent cardiac assessment of patients is therefore necessary
nd cardiac decompensation should be treated convention-
lly. There is, however, little evidence of reversibility in the
nthracycline-induced myopathic process.
5-Fluorouracil causes lethal and potentially fatal arrhythmias
rrespective of underlying coronary disease during the acute infu-
ion period, the vast majority occurring during the first adminis-
ration (1071). Cardiac monitoring during the infusion period,
specially the first, is recommended for all patients receiving
-fluorouracil therapy. Symptoms, with or without corre-
ponding ECG changes compatible with cardiac ischemia,
hould lead to an immediate discontinuation of the infusion.
schemia should be treated conservatively or conventionally
ith anticoagulants, nitrates, and calcium channel and beta
lockade as required (1071). Although this cardiotoxicity is
eversible, 5-fluorouracil sensitizes individuals and should
e avoided in the future (1071). Cesium, well -recognized to
roduce torsades de pointes in animal models, has also been
sed as “alternate therapy” for malignancy and when tor-
ades de pointes has been reported (1072).
Toad venom, an ingredient of some traditional Chinese
edicines, produces clinical toxicity resembling that of
igoxin, and in animal models, digoxin-specific antibodies
re successful in reversing the toxicity (1073). Other herbal
roducts, including foxglove tea, have been reported to
roduce similar effects (1074,1075).
Cocaine has both slow offset sodium channelblocking
roperties and QT-prolonging (IKr-blocking) properties.
rrhythmias associated with cocaine ingestion include
ide-complex tachycardias suggestive of sodium channel
lock (and responding to sodium infusion) as well as
orsades de pointes. Cocaine also causes other cardiovascular
omplications that can lead to arrhythmias, notably myo-
arditis, and coronary spasm.Dietary supplements containing ephedra alkaloids (including
ma huang”) are no longer marketed because they appeared to
ave an infrequent association with serious cardiovascular toxicity,
ncluding SCD (1076–1078). The mechanism is unknown but
ay involve direct myocardial sympathomimetic stimulation,
oronary spasm, and/or severe hypertension in susceptible indi-
iduals. Ephedrine, the active component, is also detected in a
umber of street drugs. Coronary spasm has been reported with
ultiple other medications and can present as VF: certain anti-
ancer drugs (5-fluorouracil [1079–1082]), capecitabine (1083),
riptans used in the treatment of migraines (1084), recreational
gents (e.g., ecstasy [1085], cocaine), inadvertent vascular admin-
stration of pressor catecholamines, and anaphylaxis due to any
ne of a wide range of drugs (see Section 7.5 for further
iscussion).
Bradyarrhythmias are common (and desired) pharmaco-
ogical effects of digoxin, verapamil, diltiazem, and beta
lockers. Severe bradyarrhythmias may occur with usual
oses in sensitized individuals, particularly those receiving
ombinations, or in suicidal or accidental overdose. Marked
inus bradycardia is also common with clonidine.
4. CONCLUSIONS
CD continues to be a major cause of mortality in all
eveloped countries. Using an evidence-based approach, this
ocument attempts to summarize the latest information ad-
ressing the problem, with the goal of providing recommen-
ations consistent with previous documents. However, it is
mportant to stress that the field is evolving and recommen-
ations will certainly change as more is learned about the
roblem. The lengthy list of references serves as an indication
f the large amount of research addressing SCD already, and
ndoubtedly, the list will grow in the future. Timely updates of
his information will be critical as clinicians try to care for
atients at risk of SCD (1021,1025).
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